ANNUAL REPORT

FY 2022 — Annual report (ARS)

FY 2022PDF · 86 pages19.7 MB
2 0 2 2 A N N U A L R E P O R T

-- 1 of 86 --

During a routine physical, Jay King’s doctor discovered
that Jay was suffering from atrial fibrillation. A series
of ablations using Abbott’s TactiCath Ablation Catheter
in conjunction with the EnSite X mapping system
and HD Grid Mapping Catheter helped his heart
restore a steady beat. Later, after suffering an episode
of ventricular tachycardia, Jay had our Gallant
cardioverter defibrillator implanted, which let him get
back to the active life and outdoor activities he loves.
JAY KING
ENSITE X EP SYSTEM/ ADVISOR HD GRID
MAPPING CATHETER, SENSOR ENABLED/
TACTICATH ABLATION CATHETER,
SENSOR ENABLED/GALLANT ICD
Front Cover:
TABLE OF CONTENTS
1 	Letter to Shareholders
5 	Abbott
12 	Rapid Diagnostics
14 	Laboratory Diagnostics
16 	Pediatric and Adult Nutrition
18 	Established Pharmaceuticals
20 	Structural Heart
22 	Vascular
24 	Neuromodulation
26 	Heart Failure Management
28 	Electrophysiology
30 	Cardiac Rhythm Management
32 	Diabetes Care
34 	Creating the Future
36 	Financial Report
At Abbott, we’ve been relentlessly focused
on improving people’s health for 135 years.
Today, we’re tackling some of the world’s
most pressing healthcare challenges to
help people at all ages and stages of life.
Because we believe the best medical
product is the one that helps the most
people, we design breakthrough solutions
in each of our businesses — nutrition,
branded-generic pharmaceuticals, medical
devices, and diagnostics — to help ensure
maximum access and affordability.
Our balanced leadership across diverse
markets and geographies gives us more
ways to win and helps insulate us from the
impact of global economic swings, helping
us deliver consistent growth and strong
shareholder returns.

-- 2 of 86 --

DEAR FELLOW SHAREHOLDER:
The three years of the Covid pandemic called on all of the
strengths that have made Abbott such an enduringly successful
company and demonstrated how we’ll remain one in the years
to come. Our response and performance have been true to
both our legacy of achievement and our commitment to the
future. As we emerge from the pandemic, we are ready to lead
in the dynamic new era of healthcare that lies ahead.
ROBERT FORD
Chairman of the Board and
Chief Executive Officer

-- 3 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
CHALLENGE AND OPPORTUNITY
With its breadth and impact on all aspects of society,
Covid has been the most significant global health crisis in
a century. When the world needed help as this new virus
ground it to a halt, Abbott answered the call. We quickly
formed a battery of R&D and operational teams to attack
the new virus from multiple angles.
The result: more than a dozen different tests for use at all
stages of the disease process and in a wide range of testing
styles and environments, from hospital laboratories to
self-testing.
The availability of fast, accurate, and accessible testing
was a major factor in the world’s response to the
pandemic. It gave people confidence that they could
conduct their lives safely and allowed them to regain
normalcy after the disruptions of the virus.
The success of our actions also built major new businesses
for Abbott at unprecedented speed and, importantly for
the long term, demonstrated the power and potential of
rapid diagnostics. We showed the world the many benefits
of testing — and of health technology broadly — that is
decentralized, digitized, and democratized. This greatly
accelerated the adoption of the technology and built
strong new channels to pharmacies, to doctors’ offices,
and to people’s homes.
So, while Covid testing will become a smaller part of
our business as we move from a pandemic to an endemic
level, Abbott has built a leading position for the promising
future of rapid testing.
And this is not the only long-term opportunity that the
success of our pandemic response made possible for us.
Over this period, our Covid-testing revenues allowed us to
invest an additional $2 billion to fund or accelerate R&D
programs and marketing efforts in our priority growth
areas. We also invested approximately $6 billion in capital
projects that will expand our manufacturing capacity and
improve our capabilities.
As a result of these strategic moves and investments,
Abbott is an even stronger company coming out of Covid
than we were going into it.
The pandemic has, of course, had many other impacts on
our operating environment and our business. It’s affected
our institutional customers by reducing their ability to
perform hospital procedures and routine testing. And it’s
disrupted global supply chains and work patterns, both of
which have contributed to inflation.
Abbott has dealt with challenges like these time and again
over its long history. While Covid whipped them together
into a unique storm, we’ve weathered many. Abbott is a
long-term company; we know how to plan, how to adapt,
how to find the ways we need to deliver for both our
customers and our shareholders.
That’s how, over the three years of the pandemic, we
not only returned a total of nearly $15 billion to
shareholders through dividends and share repurchases,
but, at the same time, continued to invest for our durable,
long-term growth.
Significant as today’s challenges are, you can rely on
Abbott to persevere, to perform, and to live up to our
values as we always have.
An example was our voluntary recall of infant formula
and temporary suspension of manufacturing at one of
3-YEAR FINANCIAL
HIGHLIGHTS
2
+37%
3-YEAR SALES
GROWTH
+65%1
3-YEAR ADJUSTED
EPS GROWTH

-- 4 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
our U.S. plants. We addressed this situation and resumed
production in July. With adjustments to our global
manufacturing network — running our U.S. facilities
at increased capacity and importing additional formula
from Europe — we were able to deliver roughly the same
volume of formula in the U.S. in the second half of 2022
as we did prior to the stoppage. As a result, availability on
store shelves is improving and we will continue working
to get families the consistent and dependable supply of
high-quality infant formula they’ve relied on for almost
a century.
While managing the demands of the present, we’ve kept
our eyes on the future and its opportunities, which we
believe have never been greater.
Medical science is advancing at high speed, with
significant progress in miniaturization, and greater
understanding of gene expression and the microbiome.
Data technology is doing the same, with new capabilities
from artificial intelligence to machine learning to
advanced manufacturing. And the two fields are
combining to create remarkable new possibilities.
New connected technologies allow patients to receive
care from their physicians whenever and wherever they
need it. Wearable digital sensing technologies give people
the information about their bodies that they need to
manage medical conditions or monitor and improve their
health. New diagnostic platforms are transforming the
ways testing is conducted from the lab to the home. We’re
in the midst of a new healthcare revolution, and Abbott is
among its foremost leaders.
In 2022 alone, we delivered a host of innovative new
product approvals and launches, including:
• FreeStyle Libre 3, the world’s smallest, most accurate
continuous glucose monitoring sensor
• The EnSite X EP System, our new cardiac mapping
platform, which helps physicians better treat abnormal
heart rhythms
• Aveir, our single-chamber leadless pacemaker for the
treatment of patients with slow heart rhythms
• An upgraded version of our NeuroSphere myPath digital
health app with enhanced functionality
• Our Proclaim Plus spinal cord stimulation system
featuring the next generation of Abbott’s proprietary
BurstDR therapy
• And two new Amplatzer cardiac devices: Amulet, which
helps reduce the risk of stroke in people with atrial
fibrillation; and Talisman, to treat people with a small
opening between the upper chambers of the heart that
puts them at risk of recurrent ischemic stroke
And our pipeline for the future remains very rich.
We have the technologies and opportunities we need
to fuel both therapeutic advancement and robust
growth for years to come. These technologies and
their life-changing impact for patients and consumers
can be seen throughout this report.
FINANCIAL PERFORMANCE
Despite the headwinds in our operating environment,
Abbott delivered sales of $43.7 billion in 2022 — an
increase of around 6.4 percent on an organic basis2 —
and earnings-per-share of $5.343 , exceeding our initial
forecast for the year.
~$15BRETURNED TO
SHAREHOLDERS
SINCE THE
BEGINNING OF 2020
32.5%
3-YEAR TOTAL
SHAREHOLDER RETURN
1 On a GAAP basis, 3-year EPS growth was 90% 2 On a GAAP basis, Abbott sales increased 1.3% 3 Full-year 2022 GAAP diluted EPS from continuing operations were $3.91
For full financial data and reconciliation of non-GAAP measures, please see Abbott’s 2020 through 2022 earnings releases at www.abbottinvestor.com 	3
+46%
3-YEAR DIVIDEND
GROWTH

-- 5 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
In December, we announced a dividend increase of
8.5 percent for 2023; this makes for an average annual
dividend increase of more than 12 percent since the
beginning of the pandemic. Abbott has now paid
dividends for 99 consecutive years and is in the exclusive
ranks of Dividend Kings, the small group of companies
that have increased dividends for more than 50 years
in a row.
Over the past three years, Abbott has provided
shareholders a total return of approximately 32.5
percent, versus a market return of 23.6 percent.
The key to that success in an environment like today’s is
our diversified business strategy, which gives us defensive
strength by protecting us from market downturns in
particular businesses, and offensive strength by providing
us more ways to compete and win.
THE FUTURE
The challenges of the last three years demonstrate
precisely why and how Abbott will continue to lead far
into the future. Our company has thrived for 135 years
because of its resilience and adaptability, its diversified
portfolio of leading businesses, its financial strength
and acumen, and a deep-rooted culture of service,
execution, and success.
Because of our extensive history and experience, Abbott
takes the long view. While our experience helps us
navigate the waters of the present, it also ensures that we
always steer toward the horizon. We’re inspired by the
immense potential of the future of healthcare and believe
that we are very well positioned to capture it.
Our objective, laid out in our 2030 Sustainability Plan,
is to help three billion people every year with Abbott
products — a fifty percent increase over the course of the
plan. To achieve that ambitious goal, we’re working to
transform the future of healthcare. We’ve adopted a set of
guiding innovation principles with the explicit intention
of making our technologies more accessible to more
people. That means easier to use. It means deliverable in
new ways. And it means reducing the total cost of care to
help patients, providers, and payers.
We’re energized by that vision and believe there’s never
been a better time to be in healthcare. We’re here at
Abbott to help people live fuller lives through better
health. That’s a high purpose and a responsibility that
we take very seriously. To us, it means the motivation to
create the life-changing products and technologies of
the future, the vigilance to ensure they’re of the highest
quality, and the commitment to meet the needs of the
people we’re here to serve.
Abbott Proud,
4
>125 new product
launches in 2022
ROBERT B. FORD
Chairman of the Board and
Chief Executive Officer
February 28, 2023
+18%
3-YEAR INCREASE
IN R&D INVESTMENT

-- 6 of 86 --

Creating the future of healthcare, with leading
brands and powerful new technologies
ABBOTT
A B B O T T	A B B O T T 2 0 2 2 A N N U A L R E P O R T	2 0 2 2 A N N U A L R E P O R T
5

-- 7 of 86 --

6
A B B O T T 2 0 2 2 A N N U A L R E P O R T
COMMITTED.
For 135 years, Abbott has focused
relentlessly on delivering for our stakeholders.
Today, billions of people around the world
depend on us in vital ways.
We’re committed to honoring that trust.
And we work to earn it every day.

-- 8 of 86 --

7
A B B O T T 2 0 2 2 A N N U A L R E P O R T

-- 9 of 86 --

RELIABLE.
Our portfolio spans the
spectrum of healthcare, helping
people at all ages and stages
of life. This balance — along
with market leadership aligned
with major trends, and our
broad global presence — forms
the basis for Abbott’s consistent
and reliable performance.
8
A B B O T T 2 0 2 2 A N N U A L R E P O R T
135YEARS
OF GROWTH
AND
SUCCESS

-- 10 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
9
50+YEARS OF
RISING
DIVIDENDS
99CONSECUTIVE
YEARS OF
DIVIDENDS
PAID

-- 11 of 86 --

10
A B B O T T 2 0 2 2 A N N U A L R E P O R T

-- 12 of 86 --

11
A B B O T T 2 0 2 2 A N N U A L R E P O R T
RELEVANT.	RELEVANT.
Putting our customers at the center of everything we do, we’ve
built our portfolio strategically for relevance to where medicine
and technology, our markets and society are heading.
DIAGNOSTIC systems
and tests to provide the
information people need,
when they need it, so
they and their doctors can
make better decisions.
MEDICINES that offer
reliable quality and
accessibility to help people
in the world’s emerging
markets get and stay
healthy.
MEDICAL DEVICES to keep
hearts and arteries healthy,
treat chronic pain and
movement disorders, and
give people with diabetes
more freedom and control.
NUTRITION PRODUCTS
that apply scientific
innovation to help people
build and maintain health
across every stage of life,
from infancy onward.
Abbott 2022
Business Balance
•• Diagnostics 	38%
•• Pharmaceuticals 	11%
•• Medical Devices 	34%
•• Nutrition 	17%

-- 13 of 86 --

RAPID
DIAGNOSTICS
*Not available in the United States	
12
PANBIO COVID-19 TEST
Abbott is a global leader in point-of-care testing,
with a portfolio focused on four key areas: Infectious
Disease, Cardiometabolic & Informatics, Toxicology,
and Consumer Diagnostics. Our products are used
in a variety of settings, including hospital labs,
emergency and operating rooms, physician offices,
urgent-care clinics, pharmacies, and health posts in
remote and rural areas. The pandemic has shown the
value of at-home testing and sample collection, and
Abbott plans to bring that convenience and discretion
to additional areas in the future, including for
sexually transmitted infections (STIs).
In addition to our BinaxNOW test for Covid-19, we
offer lateral-flow tests for other infectious diseases,
including the Panbio HIV Self Test *
, and the world’s
most sensitive lateral-flow tests for detecting hepatitis
B surface antigen*
. Our ID Now benchtop molecular
analyzer brings improved sensitivity and specificity
to in-office infectious-disease testing.
Our iSTAT family of portable blood analyzers can be
used at the patient’s side to deliver real-time, lab-
quality test results, making them useful in emergency
and acute-care settings.
Pioneering innovative ways to
screen, diagnose, and monitor a vast
range of health conditions.
Our benchtop molecular
analyzer offers reliable,
rapid results, giving
healthcare professionals
information they need to
make faster, more effective
treatment decisions.
ID NOW
EMPOWERING
KNOWLEDGE

-- 14 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T	A B B O T T 2 0 2 2 A N N U A L R E P O R T
13
KAMINI
SARVAISPARAN
SINGAPORE
PANBIO COVID HOME TEST
As a financial adviser,
Kamini has regular contact
with customers. She and
her husband, Sanjeev, rely on
Panbio Covid self tests to help
keep their children safe.

-- 15 of 86 --

14
Abbott systems and tests help laboratory
professionals run high volumes of
patient samples with speed, accuracy,
and efficiency.
DATA-BASED
DECISIONS
ALINITY M
MOLECULAR
DIAGNOSTICS
ANALYZER
Fully integrated and
automated molecular
diagnostics analyzer
delivers next-level
flexibility and efficiency
for core laboratories.
LABORATORY
DIAGNOSTICS

-- 16 of 86 --

15
DR. TULIO
DE OLIVIERA
DURBAN, SOUTH AFRICA
ABBOTT PANDEMIC
DEFENSE COALITION
Dr. Oliviera, of the Genomic Centre of
the University of KwaZulu-Natal, is an
important contributor to Abbott’s Pandemic
Defense Coalition, which identifies
new pathogens, analyzes potential risk
levels, rapidly develops and deploys new
diagnostic testing, and assesses public
health impact in real time.
A B B O T T 2 0 2 2 A N N U A L R E P O R T
GLP SYSTEMS
An innovative laboratory
automation solution that
offers proven technology
with flexibility and options
to meet the needs of
high-volume diagnostic
laboratories.
Abbott’s innovative tests and instrument systems
that support healthcare professionals with health
screening, disease diagnosis, and monitoring have
made us a leading name in immunoassay diagnostics,
companion diagnostics, clinical chemistry, and
blood screening. Our blood-screening systems and
tests are used to safeguard approximately 60% of
the world’s blood supply.
Our information solutions enable efficient
information sharing across functions, allowing faster
and better-informed treatment decisions.
Over the next few years, Abbott will continue rolling
out our Alinity family of harmonized systems, which
are being designed to run more tests in less space,
generate test results faster, and minimize human
errors, while continuing to provide high-quality
results. In 2022, Abbott received U.S. FDA clearance
for our first-of-its-kind Alinity m STI Assay, which
simultaneously detects and differentiates up to four
common sexually transmitted infections (STIs);
and U.S. FDA Emergency Use Authorization of its
molecular test for detecting the Mpox virus (formerly
known as monkeypox).

-- 17 of 86 --

PEDIATRIC AND
ADULT NUTRITION
16
NOURISHING
POTENTIAL
For more than 90
years, Abbott has
developed innovative
products to help
people reach their
full potential at every
stage of life.
SANTIAGO
BLANCO
VERACRUZ, MEXICO
PEDIASURE
Santiago is a very
active 4-year-old.
His mom, Emilse, relies
on PediaSure to make
sure he’s getting all
the nutrition he needs
to keep going — and
growing — strong.

-- 18 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
17
At Abbott, we understand that proper nutrition is the
foundation for living the best and fullest life possible.
That’s why we develop science-based nutrition
products for people of all ages. Abbott products help
babies and children grow, keep adult bodies strong
and active, and support the unique nutrition needs of
people with chronic illnesses — to make every stage
of life a healthy one.
Our pediatric product line includes Similac infant
and toddler formulas, which support healthy growth
and development; PediaSure, our complete, balanced
nutritional drink designed with the optimal balance
of protein, carbohydrates, vitamins and minerals;
and Pedialyte, our advanced rehydration solution
specially formulated to help kids and adults replenish
vital fluids and electrolytes.
Our Adult Nutrition portfolio is anchored by our
Ensure line of products, with complete, balanced,
and targeted nutrition to help people stay active and
healthy, as well as support recovery from illness,
injury, or surgery. Launched in 1973, Ensure is the
most-recommended brand among doctors who
suggest oral nutritional products to their patients.
Our portfolio is rounded out by Glucerna shakes
and bars for people with diabetes; Juven, which
supports wound healing; and Nepro, for people with
kidney disease.
MARGY
MARTINDALE
WEST CHESTER,
OHIO, USA
JUVEN
After a fall left her with a broken arm
that required surgery, Margy (seen here
enjoying time with her granddaughter)
relied on Juven, our nutritional supplement
that has been clinically shown to support
wound healing, during her recovery.
ENSURE
COMPLETE
The only complete,
balanced nutrition
shake with 30 grams
of protein and
nutrients to support
immune health.
PEDIASURE
Complete,
balanced
nutritional
drink.

-- 19 of 86 --

18
TRUSTED
BRANDS
Applying new technologies
and services to transform
the way people in emerging
markets use medicines.
Every day, more than 19 million people in 95 countries
benefit from Abbott’s medicines. In this business,
we innovate in all areas beyond the molecule, using
local insights to apply new ways to make good
medicines better. Our product portfolios are localized
and offer solutions to help treat some of the most
prevalent health conditions. Through our a:care
program, we leverage advances in digital tools and
behavioral science to support healthcare professionals
and empower people to take small, manageable steps
to take charge of their health.
We drive scale and market share by having breadth
and depth in high-growth therapeutic areas — tailored
to local needs and supported through innovations and
new partnerships. This portfolio approach helps us
provide efficiencies, focus, and therapeutic expertise,
and to build deep stakeholder relationships. Our most-
used products in this business include the world’s
leading medicines for pancreatic enzyme deficiency,
progesterone hormone therapy, and vertigo.
ESTABLISHED
PHARMACEUTICALS

-- 20 of 86 --

19
DIMPLE BHATNAGAR
NEW DELHI, INDIA
FEMOSTON CONTI
When Dimple began experiencing
the symptoms of menopause,
she just didn’t feel like herself
anymore, enduring mood swings,
muscle weakness and, as she puts
it, frequent mental breakdowns.
Since she began taking Abbott’s
Femoston conti, she says “I feel
like me again!” Dimple shared her
experience as part of “The Next
Chapter,” an initiative we launched
in 2022 to help break the silence
around menopause and empower
women to live their fullest lives.
MORE THAN 1,500
PRODUCTS
Abbott offers a
broad portfolio
of high-quality
medicines
across multiple
therapeutic areas
• Gastroenterology
• Women’s Health
• Cardiometabolic
• Pain Management/
Central Nervous System
• Respiratory
A B B O T T 2 0 2 2 A N N U A L R E P O R T
19million people in
emerging markets take
Abbott medicines
every day
manufacturing
facilities and
development centers
worldwide
24
95 countries
Commercial presence in
A representative sample of our broad portfolio
of leading medicines in emerging markets.

-- 21 of 86 --

ADVANCED
ENGINEERING
ALICE TERRA DE MORAIS
RIO DE JANEIRO, BRAZIL
AMPLATZER PICCOLO
Alice has always dreamed of being a professional
soccer player, but congenital heart disease prevented
her from participating in physical activities. Abbott’s
Amplatzer Piccolo Occluder repaired her heart, and
now she’s free to pursue her dreams.
Minimally invasive
devices to repair
damage and rebuild
healthier hearts.
20
STRUCTURAL
HEART

-- 22 of 86 --

*Currently available in Europe and countries that recognize the CE mark.
TRICLIP G4* 	NAVITOR TAVI
Transcatheter aortic valve
implantation system combines
our Navitor valve with the
stability and accuracy of our
FlexNav delivery system.
AMPLATZER PICCOLO
An often lifesaving device
designed to help repair patent
ductus arteriosus, a life-
threatening opening in the hearts
of some premature infants.
A continued emphasis on patient-focused
innovation has helped Abbott build our broad
portfolio of structural heart devices. Our leading
technologies include MitraClip and TriClip*, our
market-leading transcatheter valve-repair devices;
Navitor, Portico, and Tendyne* valve-replacement
systems; and our line of Amplatzer occluders,
which treat a variety of defects resulting from
holes in the heart.
In 2022, we launched several important new
products, including the Amplatzer Steerable
Delivery Sheath for our Amplatzer Amulet
Occluder, the first and only steerable delivery
system designed to help seal the left atrial
appendage (LAA) in people with atrial fibrillation
who are at an increased risk of ischemic stroke;
and the Amplatzer Talisman system, which seals
an opening in the heart known as a patent foramen
ovale (PFO) to prevent blood clots from passing
from the right to the left side of the heart and on to
the brain, where they can cause a stroke.
21
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Next-generation
transcatheter
edge-to-edge
repair system
for leaky
tricuspid valves.

-- 23 of 86 --

22
Advanced imaging systems
help optimize treatments
and improve outcomes for
vascular interventions.
Abbott’s comprehensive vascular portfolio includes:
• The market-leading XIENCE family of drug-coated stents
• Diagnostic and imaging devices to help doctors
assess blockages in the arteries
• Catheters and guidewires to support optimal treatment
• Vessel-closure devices used to close vascular and
structural heart access sites following stent placements.
Our Ultreon 1.0 software, which merges imaging technology
with artificial intelligence to enhance visualization of
stenting procedures, works with our OPTIS imaging systems
VASCULAR
INFORMED
INTERVENTIONS
JULIE BAKER
BUCKNER, MISSOURI, USA
JETi SYSTEM
When Julie went to the hospital with severe pain
in her leg, doctors discovered a blood clot that
put her in danger of losing the limb altogether.
She’s grateful her doctors were able to use
Abbott’s JETi thrombectomy system to safely
remove the clot, saving her leg and helping make
sure she could still enjoy walks in the woods
with her granddaughter, Irelyn.

-- 24 of 86 --

23
to automatically detect blockage severity and
measure blood vessel characteristics, supporting
more precise decisions.
In 2022, Abbott expanded the rollout of its JETi
thrombectomy device, which leverages cutting-edge
technology to remove blood clots. Using a uniquely
positioned high-pressure saline jet, JETi fragments a
clot within the safety of the catheter tip, and can
also selectively deliver diagnostics or therapeutics
during the clot-removal procedure.
A B B O T T 2 0 2 2 A N N U A L R E P O R T
XIENCE SKYPOINT
The newest DES in the
XIENCE family has an
enhanced design that offers
better expansion and
excellent deliverability.
JETi
THROMBECTOMY
SYSTEM
COMPREHENSIVE VASCULAR
PORTFOLIO
• Perclose ProGlide vascular closure system
• JETi thrombectomy system
• Supera Peripheral Stent system
• Dragonfly OpStar Imaging Catheter
• OPTIS Next Imaging System with Ultreon Software
• PressureWire family of pressure-sensing guidewires
• XIENCE family of drug-eluting stents

-- 25 of 86 --

NEW PATHS
FORWARD
24
Abbott is the global leader in the
development of chronic pain therapy
solutions, offering a unique portfolio that
includes radiofrequency ablation and spinal-
cord stimulation (SCS) therapy technologies.
In 2022, we received U.S. FDA approval
for our Proclaim Plus SCS system, which
features FlexBurst360, the next generation
of our proprietary BurstDR stimulation.
This advanced device offers pain coverage
across up to six areas of the trunk and/or
limbs and lets doctors adjust programming
as a person’s therapeutic needs evolve.
For people with Parkinson’s disease and
essential tremor, we’ve developed the
Infinity Deep Brain Stimulation (DBS)
system, the first DBS system available
that offers both directional leads to target
therapy to specific needs and a patient-
friendly iOS® software platform that gives
them more control over managing their
symptoms.
These devices are designed to be used in
conjunction with Abbott’s NeuroSphere
Virtual Clinic, which allows people to
connect with their doctors and receive
remote programming adjustments from the
comfort of their homes. In 2022, we launched
an upgraded version of our NeuroSphere
myPath digital health app, which helps
doctors more closely track their patients
as they evaluate Abbott neurostimulation
devices to address their chronic pain.
Our specialized devices help people suffering
from chronic pain and movement disorders
get back to living their lives.
FlexBurst360 therapy offers
pain coverage for up to six
areas of the trunk and/or limbs
and enables programming that
can be adjusted as a person’s
therapeutic needs evolve.
NEUROMODULATION	NEUROMODULATION

-- 26 of 86 --

25
A B B O T T 2 0 2 2 A N N U A L R E P O R T
ANITTA MEIJER
‘S-HERTOGENBOSCH, NETHERLANDS
PROCLAIM SCS SYSTEM
For years, chronic leg pain made it difficult for Anitta to do even
the simplest things. After trying several unsuccessful therapies, she
wondered if the pain was just something she’d have to learn to live
with. But then her doctor implanted Abbott’s Proclaim SCS system,
and Anitta was delighted by the difference. Today, she is largely
pain-free and can once again enjoy her active life.

-- 27 of 86 --

26
A FULL
SPECTRUM
OF CARE
HEART FAILURE
MANAGEMENT
AVERY
JASTER
MCKINNEY, TEXAS, USA
CARDIOMEMS HF SYSTEM
Since being diagnosed
with heart failure,
Avery has relied on our
CardioMEMS HF System
to continually monitor
changes in her pulmonary
artery pressure, helping
identify problems even
before her symptoms
appear. This allows her
doctor to take an earlier
and more proactive
approach to her care.

-- 28 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
27
GALLANT HF
CARDIAC
RESYNCHRONIZATION
THERAPY
DEFIBRILLATOR
Smartphone connectivity
lets this device transmit
important data to a doctor’s
office without the need for
an in-person visit.
CARDIOMEMS
HF SYSTEM
Abbott’s paper-
clip-sized device
can alert doctors
to worsening heart
failure before
symptoms arise.
Abbott is the leader in heart-failure management
technology, with innovative devices that meet
patient and clinician needs from the earliest stages
to the most advanced stages of the disease.
Our CardioMEMS HF system is the first and only
U.S. FDA-approved heart-failure monitoring system
that allows clinicians to remotely monitor changes
in pulmonary artery pressure before a patient’s
heart-failure symptoms show or progress. This
allows physicians to proactively adjust medication or
treatment and help reduce hospitalization. In 2022,
our CardioMEMS HF System was approved in the
U.S. to support the care of people with earlier-stage
heart failure, giving more than a million more people
access to this important technology.
Our HeartMate 3 LVAD, the leading left ventricular
assist device, is an implantable heart pump for
people living with advanced heart failure who do not
qualify for, or are awaiting, a heart transplant. The
HeartMate 3 LVAD is the only device of its kind to use
Full MagLev Flow Technology, a proprietary system
designed to reduce trauma to the blood as it passes
through the pump.
In 2022, we announced new clinical data that showed
for the first time that a heart pump can help the
majority of patients with advanced heart failure
extend survival beyond five years in a population of
patients who otherwise would not be expected
to survive a year.
A comprehensive approach
to heart-failure treatment and
management.

-- 29 of 86 --

28
BOLD
SOLUTIONS
Cutting-edge technology to
deliver reliable treatment for
atrial fibrillation.
ELECTROPHYSIOLOGY
JAY KING
SAN DIEGO, CALIFORNIA, USA
ENSITE X EP SYSTEM/ ADVISOR HD GRID
MAPPING CATHETER, SENSOR ENABLED/
TACTICATH ABLATION CATHETER, SENSOR
ENABLED/GALLANT ICD
When Jay went into atrial fibrillation during
a routine physical, his doctor recommended
an ablation. Abbott’s EnSite X EP System
and Advisor HD Mapping Catheter, Sensor
Enabled helped the doctor more accurately
identify the part of Jay’s heart that was
causing the trouble.

-- 30 of 86 --

29
A B B O T T 2 0 2 2 A N N U A L R E P O R T
TACTIFLEX
The first and only
contact force catheter
with a flexible tip.
Our electrophysiology portfolio includes next-
generation cardiac mapping systems and catheters
that let doctors deliver precise treatments, and
ablation catheters that work with those
advanced systems and are designed to be easier
for doctors to use.
Our EnSite X EP System with EnSite Omnipolar
Technology is our cardiac mapping platform that
creates highly detailed three-dimensional maps of the
heart to help physicians identify and then treat areas
of the heart where abnormal rhythms originate.
Our portfolio also includes the Advisor HD Grid
Mapping Catheter, Sensor Enabled, which uses a first-
of-its-kind electrode configuration to create more-
highly detailed maps of the heart; and our TactiCath
Contact Force Ablation Catheter, Sensor Enabled
which helps physicians determine where to apply
optimal pressure during a cardiac ablation.
In 2022, Abbott released the results from a study
showing that 89% of patients treated for persistent
atrial fibrillation using our TactiCath Contact Force
Ablation Catheter, Sensor Enabled device remained
symptom-free for at least 15 months.
ENSITE X EP SYSTEM
Designed for accurate and efficient
mapping of the heart.
37 million
PEOPLE
WORLDWIDE
WITH AFIB

-- 31 of 86 --

30	30
NEVER MISS
A BEAT
CARDIAC RHYTHM
MANAGEMENT
JACK BURBAGE
OCEAN CITY,
MARYLAND, USA
AVEIR VR
Jack struggled with atrial
fibrillation for roughly 20
years and had resigned
himself to living with the
condition. But now, with
Abbott’s leadless pacemaker
helping ensure a steady
heartbeat, Jack feels better
than he has in years, and is
able to more fully enjoy time
with his partner, Ginny.

-- 32 of 86 --

A B B O T T 2 0 2 2 A N N U A L R E P O R T
JOT Dx
Smartphone-compatible
implantable cardiac monitor.
AVEIR VR
Single-chamber
leadless
pacemaker.
31
In cardiac rhythm management, we offer
pacemakers that restore normal heart rates,
implantable cardiac defibrillators that can
terminate dangerous heart rhythms and extend
life, cardiac resynchronization devices that
help the heart pump more effectively, and
implantable monitors that can document heart
rhythm abnormalities.
Our Confirm Rx and JOT DX ICM are Bluetooth®-
enabled implantable cardiac monitors — small
insertable devices that wirelessly transmit data
via the patient’s smartphone to the physician’s
office, facilitating more prompt diagnosis of
heart-rhythm abnormalities.
In 2022, we added to our portfolio of pacemakers
with the launch of our Aveir VR single-chamber
leadless pacemaker for the treatment of patients
with slow heart rhythms. Aveir is implanted
directly inside the heart’s right ventricle via
a minimally invasive procedure, eliminating
the need for a power generator to be surgically
implanted in the upper chest. Aveir is the world’s
only leadless pacemaker with a unique mapping
capability to assess correct positioning prior
to placement, and is designed to be completely
retrievable should the patient’s therapy needs
change or if the device needs to be replaced.
A full portfolio of solutions
for managing abnormal heart
rhythms.

-- 33 of 86 --

32
PEOPLE
POWER
DIABETES
CARE
JOHN SIMS
COLUMBUS, OHIO, USA
FREESTYLE LIBRE
Knowing his FreeStyle Libre 2
system is continuously
monitoring his glucose levels
gives John the peace of
mind he needs to focus on
the things that really matter,
like spending time with his
grandson, Jayden.

-- 34 of 86 --

33
#	#1	1CONTINUOUS
GLUCOSE
MONITORING
A B B O T T 2 0 2 2 A N N U A L R E P O R T
FreeStyle Libre was named the
Best Medical Technology of
the past 50 years by the Galien
Foundation, the premier global
institution dedicated to honoring
innovation in life sciences.
FREESTYLE LIBRE 3
CONTINUOUS GLUCOSE
MONITORING SYSTEM
HELPING PEOPLE WITH
DIABETES LIVE
HEALTHIER, MORE
ACTIVE LIVES
1 Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre portfolio
compared to the number of users for other leading personal-use, sensor-based glucose monitoring systems.
2 Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see the Check
Blood Glucose symbol during the first 12 hours.
3 FreeStyle Libre apps are only compatible with certain mobile devices and operating systems.
4 Among patient-applied sensors. Data on File. Abbott Diabetes Care
Approximately 4.5 million people in 60 countries rely on our
FreeStyle Libre portfolio to help them manage their diabetes.
Our Diabetes Care business is powered by our
FreeStyle Libre system, the Number One continuous
glucose monitoring (CGM) system in the world 1 .
Designed from the start to be a more accessible
and affordable option, FreeStyle Libre is making a
life-changing difference for people in 60 countries.
The system features breakthrough sensor
technology that frees people from the pain and
hassles of fingersticks 2 , capturing accurate,
real-time glucose readings every minute and
providing trends in glucose levels with a swipe
of a compatible smartphone 3 or a reader.
In 2022, Abbott launched our next-generation
FreeStyle Libre 3 — the world’s smallest, most
accurate CGM sensor 4 — in the United States.
The impact of the FreeStyle Libre portfolio will be
multiplied by a strategic partnership, announced
in 2022, that will integrate our FreeStyle Libre
portfolio with WeightWatchers ® ’ diabetes-tailored
weight-management program to create a seamless
mobile experience that gives people living with
diabetes the information and insights they need to
gain better control of their health.
We also announced a partnership with CamDiab and
Ypsomed to develop and commercialize an integrated
automated insulin delivery (AID) system, connecting
the FreeStyle Libre 3 sensor to CamDiab’s mobile
app, which is authorized to connect with Ypsomed’s
insulin pump.
And, we received breakthrough device designation
from the U.S. FDA for a new biowearable we’re
developing that will continuously monitor both
glucose and ketone levels in one sensor.

-- 35 of 86 --

TRANSFORMING
DIAGNOSTIC LABS
Systems and
automation that help
maximize efficiency.
34
SCIENCE-BASED
NUTRITION
Responding to
consumer preference
by building on
the latest science
to deliver next-
generation products.
By anticipating changes in
medical science and technology,
Abbott continually refreshes
our new-product pipeline with
leading-edge innovations.
CREATING
THE FUTURE
ETERNA SCS
The smallest implantable,
rechargeable spinal cord stimulator
on the market provides for long-
term pain relief.
A B B O T T 2 0 2 2 A N N U A L R E P O R T

-- 36 of 86 --

35
ADVANCED
MITRAL VALVE
REPLACEMENT
Novel device can
be implanted
without the need
for open-heart
surgery.
AVEIR DUAL-
CHAMBER
PACEMAKER
Innovative technology
being designed to
provide beat-by-
beat communication
between two leadless
pacemakers.
ADVANCED
DIGITAL
TOOLS
to help people
around the
world take
charge of their
health.
A B B O T T 2 0 2 2 A N N U A L R E P O R T
LINGO
A new line of biowearables being
designed to measure key biomarkers
like glucose and ketones to help
people understand the connection to
their energy levels, cravings, athletic
performance or general wellbeing.
FIRST-OF-ITS-KIND
MULTIPLEX TEST
Simultaneously detects and
differentiates four common
sexually transmitted infections.

-- 37 of 86 --

36
A B B O T T 2 0 2 2 A N N U A L R E P O R T
36
2022 FINANCIAL
REPORT
37 	Consolidated Statement of Earnings
38 Consolidated Statement of
Comprehensive Income
39 	Consolidated Statement of Cash Flows
40 Consolidated Balance Sheet
42 Consolidated Statement of
Shareholders’ Investment
43 Notes to Consolidated
Financial Statements
62 	Management Report on Internal
Control Over Financial Reporting
62 	Report of Independent Registered
Public Accounting Firm
64 Report of Independent Registered
Public Accounting Firm
65 	Financial Instruments and
Risk Management
66 Financial Review
79 	Performance Graph
80 Summary of Selected Financial Data
81 	Directors and Corporate Officers
82 	Shareholder and Corporate
Information

-- 38 of 86 --

37
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Year Ended December 31 	2022 	2021 	2020
Net Sales 	$43,653 	$43,075 	$34,608
Cost of products sold, excluding amortization of intangible assets 	19,142 	18,537 	15,003
Amortization of intangible assets 	2,013 	2,047 	2,132
Research and development 	2,888 	2,742 	2,420
Selling, general and administrative 	11,248 	11,324 	9,696
Total Operating Cost and Expenses 	35,291 	34,650 	29,251
Operating Earnings 	8,362 	8,425 	5,357
Interest expense 	558 	533 	546
Interest income 	(183) 	(43) 	(46)
Net foreign exchange (gain) loss 	2 	1 	(8)
Other (income) expense, net 	(321) 	(277) 	(103)
Earnings from Continuing Operations Before Taxes 	8,306 	8,211 	4,968
Taxes on Earnings from Continuing Operations 	1,373 	1,140 	497
Earnings from Continuing Operations 	6,933 	7,071 	4,471
Net Earnings from Discontinued Operations, net of taxes 	— 	— 	24
Net Earnings 	$÷6,933 	$÷7,071 	$÷4,495
Basic Earnings Per Common Share —
Continuing Operations 	$÷÷3.94 	$÷÷3.97 	$÷÷2.51
Discontinued Operations 	— 	— 	0.01
Net Earnings 	$÷÷3.94 	$÷÷3.97 	$÷÷2.52
Diluted Earnings Per Common Share —
Continuing Operations 	$÷÷3.91 	$÷÷3.94 	$÷÷2.49
Discontinued Operations 	— 	— 	0.01
Net Earnings 	$÷÷3.91 	$÷÷3.94 	$÷÷2.50
Average Number of Common Shares Outstanding Used for
Basic Earnings Per Common Share 	1,753 	1,775 	1,773
Dilutive Common Stock Options 	11 	14 	13
Average Number of Common Shares Outstanding Plus
Dilutive Common Stock Options 	1,764 	1,789 	1,786
Outstanding Common Stock Options Having No Dilutive Effect 	3 	— 	9
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D S TAT E M E N T O F E A R N I N G S
(in millions except per share data)

-- 39 of 86 --

38
A B B O T T 2 0 2 2 A N N U A L R E P O R T
C O N S O L I D AT E D S TAT E M E N T O F C O M P R E H E N S I V E I N C O M E
(in millions)
Year Ended December 31 	2022 	2021 	2020
Net Earnings 	$«6,933 	$«7,071 	$«4,495
Foreign currency translation gain (loss) adjustments 	(894) 	(980) 	65
Net actuarial gains (losses) and prior service cost and credits and amortization
of net actuarial losses and prior service cost and credits, net of taxes of $330 in
2022, $340 in 2021 and $(79) in 2020 	1,177 	1,201 	(331)
Net gains (losses) on derivative instruments designated
as cash flow hedges, net of taxes of $11 in 2022, $63 in 2021 and $(87) in 2020 	40 	351 	(215)
Other Comprehensive Income (Loss) 	323 	572 	(481)
Comprehensive Income 	$«7,256 	$«7,643 	$«4,014
Supplemental Accumulated Other Comprehensive Income (Loss) Information,
net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments 	$(6,733) 	$(5,839) 	$(4,859)
Net actuarial (losses) and prior service (cost) and credits 	(1,493) 	(2,670) 	(3,871)
Cumulative gains (losses) on derivative instruments designated as cash flow
hedges 	175 	135 	(216)
Accumulated other comprehensive income (loss) 	$(8,051) 	$(8,374) 	$(8,946)
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 40 of 86 --

39
A B B O T T 2 0 2 2 A N N U A L R E P O R T
C O N S O L I D AT E D S TAT E M E N T O F C A S H F L O W S
(in millions)
Year Ended December 31 	2022 	2021 	2020
Cash Flow From (Used in) Operating Activities:
Net earnings 	$«6,933 	$÷7,071 	$«4,495
Adjustments to reconcile earnings to net cash from operating activities —
Depreciation 	1,254 	1,491 	1,195
Amortization of intangible assets 	2,013 	2,047 	2,132
Share-based compensation 	685 	640 	546
Investing and financing losses, net 	215 	55 	425
Trade receivables 	(68) 	(383) 	(924)
Inventories 	(1,413) 	(456) 	(493)
Prepaid expenses and other assets 	(75) 	(312) 	(627)
Trade accounts payable and other liabilities 	420 	1,288 	1,766
Income taxes 	(383) 	(908) 	(614)
Net Cash From Operating Activities 	9,581 	10,533 	7,901
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(1,777) 	(1,885) 	(2,177)
Acquisitions of businesses and technologies, net of cash acquired 	— 	(187) 	(42)
Proceeds from business dispositions 	48 	134 	58
Purchases of investment securities 	(185) 	(173) 	(83)
Proceeds from sales of investment securities 	152 	77 	10
Other 	22 	26 	19
Net Cash From (Used in) Investing Activities 	(1,740) 	(2,008) 	(2,215)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of ) short-term debt, net and other 	47 	(204) 	2
Proceeds from issuance of long-term debt and debt with maturities over 3 months 	7 	4 	1,281
Repayments of long-term debt and debt with maturities over 3 months 	(753) 	(48) 	(1,333)
Purchases of common shares 	(3,795) 	(2,299) 	(403)
Proceeds from stock options exercised 	167 	255 	245
Dividends paid 	(3,309) 	(3,202) 	(2,560)
Other 	— 	— 	(11)
Net Cash From (Used in) Financing Activities 	(7,636) 	(5,494) 	(2,779)
Effect of exchange rate changes on cash and cash equivalents 	(122) 	(70) 	71
Net Increase (Decrease) in Cash and Cash Equivalents 	83 	2,961 	2,978
Cash and Cash Equivalents, Beginning of Year 	9,799 	6,838 	3,860
Cash and Cash Equivalents, End of Year 	$«9,882 	$«9,799 	$«6,838
Supplemental Cash Flow Information:
Income taxes paid 	$«1,864 	$«1,941 	$÷÷970
Interest paid 	563 	544 	549
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 41 of 86 --

40
A B B O T T 2 0 2 2 A N N U A L R E P O R T
December 31 	2022 	2021
Assets
Current assets:
Cash and cash equivalents 	$÷9,882 	$÷9,799
Investments, primarily bank time deposits and U.S. treasury bills 	288 	450
Trade receivables, less allowances of — 2022: $500; 2021: $519 	6,218 	6,487
Inventories:
Finished products 	3,805 	3,081
Work in process 	680 	694
Materials 	1,688 	1,382
Total inventories 	6,173 	5,157
Other prepaid expenses and receivables 	2,663 	2,346
Total current assets 	25,224 	24,239
Investments 	766 	816
Property and equipment, at cost:
Land 	511 	525
Buildings 	4,053 	4,007
Equipment 	14,164 	13,528
Construction in progress 	1,484 	1,304
20,212 	19,364
Less: accumulated depreciation and amortization 	11,050 	10,405
Net property and equipment 	9,162 	8,959
Intangible assets, net of amortization 	10,454 	12,739
Goodwill 	22,799 	23,231
Deferred income taxes and other assets 	6,033 	5,212
$74,438 	$75,196
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D B A L A N C E S H E E T
(dollars in millions)

-- 42 of 86 --

41
A B B O T T 2 0 2 2 A N N U A L R E P O R T
December 31 	2022 	2021
Liabilities and Shareholders’ Investment
Current liabilities:
Trade accounts payable 	$÷«4,607 	$«÷4,408
Salaries, wages and commissions 	1,556 	1,625
Other accrued liabilities 	5,845 	5,181
Dividends payable 	887 	831
Income taxes payable 	343 	306
Current portion of long-term debt 	2,251 	754
Total current liabilities 	15,489 	13,105
Long-term debt 	14,522 	17,296
Post-employment obligations and other long-term liabilities 	7,522 	8,771
Commitments and contingencies
Shareholders’ investment:
Preferred shares, one dollar par value
Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value
Authorized — 2,400,000,000 shares
Issued at stated capital amount —
Shares: 2022: 1,986,519,278; 2021: 1,985,273,421 	24,709 	24,470
Common shares held in treasury, at cost —
Shares: 2022: 248,724,257; 2021: 221,191,228 	(15,229) 	(11,822)
Earnings employed in the business 	35,257 	31,528
Accumulated other comprehensive income (loss) 	(8,051) 	(8,374)
Total Abbott Shareholders’ Investment 	36,686 	35,802
Noncontrolling interests in subsidiaries 	219 	222
Total Shareholders’ Investment 	36,905 	36,024
$«74,438 	$«75,196
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D B A L A N C E S H E E T
(dollars in millions)

-- 43 of 86 --

42
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Year Ended December 31 	2022 	2021 	2020
Common Shares:
Beginning of Year
Shares: 2022: 1,985,273,421; 2021: 1,981,156,896; 2020: 1,976,855,085 	$«24,470 	$«24,145 	$«23,853
Issued under incentive stock programs
Shares: 2022: 1,245,857; 2021: 4,116,525; 2020: 4,301,811 	72 	173 	181
Share-based compensation 	687 	642 	548
Issuance of restricted stock awards 	(520) 	(490) 	(437)
End of Year
Shares: 2022: 1,986,519,278; 2021: 1,985,273,421; 2020: 1,981,156,896 	$«24,709 	$«24,470 	$«24,145
Common Shares Held in Treasury:
Beginning of Year
Shares: 2022: 221,191,228; 2021: 209,926,622; 2020: 214,351,838 	$(11,822) 	$(10,042) 	$(10,147)
Issued under incentive stock programs
Shares: 2022: 4,980,202; 2021: 5,650,168; 2020: 6,290,757 	269 	271 	298
Purchased
Shares: 2022: 32,513,231; 2021: 16,914,774; 2020: 1,865,541 	(3,676) 	(2,051) 	(193)
End of Year
Shares: 2022: 248,724,257; 2021: 221,191,228; 2020: 209,926,622 	$(15,229) 	$(11,822) 	$(10,042)
Earnings Employed in the Business:
Beginning of Year 	$«31,528 	$«27,627 	$«25,847
Impact of adoption of new accounting standards 	— 	— 	(5)
Net earnings 	6,933 	7,071 	4,495
Cash dividends declared on common shares
(per share — 2022: $1.92; 2021: $1.82; 2020: $1.53) 	(3,365) 	(3,235) 	(2,722)
Effect of common and treasury share transactions 	161 	65 	12
End of Year 	$«35,257 	$«31,528 	$«27,627
Accumulated Other Comprehensive Income (Loss):
Beginning of Year 	$÷(8,374) 	$÷(8,946) 	$÷(8,465)
Other comprehensive income (loss) 	323 	572 	(481)
End of Year 	$÷(8,051) 	$÷(8,374) 	$÷(8,946)
Noncontrolling Interests in Subsidiaries:
Beginning of Year 	$÷÷÷222 	$÷÷÷219 	$÷÷÷213
Noncontrolling Interests’ share of income, business combinations,
net of distributions and share repurchases 	(3) 	3 	6
End of Year 	$÷÷÷219 	$÷÷÷222 	$÷÷÷219
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D S TAT E M E N T O F S H A R E H O L D E R S ’ I N V E S T M E N T
(in millions except shares and per share data)

-- 44 of 86 --

43
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Business — Abbott’s principal business is the discovery,
development, manufacture and sale of a broad line of health care
products.
Basis of Consolidation — The consolidated financial statements
include the accounts of the parent company and subsidiaries, after
elimination of intercompany transactions.
Use of Estimates — The consolidated financial statements have
been prepared in accordance with generally accepted accounting
principles in the United States and necessarily include amounts
based on estimates and assumptions by management. Actual
results could differ from those amounts. Significant estimates
include amounts for sales rebates, income taxes, pension and other
post-employment benefits, valuation of intangible assets, litiga-
tion, derivative financial instruments, and inventory and accounts
receivable exposures.
Foreign Currency Translation — The statements of earnings of
foreign subsidiaries whose functional currencies are other than
the U.S. dollar are translated into U.S. dollars using average
exchange rates for the period. The net assets of foreign subsidiar-
ies whose functional currencies are other than the U.S. dollar are
translated into U.S. dollars using exchange rates as of the balance
sheet date. The U.S. dollar effects that arise from translating the
net assets of these subsidiaries at changing rates are recorded in
the foreign currency translation adjustment account, which is
included in equity as a component of Accumulated other compre-
hensive income (loss). Transaction gains and losses are recorded
on the Net foreign exchange (gain) loss line of the Consolidated
Statement of Earnings.
Revenue Recognition — Revenue from product sales is recognized
upon the transfer of control, which is generally upon shipment or
delivery, depending on the delivery terms set forth in the customer
contract. Provisions for discounts, rebates and sales incentives to
customers, and returns and other adjustments are provided for in
the period the related sales are recorded. Sales incentives to cus-
tomers are not material. Historical data is readily available and
reliable, and is used for estimating the amount of the reduction in
gross sales. Revenue from the launch of a new product, from an
improved version of an existing product, or for shipments in
excess of a customer’s normal requirements are recorded when
the conditions noted above are met. In those situations, manage-
ment records a returns reserve for such revenue, if necessary.
In certain of Abbott’s businesses, primarily within diagnostics,
Abbott participates in selling arrangements that include multiple
performance obligations (e.g., instruments, reagents, procedures,
and service agreements). The total transaction price of the con-
tract is allocated to each performance obligation in an amount
based on the estimated relative standalone selling prices of the
promised goods or services underlying each performance obliga-
tion. Sales of product rights for marketable products are recorded
as revenue upon disposition of the rights.
Income Taxes — Deferred income taxes are provided for the tax
effect of differences between the tax bases of assets and liabilities
and their reported amounts in the financial statements at the
enacted statutory rate to be in effect when the taxes are paid. No
additional income taxes have been provided for any remaining
undistributed foreign earnings not subject to the transition tax
related to the U.S. Tax Cuts and Jobs Act (TCJA), or any additional
outside basis differences that exist, as these amounts continue to
be indefinitely reinvested in foreign operations. Effective for fiscal
years beginning after December 31, 2017, the TCJA subjects tax-
payers to tax on global intangible low-taxed income (GILTI)
earned by certain foreign subsidiaries. Abbott treats the GILTI tax
as a period expense and provides for the tax in the year that the
tax is incurred. Interest and penalties on income tax obligations
are included in taxes on earnings.
Earnings Per Share — Unvested restricted stock units and awards
that contain non-forfeitable rights to dividends are treated as
participating securities and are included in the computation of
earnings per share under the two-class method. Under the two-
class method, net earnings are allocated between common shares
and participating securities. Earnings from Continuing Operations
allocated to common shares in 2022, 2021 and 2020 were
$6.905 billion, $7.042 billion and $4.449 billion, respectively. Net
earnings allocated to common shares in 2022, 2021 and 2020 were
$6.905 billion, $7.042 billion and $4.473 billion, respectively.
Pension and Post-Employment Benefits — Abbott accrues for the
actuarially determined cost of pension and post-employment
benefits over the service attribution periods of the employees.
Abbott must develop long-term assumptions, the most significant
of which are the health care cost trend rates, discount rates and
the expected return on plan assets. Differences between the
expected long-term return on plan assets and the actual return are
amortized over a five-year period. Actuarial losses and gains are
amortized over the remaining service attribution periods of the
employees under the corridor method.
Fair Value Measurements — For assets and liabilities that are
measured using quoted prices in active markets, total fair value is
the published market price per unit multiplied by the number of
units held without consideration of transaction costs. Assets and
liabilities that are measured using significant other observable
inputs are valued by reference to similar assets or liabilities,
adjusted for contract restrictions and other terms specific to
that asset or liability. For these items, a significant portion of
fair value is derived by reference to quoted prices of similar
assets or liabilities in active markets. For all remaining assets and
liabilities, fair value is derived using a fair value model, such as a
discounted cash flow model or Black-Scholes model. Purchased
intangible assets are recorded at fair value. The fair value of
significant purchased intangible assets is based on independent
appraisals. Abbott uses a discounted cash flow model to value
intangible assets. The discounted cash flow model requires
assumptions about the timing and amount of future net cash flows,
risk, the cost of capital, terminal values and market participants.
Intangible assets are reviewed for impairment on a quarterly basis.
Goodwill and indefinite-lived intangible assets are tested for
impairment at least annually.
Share-Based Compensation — The fair value of stock options
and restricted stock awards and units are amortized over their
requisite service period, which could be shorter than the vesting
period if an employee is retirement eligible, with a charge to
compensation expense.

-- 45 of 86 --

44
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. Legal fees are recorded as incurred.
Cash, Cash Equivalents and Investments — Cash equivalents
consist of bank time deposits, U.S. government securities, money
market funds and U.S. treasury bills with original maturities of
three months or less. Abbott holds certain investments with a
carrying value of $169 million that are accounted for under the
equity method of accounting. Investments held in a rabbi trust
and investments in publicly traded equity securities are recorded
at fair value and changes in fair value are recorded in earnings.
Investments in equity securities that are not traded on public stock
exchanges are recorded at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly
transactions for identical or similar investments of the same issuer.
Trade Receivable Valuations — Accounts receivable are stated at
the net amount expected to be collected. The allowance for doubt-
ful accounts reflects the current estimate of credit losses expected
to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjust-
ing its allowance for doubtful accounts, including the aging of the
accounts and aging trends, the historical level of charge-offs, and
specific exposures related to particular customers. Abbott also
monitors other risk factors and forward-looking information, such
as country risk, when determining credit limits for customers and
establishing adequate allowances. Accounts receivable are charged
off after all reasonable means to collect the full amount (including
litigation, where appropriate) have been exhausted.
Inventories — Inventories are stated at the lower of cost (first-in,
first-out basis) or net realizable value. Cost includes material and
conversion costs.
Property and Equipment — Depreciation and amortization are
provided on a straight-line basis over the estimated useful lives of
the assets. The following table shows estimated useful lives of
property and equipment:
Classification 	Estimated Useful Lives
Buildings 	10 to 50 years
Equipment 	2 to 20 years
Product Liability — Abbott accrues for product liability claims
when it is probable that a liability has been incurred and the
amount of the liability can be reasonably estimated based on
existing information. The liabilities are adjusted quarterly as
additional information becomes available. Product liability losses
are self-insured.
Research and Development Costs — Internal research and develop-
ment costs are expensed as incurred. Clinical trial costs incurred
by third parties are expensed as the contracted work is performed.
Where contingent milestone payments are due to third parties
under research and development arrangements, the milestone
payment obligations are expensed when the milestone results
are achieved.
Acquired In-Process and Collaborations Research and Development
(IPR&D) — The initial costs of rights to IPR&D projects obtained
in an asset acquisition are expensed as IPR&D unless the project
has an alternative future use. These costs include initial payments
incurred prior to regulatory approval in connection with research
and development collaboration agreements that provide rights
to develop, manufacture, market and/or sell pharmaceutical or
medical device products. The fair value of IPR&D projects
acquired in a business combination are capitalized and accounted
for as indefinite-lived intangible assets until completed and are
then amortized over the remaining useful life. Collaborations are
not significant.
Concentration of Risk and Guarantees — Due to the nature of its
operations, Abbott is not subject to significant concentration risks
relating to customers, products or geographic locations. Product
warranties are not significant.
Abbott has no material exposures to off-balance sheet arrange-
ments; no special purpose entities; nor activities that include
non-exchange-traded contracts accounted for at fair value. Abbott
periodically acquires a business or product rights in which Abbott
agrees to pay contingent consideration based on attaining certain
thresholds or based on the occurrence of certain events.
NOTE 2 — NEW ACCOUNTING STANDARDS
RECENTLY ADOPTED ACCOUNTING STANDARDS
In December 2020, the FASB issued ASU 2019-12, Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes, which
among other things, eliminates certain exceptions in the current
rules regarding the approach for intraperiod tax allocations and
the methodology for calculating income taxes in an interim period,
and clarifies the accounting for transactions that result in a
step-up in the tax basis of goodwill. Abbott adopted the standard
on January 1, 2021. The new standard did not have an impact on
its consolidated financial statements.
RECENT ACCOUNTING STANDARDS NOT YET ADOPTED
In September 2022, the FASB issued ASU 2022-04, Disclosure
of Supplier Finance Program Obligations, which requires an entity
to report information about its supplier finance program. The
standard becomes effective for Abbott in the first quarter of 2023.
Abbott does not expect adoption of this new standard to have a
material impact on its consolidated financial statements.
NOTE 3 — REVENUE
Abbott’s revenues are derived primarily from the sale of a
broad line of health care products under short-term receivable
arrangements. Patent protection and licenses, technological and
performance features, and inclusion of Abbott’s products under
a contract most impact which products are sold; price controls,
competition and rebates most impact the net selling prices of
products; and foreign currency translation impacts the measure-
ment of net sales and costs. Abbott’s products are generally sold
directly to retailers, wholesalers, distributors, hospitals, health
care facilities, laboratories, physicians’ offices and government
agencies throughout the world. Abbott has four reportable seg-
ments: Established Pharmaceutical Products, Diagnostic Products,
Nutritional Products, and Medical Devices.

-- 46 of 86 --

45
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following tables provide detail by sales category:
2022 	2021 	2020
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$÷÷÷÷— 	$÷3,728 	$÷3,728 	$÷÷÷÷— 	$÷3,539 	$÷3,539 	$÷÷÷÷— 	$÷3,209 	$÷3,209
Other 	— 	1,184 	1,184 	— 	1,179 	1,179 	— 	1,094 	1,094
Total 	— 	4,912 	4,912 	— 	4,718 	4,718 	— 	4,303 	4,303
Nutritionals —
Pediatric Nutritionals 	1,562 	1,919 	3,481 	2,192 	2,106 	4,298 	1,987 	2,140 	4,127
Adult Nutritionals 	1,357 	2,621 	3,978 	1,364 	2,632 	3,996 	1,292 	2,228 	3,520
Total 	2,919 	4,540 	7,459 	3,556 	4,738 	8,294 	3,279 	4,368 	7,647
Diagnostics —
Core Laboratory 	1,137 	3,751 	4,888 	1,145 	3,983 	5,128 	1,166 	3,309 	4,475
Molecular 	370 	625 	995 	566 	861 	1,427 	621 	817 	1,438
Point of Care 	372 	153 	525 	384 	152 	536 	369 	147 	516
Rapid Diagnostics 	6,767 	3,409 	10,176 	5,034 	3,519 	8,553 	2,618 	1,758 	4,376
Total 	8,646 	7,938 	16,584 	7,129 	8,515 	15,644 	4,774 	6,031 	10,805
Medical Devices —
Rhythm Management 	1,029 	1,090 	2,119 	1,018 	1,180 	2,198 	903 	1,011 	1,914
Electrophysiology 	909 	1,018 	1,927 	778 	1,129 	1,907 	660 	918 	1,578
Heart Failure 	694 	226 	920 	654 	235 	889 	547 	193 	740
Vascular 	864 	1,619 	2,483 	915 	1,739 	2,654 	853 	1,486 	2,339
Structural Heart 	818 	894 	1,712 	730 	880 	1,610 	540 	707 	1,247
Neuromodulation 	619 	151 	770 	616 	165 	781 	564 	138 	702
Diabetes Care 	1,633 	3,123 	4,756 	1,212 	3,116 	4,328 	864 	2,403 	3,267
Total 	6,566 	8,121 	14,687 	5,923 	8,444 	14,367 	4,931 	6,856 	11,787
Other 	11 	— 	11 	34 	18 	52 	38 	28 	66
Total 	$18,142 	$25,511 	$43,653 	$16,642 	$26,433 	$43,075 	$13,022 	$21,586 	$34,608
Products sold by the Diagnostics segment include various types of
diagnostic tests to detect the COVID-19 coronavirus. Abbott’s
COVID-19 testing-related sales totaled approximately $8.4 billion
in 2022, $7.7 billion in 2021, and $3.9 billion in 2020.
Abbott recognizes revenue from product sales upon the transfer of
control, which is generally upon shipment or delivery, depending
on the delivery terms set forth in the customer contract. For main-
tenance agreements that provide service beyond Abbott’s standard
warranty and other service agreements, revenue is recognized
ratably over the contract term. A time-based measure of progress
appropriately reflects the transfer of services to the customer.
Payment terms between Abbott and its customers vary by the type of
customer, country of sale, and the products or services offered. The
term between invoicing and the payment due date is not significant.
Management exercises judgment in estimating variable consider-
ation. Provisions for discounts, rebates and sales incentives to
customers, and returns and other adjustments are provided for in
the period the related sales are recorded. Sales incentives to cus-
tomers are not material. Historical data is readily available and
reliable, and is used for estimating the amount of the reduction in
gross sales. Abbott provides rebates to government agencies, whole-
salers, group purchasing organizations and other private entities.
Rebate amounts are usually based upon the volume of purchases
using contractual or statutory prices for a product. Factors used in
the rebate calculations include the identification of which prod-
ucts have been sold subject to a rebate, which customer or
government agency price terms apply, and the estimated lag time
between sale and payment of a rebate. Using historical trends,
adjusted for current changes, Abbott estimates the amount of the
rebate that will be paid, and records the liability as a reduction of
gross sales when Abbott records its sale of the product. Settlement
of the rebate generally occurs from one to six months after sale.
Abbott regularly analyzes the historical rebate trends and makes
adjustments to reserves for changes in trends and terms of rebate
programs. Historically, adjustments to prior years’ rebate accruals
have not been material to net income.
Other allowances charged against gross sales include cash discounts
and returns, which are not significant. Cash discounts are known
within 15 to 30 days of sale, and therefore can be reliably estimated.
Returns can be reliably estimated because Abbott’s historical
returns are low, and because sales return terms and other sales
terms have remained relatively unchanged for several periods.
Product warranties are also not significant.
Abbott also applies judgment in determining the timing of revenue
recognition related to contracts that include multiple performance
obligations. The total transaction price of the contract is allocated to
each performance obligation in an amount based on the estimated
relative standalone selling prices of the promised goods or services
underlying each performance obligation. For goods or services for
which observable standalone selling prices are not available, Abbott
uses an expected cost plus a margin approach to estimate the
standalone selling price of each performance obligation.

-- 47 of 86 --

46
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
REMAINING PERFORMANCE OBLIGATIONS
As of December 31, 2022, the estimated revenue expected to be
recognized in the future related to performance obligations that
are unsatisfied (or partially unsatisfied) was approximately
$4 billion in the Diagnostic Products segment and approximately
$432 million in the Medical Devices segment. Abbott expects
to recognize revenue on approximately 60 percent of these
remaining performance obligations over the next 24 months,
approximately 17 percent over the subsequent 12 months and
the remainder thereafter.
These performance obligations primarily reflect the future sale
of reagents/consumables in contracts with minimum purchase
obligations, extended warranty or service obligations related to
previously sold equipment, and remote monitoring services
related to previously implanted devices. Abbott has applied the
practical expedient described in ASC 606-10-50-14 and has not
included remaining performance obligations related to contracts
with original expected durations of one year or less in the
amounts above.
ASSETS RECOGNIZED FOR COSTS TO OBTAIN A
CONTRACT WITH A CUSTOMER
Abbott has applied the practical expedient in ASC 340-40-25-4
and records as an expense the incremental costs of obtaining
contracts with customers in the period of occurrence when the
amortization period of the asset that Abbott otherwise would have
recognized is one year or less. Upfront commission fees paid to
sales personnel as a result of obtaining or renewing contracts with
customers are incremental to obtaining the contract. Abbott capi-
talizes these amounts as contract costs. Capitalized commission
fees are amortized based on the contract duration to which the
assets relate which ranges from two to ten years. The amounts as
of December 31, 2022 and 2021 were not significant.
Additionally, the cost of transmitters provided to customers that
use Abbott’s remote monitoring service with respect to certain
medical devices are capitalized as contract costs. Capitalized
transmitter costs are amortized based on the timing of the transfer
of services to which the assets relate, which typically ranges from
eight to ten years. The amounts as of December 31, 2022 and 2021
were not significant.
OTHER CONTRACT ASSETS AND LIABILITIES
Abbott discloses Trade receivables separately in the Consolidated
Balance Sheet at the net amount expected to be collected. Contract
assets primarily relate to Abbott’s conditional right to consideration
for work completed but not billed at the reporting date. Contract
assets at the beginning and end of the period, as well as the
changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from
customers in advance of performance under the contract. Abbott’s
contract liabilities arise primarily in the Medical Devices
reportable segment when payment is received upfront for various
multi-period extended service arrangements. Changes in the
contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2020 	$«405
Unearned revenue from cash received during the period 	615
Revenue recognized related to contract liability balance 	(500)
Balance at December 31, 2021 	520
Unearned revenue from cash received during the period 	578
Revenue recognized related to contract liability balance 	(598)
Balance at December 31, 2022 	$«500
NOTE 4 — SUPPLEMENTAL FINANCIAL INFORMATION
Other (income) expense, net, for 2022, 2021 and 2020 includes
approximately $406 million, $270 million and $205 million of
income, respectively, related to the non-service cost components
of the net periodic benefit costs associated with the pension and
post-retirement medical plans.
The following summarizes the activity related to the allowance
for doubtful accounts:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2020 	$288
Provisions/charges to income 	51
Amounts charged off and other deductions 	(26)
Balance at December 31, 2021 	313
Provisions/charges to income 	6
Amounts charged off and other deductions 	(57)
Balance at December 31, 2022 	$262
The allowance for doubtful accounts reflects the current estimate
of credit losses expected to be incurred over the life of the
accounts receivable. Abbott considers various factors in establish-
ing, monitoring, and adjusting its allowance for doubtful accounts,
including the aging of the accounts and aging trends, the historical
level of charge-offs, and specific exposures related to particular
customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining
credit limits for customers and establishing adequate allowances.
The detail of various balance sheet components is as follows:
(in millions)
December 31 	2022 	2021
Long-term Investments:
Equity securities 	$558 	$748
Other 	208 	68
Total 	$766 	$816

-- 48 of 86 --

47
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The decrease in Abbott’s long-term investments as of
December 31, 2022 versus the balance as of December 31, 2021
primarily relates to a decrease in the fair value of investments held
in a rabbi trust, the impact of asset impairments and a distribution
from an investment held in a joint venture partially offset by
increased investment in long-term time deposits.
Abbott’s equity securities as of December 31, 2022 and December 31,
2021, include $298 million and $391 million, respectively, of invest-
ments in mutual funds that are held in a rabbi trust acquired as part
of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition.
These investments, which are specifically designated as available for
the purpose of paying benefits under a deferred compensation plan,
are not available for general corporate purposes and are subject to
creditor claims in the event of insolvency.
Abbott also holds certain investments as of December 31, 2022
with a carrying value of $169 million that are accounted for under
the equity method of accounting and other equity investments
with a carrying value of $83 million that do not have a readily
determinable fair value.
In September 2021, Abbott acquired 100 percent of Walk Vascular,
LLC (Walk Vascular), a commercial-stage medical device com-
pany with a minimally invasive thrombectomy system designed to
remove peripheral blood clots. Walk Vascular’s peripheral throm-
bectomy system has been incorporated into Abbott’s existing
endovascular portfolio. The purchase price, the allocation of
acquired assets and liabilities, and the revenue and net income
contributed by Walk Vascular since the date of acquisition are not
material to Abbott’s consolidated financial statements.
(in millions)
December 31 	2022 	2021
Other Accrued Liabilities:
Accrued rebates payable to government agencies 	$÷«638 	$÷«364
Accrued other rebates (a) 	1,087 	1,082
All other 	4,120 	3,735
Total 	$5,845 	$5,181
(a) Accrued wholesaler chargeback rebates of $234 million and $211 million at December 31, 2022
and 2021, respectively, are netted in trade receivables because Abbott’s customers are invoiced
at a higher catalog price but only remit to Abbott their contract price for the products.
(in millions)
December 31 	2022 	2021
Post-employment Obligations and
Other Long-term Liabilities:
Defined benefit pension plans and post-employment
medical and dental plans for significant plans 	$1,784 	$2,738
Deferred income taxes 	991 	1,392
Operating lease liabilities 	943 	956
All other (b) 	3,804 	3,685
Total 	$7,522 	$8,771
(b) Includes approximately $850 million and $680 million of net unrecognized tax benefits
in 2022 and 2021, respectively.
NOTE 5 — ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
The components of the changes in accumulated other comprehensive income (loss) from continuing operations, net of income taxes,
are as follows:
(in millions)
Cumulative Foreign
Currency Translation
Adjustments
Net Actuarial Gains
(Losses) and Prior
Service (Costs)
and Credits
Cumulative Gains
(Losses) on Derivative
Instruments Designated
as Cash Flow Hedges 	Total
Balance at December 31, 2020 	$(4,859) 	$(3,871) 	$(216) 	$(8,946)
Other comprehensive income (loss) before reclassifications 	(980) 	954 	137 	111
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	— 	247 	214 	461
Net current period other comprehensive income (loss) 	(980) 	1,201 	351 	572
Balance at December 31, 2021 	(5,839) 	(2,670) 	135 	(8,374)
Other comprehensive income (loss) before reclassifications 	(894) 	1,007 	199 	312
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	— 	170 	(159) 	11
Net current period other comprehensive income (loss) 	(894) 	1,177 	40 	323
Balance at December 31, 2022 	$(6,733) 	$(1,493) 	$«175 	$(8,051)
(a) (Income) loss amounts reclassified from accumulated other comprehensive income related to cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost
is included as a component of net periodic benefit cost – see Note 13 for additional information.

-- 49 of 86 --

48
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 6 — GOODWILL AND INTANGIBLE ASSETS
The total amount of goodwill reported was $22.8 billion at
December 31, 2022 and $23.2 billion at December 31, 2021.
Foreign currency translation adjustments decreased goodwill by
$431 million in 2022 and by $532 million in 2021. The amount of
goodwill related to reportable segments at December 31, 2022 was
$2.7 billion for the Established Pharmaceutical Products segment,
$286 million for the Nutritional Products segment, $3.6 billion for
the Diagnostic Products segment, and $16.2 billion for the Medical
Devices segment. There were no reductions of goodwill relating
to impairments in 2022 and 2021.
Indefinite-lived intangible assets, which relate to IPR&D acquired
in a business combination, were approximately $807 million and
$919 million at December 31, 2022 and 2021, respectively. In 2022,
$111 million of impairment charges were recorded on the Research
and development line of the Consolidated Statement of Earnings
related to certain IPR&D intangible assets associated with the
Medical Devices business segment.
The gross amount of amortizable intangible assets, primarily
product rights and technology, was $27.2 billion and $27.7 billion
as of December 31, 2022 and 2021, respectively, and accumulated
amortization was $17.6 billion and $15.9 billion as of December 31,
2022 and 2021, respectively. Foreign currency translation adjust-
ments decreased intangible assets by $150 million in 2022 and by
$197 million in 2021. The estimated annual amortization expense
for intangible assets recorded at December 31, 2022 is approxi-
mately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in
2025, $1.5 billion in 2026 and $1.2 billion in 2027. Amortizable
intangible assets are amortized over 2 to 20 years.
NOTE 7 — RESTRUCTURING PLANS
In 2022, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in
its medical devices, nutritional, diagnostic, and established
pharmaceutical businesses. Abbott recorded employee related
severance and other charges of approximately $234 million of
which approximately $59 million was recorded in Cost of products
sold, approximately $36 million was recorded in Research and
development and approximately $139 million was recorded in
Selling, general and administrative expenses. In addition, Abbott
recognized inventory related charges of approximately $23 million
and fixed assets impairment charges of approximately $4 million
related to these restructuring plans.
The following summarizes the activity related to these
restructuring actions and the status of the related accruals
as of December 31, 2022:
(in millions)
Restructuring charges in 2022 	$234
Payments and other adjustments 	(6)
Accrued balance at December 31, 2022 	$228
On May 27, 2021, Abbott management approved a restructuring
plan related to its Diagnostic Products segment to align its manu-
facturing network for COVID-19 diagnostic tests with changes in
the second quarter of 2021 in projected testing demand driven by
several factors, including significant reductions in cases in the U.S.
and other major developed countries, the accelerated rollout
of COVID-19 vaccines globally and the U.S. health authority’s
updated guidance on testing for fully vaccinated individuals.
In the second quarter of 2021, Abbott recorded charges of
$499 million under this plan in Cost of products sold. The charge
recognized in the second quarter included fixed asset write-downs
of $80 million, inventory-related charges of $248 million, and
other exit costs, which included contract cancellations and
employee-related costs of $171 million.
In the second half of 2021, as the Delta and Omicron variants
of COVID-19 spread and the number of new COVID-19 cases
increased significantly, particularly in the U.S., demand for rapid
COVID-19 tests increased significantly. As a result, in the second
half of 2021, Abbott sold approximately $181 million of inventory
that was previously estimated to have no net realizable value
under the second quarter restructuring action. In addition, the
estimate of other exit costs was reduced by a net $58 million as
Abbott fulfilled its purchase obligations under certain contracts
for which a liability was recorded in the second quarter or Abbott
settled with the counterparty in the second half of 2021.
The following summarizes the activity related to this restructuring
action and the status of the related accruals as of December 31,
2022:
(in millions)
Inventory-
Related
Charges
Fixed
Asset
Write-
Downs
Other
Exit
Costs 	Total
Restructuring charges
recorded in 2021 	$«248 	$«80 	$113 	$«441
Payments 	— 	— 	(90) 	(90)
Other non-cash 	(248) 	(80) 	— 	(328)
Accrued balance at
December 31, 2021 	— 	— 	23 	23
Payments and other
adjustments 	— 	— 	(10) 	(10)
Accrued balance at
December 31, 2022 	$÷÷— 	$÷— 	$÷13 	$÷«13
In 2021, Abbott management approved plans to streamline opera-
tions in order to reduce costs and improve efficiencies in Abbott’s
diagnostic, established pharmaceutical, nutritional, and medical
device businesses. Abbott recorded employee related severance
and other charges of approximately $68 million of which approxi-
mately $16 million was recorded in Cost of products sold,
approximately $4 million was recorded in Research and develop-
ment and approximately $48 million was recorded in Selling,
general and administrative expenses.
The following summarizes the activity for these restructuring actions
and the status of the related accruals as of December 31, 2022:
(in millions)
Restructuring charges recorded in 2021 	$«68
Payments and other adjustments 	(7)
Accrued balance at December 31, 2021 	61
Payments and other adjustments 	(46)
Accrued balance at December 31, 2022 	$«15

-- 50 of 86 --

49
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 8 — INCENTIVE STOCK PROGRAM
The 2017 Incentive Stock Program authorizes the granting of
nonqualified stock options, restricted stock awards, restricted
stock units, performance awards, foreign benefits and other share-
based awards. Stock options and restricted stock awards and units
comprise the majority of benefits that have been granted and are
currently outstanding under this program and a prior program.
In 2022, Abbott granted 2,634,647 stock options, 514,205 restricted
stock awards and 5,487,715 restricted stock units under this program.
Under Abbott’s stock incentive programs, the purchase price of
shares under option must be at least equal to the fair market value
of the common stock on the date of grant, and the maximum term
of an option is 10 years. Options generally vest equally over three
years. Restricted stock awards generally vest over three years, with
no more than one-third of the award vesting in any one year upon
Abbott reaching a minimum return on equity target. Restricted
stock units vest over three years and upon vesting, the recipient
receives one share of Abbott stock for each vested restricted stock
unit. The aggregate fair market value of options and restricted
stock awards and units is recognized as expense over the requisite
service period, which may be shorter than the vesting period if an
employee is retirement eligible. Forfeitures are estimated at the
time of grant. Restricted stock awards and settlement of vested
restricted stock units are issued out of treasury shares. Abbott
generally issues new shares for exercises of stock options. As a
policy, Abbott does not purchase its shares relating to its share-
based programs.
In April 2017, Abbott’s shareholders authorized the 2017 Incentive
Stock Program under which a maximum of 170 million shares
were available for issuance. At December 31, 2022, approximately
87 million shares remained available for future issuance.
The following table summarizes stock option activity for the year
ended December 31, 2022 and the outstanding stock options as of
December 31, 2022.
(intrinsic values in millions) 	Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Life (Years)
Aggregate
Intrinsic Value
Outstanding at December 31, 2021 	27,199,851 	$÷65.16 	5.7 	$2,056
Granted 	2,634,647 	117.54
Exercised 	(1,520,074) 	53.06
Lapsed 	(26,378) 	110.72
Outstanding at December 31, 2022 	28,288,046 	$÷70.64 	5.3 	$1,167
Exercisable at December 31, 2022 	22,553,089 	$÷59.87 	4.5 	$1,139

-- 51 of 86 --

50
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes restricted stock awards and units
activity for the year ended December 31, 2022.
Share Units
Weighted
Average
Grant-Date
Fair Value
Outstanding at December 31, 2021 	10,558,525 	$102.40
Granted 	6,001,920 	117.34
Vested 	(5,456,368) 	94.20
Forfeited 	(703,749) 	113.18
Outstanding at December 31, 2022 	10,400,328 	$114.59
The fair market value of restricted stock awards and units vested
in 2022, 2021 and 2020 was $639 million, $809 million and
$631 million, respectively.
The total intrinsic value of options exercised in 2022, 2021 and
2020 was $85 million, $393 million and $279 million, respectively.
The total unrecognized compensation cost related to all share-
based compensation plans at December 31, 2022 amounted to
approximately $494 million, which is expected to be recognized
over the next three years.
Total non-cash stock compensation expense charged against
income from continuing operations in 2022, 2021 and 2020 for
share-based plans totaled approximately $685 million, $640 million
and $546 million, respectively, and the tax benefit recognized
was approximately $170 million, $267 million and $200 million,
respectively. Stock compensation cost capitalized as part of
inventory is not significant.
The table below summarizes the fair value of an option granted
in 2022, 2021 and 2020 and the assumptions included in the
Black-Scholes option-pricing model used to estimate the fair value:
2022 	2021 	2020
Fair value 	$25.26 	$24.17 	$14.39
Risk-free interest rate 	1.9% 	0.8% 	1.3%
Average life of options (years) 	6.0 	6.0 	6.0
Volatility 	23.8% 	23.8% 	19.4%
Dividend yield 	1.6% 	1.5% 	1.6%
The risk-free interest rate is based on the rates available at the
time of the grant for zero-coupon U.S. government issues with a
remaining term equal to the option’s expected life. The average life
of an option is based on both historical and projected exercise and
lapsing data. Expected volatility is based on implied volatilities
from traded options on Abbott’s stock and historical volatility of
Abbott’s stock over the expected life of the option. Dividend yield
is based on the option’s exercise price and annual dividend rate
at the time of grant.
NOTE 9 — DEBT AND LINES OF CREDIT
The following is a summary of long-term debt at December 31:
(in millions) 	2022 	2021
2.55% Notes, due 2022 	$÷÷÷÷— 	$÷÷«750
0.875% Notes, due 2023 	1,215 	1,294
3.40% Notes, due 2023 	1,050 	1,050
5-year term loan due 2024 	446 	521
0.10% Notes, due 2024 	629 	670
3.875% Notes, due 2025 	500 	500
2.95% Notes, due 2025 	1,000 	1,000
1.50% Notes, due 2026 	1,215 	1,294
3.75% Notes, due 2026 	1,700 	1,700
0.375% Notes, due 2027 	629 	670
1.15% Notes, due 2028 	650 	650
1.40% Notes, due 2030 	650 	650
4.75% Notes, due 2036 	1,650 	1,650
6.15% Notes, due 2037 	547 	547
6.00% Notes, due 2039 	515 	515
5.30% Notes, due 2040 	694 	694
4.75% Notes, due 2043 	700 	700
4.90% Notes, due 2046 	3,250 	3,250
Unamortized debt issuance costs 	(71) 	(78)
Other, including fair value adjustments
relating to interest rate hedge contracts
designated as fair value hedges 	(196) 	23
Total carrying amount of long-term debt 	16,773 	18,050
Less: Current portion 	2,251 	754
Total long-term portion 	$14,522 	$17,296
On March 15, 2022, Abbott repaid the $750 million outstanding
principal amount of its 2.55% Notes upon maturity.
On June 24, 2020, Abbott completed the issuance of $1.3 billion
aggregate principal amount of senior notes, consisting of
$650 million of its 1.15% Notes due 2028 and $650 million of
its 1.40% Notes due 2030.
On September 28, 2020, Abbott repaid the €1.140 billion outstand-
ing principal amount of its 0.00% Notes due 2021 upon maturity.
The repayment equated to approximately $1.3 billion.
Abbott has readily available financial resources, including
unused lines of credit that support commercial paper borrowing
arrangements and provide Abbott with the ability to borrow up to
$5 billion on an unsecured basis. The lines of credit are part of a
Five Year Credit Agreement (Revolving Credit Agreement) that
Abbott entered into on November 12, 2020. Any borrowings under
the Revolving Credit Agreement will mature and be payable on
November 12, 2025, and will bear interest, at Abbott’s option,
based on either a base rate or Eurodollar rate, plus an applicable
margin based on Abbott’s credit ratings.

-- 52 of 86 --

51
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
In September 2019, the board of directors approved a bond
redemption authorization for the early redemption of up to
$5 billion of outstanding long-term debt. Of the $5 billion authori-
zation, $2.15 billion remains available as of December 31, 2022.
Principal payments required on long-term debt outstanding at
December 31, 2022 are $2.3 billion in 2023, $1.1 billion in 2024,
$1.5 billion in 2025, $2.9 billion in 2026, $0.6 billion in 2027 and
$8.7 billion in 2028 and thereafter.
At December 31, 2022, Abbott’s long-term debt rating was AA-
by Standard & Poor’s Corporation and A1 by Moody’s.
In December 2021, Abbott repaid a short-term facility for
approximately $195 million. After the repayment, Abbott has
no short-term borrowings.
NOTE 10 — LEASES
LEASES WHERE ABBOTT IS THE LESSEE
Abbott has entered into operating leases as the lessee for office
space, manufacturing facilities, R&D laboratories, warehouses,
vehicles and equipment. Finance leases are not significant.
Abbott’s operating leases generally have remaining lease terms
of 1 to 10 years. Some leases include options to extend beyond
the original lease term, generally up to 10 years and some include
options to terminate early. These options have been included
in the determination of the lease liability when it is reasonably
certain that the option will be exercised.
For all of its asset classes, Abbott elected the practical expedient
allowed under FASB ASC No. 842, “Leases” to account for each
lease component (e.g., the right to use office space) and the
associated non-lease components (e.g., maintenance services) as
a single lease component. Abbott also elected the short-term
lease accounting policy for all asset classes; therefore, Abbott is
not recognizing a lease liability or right of use (ROU) asset for
any lease that, at the commencement date, has a lease term of
12 months or less and does not include an option to purchase the
underlying asset that Abbott is reasonably certain to exercise.
As Abbott’s leases typically do not provide an implicit rate,
the interest rate used to determine the present value of the pay-
ments under each lease typically reflects Abbott’s incremental
borrowing rate based on information available at the lease
commencement date.
The following table provides information related to Abbott’s
operating leases:
(in millions, except weighted averages) 	2022 	2021 	2020
Operating lease cost (a) 	$355 	$359 	$329
Cash paid for amounts included in the
measurement of operating lease liabilities 	274 	287 	264
ROU assets arising from entering into new
operating lease obligations 	263 	343 	396
Weighted average remaining lease term at
December 31 (in years) 	8 	8 	8
Weighted average discount rate at December 31 	2.9% 	2.7% 	3.2%
(a) Includes short-term lease expense and variable lease costs, which were immaterial in the
years ended December 31, 2022, 2021 and 2020.
Future minimum lease payments under non-cancellable operating
leases as of December 31, 2022 were as follows:
(in millions)
2023 	$÷«258
2024 	218
2025 	182
2026 	151
2027 	110
Thereafter 	422
Total future minimum lease payments – undiscounted 	1,341
Less: imputed interest 	(168)
Present value of lease liabilities 	$1,173
The following table summarizes the amounts and location of
operating lease ROU assets and lease liabilities:
(in millions)
December 31 	2022 	2021 	Balance Sheet Caption
Operating Lease –
ROU Asset
$1,116 	$1,153 	Deferred income taxes
and other assets
Operating Lease Liability:
Current 	$÷«230 	$÷«245 	Other accrued liabilities
Non-current 	943 	956 	Post-employment
obligations and other
long-term liabilities
Total Liability 	$1,173 	$1,201

-- 53 of 86 --

52
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
LEASES WHERE ABBOTT IS THE LESSOR
Certain assets, primarily diagnostics instruments, are leased to
customers under contractual arrangements that typically include
an operating or sales-type lease as well as performance obligations
for reagents and other consumables. Sales-type leases are not
significant. Contract terms vary by customer and may include
options to terminate the contract or options to extend the contract.
Where instruments are provided under operating lease arrange-
ments, some portion or the entire lease revenue may be variable
and subject to subsequent non-lease component (e.g., reagent)
sales. The allocation of revenue between the lease and non-lease
components is based on standalone selling prices. Operating lease
revenue represented less than 3 percent of Abbott’s total net sales
in the years ended December 31, 2022, 2021 and 2020.
Assets related to operating leases are reported within Net property
and equipment on the Consolidated Balance Sheet. The original
cost and the net book value of such assets were $3.6 billion and
$1.6 billion, respectively, as of December 31, 2022 and $3.5 billion
and $1.6 billion, respectively, as of December 31, 2021.
NOTE 11 — FINANCIAL INSTRUMENTS, DERIVATIVES AND
FAIR VALUE MEASURES
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates primarily for anticipated intercompany
purchases by those subsidiaries whose functional currencies are
not the U.S. dollar. These contracts, with gross notional amounts
totaling $7.7 billion at December 31, 2022, and $8.6 billion at
December 31, 2021, are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign exchange
rates and are recorded at fair value. Accumulated gains and losses
as of December 31, 2022 will be included in Cost of products
sold at the time the products are sold, generally through the
next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts
to manage currency exposures for foreign currency denominated
third-party trade payables and receivables, and for intercompany
loans and trade accounts payable where the receivable or payable
is denominated in a currency other than the functional currency of
the entity. For intercompany loans, the contracts require Abbott to
sell or buy foreign currencies, primarily European currencies, in
exchange for primarily U.S. dollars and European currencies. For
intercompany and trade payables and receivables, the currency
exposures are primarily the U.S. dollar and European currencies.
At December 31, 2022 and 2021, Abbott held gross notional
amounts of $12.0 billion and $12.2 billion, respectively, of such
foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of
approximately $446 million and $521 million as of December 31, 2022
and December 31, 2021, respectively, as a hedge of the net investment
in certain foreign subsidiaries. The change in the value of the debt,
which is due to changes in foreign exchange rates, is recorded in
Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts totaling approxi-
mately $2.9 billion at December 31, 2022 and 2021, to manage its
exposure to changes in the fair value of fixed-rate debt. These
contracts are designated as fair value hedges of the variability of
the fair value of fixed-rate debt due to changes in the long-term
benchmark interest rates. The effect of the hedge is to change a
fixed-rate interest obligation to a variable rate for that portion of
the debt. Abbott records the contracts at fair value and adjusts the
carrying amount of the fixed-rate debt by an offsetting amount.

-- 54 of 86 --

53
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the amounts and location of certain derivative financial instruments as of December 31:
(in millions)
Fair Value—Assets 	Fair Value—Liabilities
2022 	2021 	Balance Sheet Caption 	2022 	2021 	Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current 	$÷«— 	$÷87 	Deferred income taxes
and other assets
$136 	$÷«— 	Post-employment
obligations and other
long-term liabilities
Current 	— 	— 	20 	— 	Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments 	304 	222 	Other prepaid expenses
and receivables
96 	65 	Other accrued liabilities
Others not designated as hedges 	108 	70 	Other prepaid expenses
and receivables
130 	32 	Other accrued liabilities
Debt designated as a hedge of net investment in a
foreign subsidiary
— 	— 	n/a 	446 	521 	Long-term debt
$412 	$379 	$828 	$618
The following table summarizes the activity for foreign currency
forward exchange contracts designated as cash flow hedges, debt
designated as a hedge of net investment in a foreign subsidiary
and certain other derivative financial instruments, as well as
the amounts and location of income (expense) and gain (loss)
reclassified into income.
(in millions)
Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Income Statement Caption	2022 	2021 	2020 	2022 	2021 	2020
Foreign currency forward exchange contracts
designated as cash flow hedges
$281 	$164 	$(207) 	$234 	$(252) 	$102 	Cost of products sold
Debt designated as a hedge of net investment in a
foreign subsidiary
75 	56 	(31) 	n/a 	n/a 	n/a 	n/a
Interest rate swaps designated as fair value hedges 	n/a 	n/a 	n/a 	(243) 	(123) 	162 	Interest expense
A gain of $70 million, a gain of $19 million and a loss of
$171 million were recognized in 2022, 2021 and 2020, respectively,
related to foreign currency forward exchange contracts not desig-
nated as hedges. These amounts are reported in the Consolidated
Statement of Earnings on the Net foreign exchange (gain) loss line.
The interest rate swaps are designated as fair value hedges of the
variability of the fair value of fixed-rate debt due to changes in
the long-term benchmark interest rates. The hedged debt is
marked to market, offsetting the effect of marking the interest
rate swaps to market.
The carrying values and fair values of certain financial instruments
as of December 31 are shown in the table below. The carrying values
of all other financial instruments approximate their estimated fair
values. The counterparties to financial instruments consist of select
major international financial institutions. Abbott does not expect
any losses from nonperformance by these counterparties.
(in millions)
2022 	2021
Carrying Value 	Fair Value 	Carrying Value 	Fair Value
Long-term Investment Securities:
Equity securities 	$÷÷÷558 	$÷÷÷558 	$÷÷÷748 	$÷÷÷748
Other 	208 	208 	68 	68
Total long-term debt 	(16,773) 	(16,313) 	(18,050) 	(21,152)
Foreign Currency Forward Exchange Contracts:
Receivable position 	412 	412 	292 	292
(Payable) position 	(226) 	(226) 	(97) 	(97)
Interest Rate Hedge Contracts:
Receivable position 	— 	— 	87 	87
(Payable) position 	(156) 	(156) 	— 	—
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

-- 55 of 86 --

54
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the
balance sheet:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted Prices in
Active Markets
Significant Other
Observable
Inputs
Significant
Unobservable
Inputs
December 31, 2022:
Equity securities 	$÷«307 	$307 	$÷÷÷— 	$÷«—
Foreign currency forward exchange contracts 	412 	— 	412 	—
Total Assets 	$÷«719 	$307 	$÷«412 	$÷«—
Fair value of hedged long-term debt 	$2,691 	$÷«— 	$2,691 	$÷«—
Interest rate swap derivative financial instruments 	156 	— 	156 	—
Foreign currency forward exchange contracts 	226 	— 	226 	—
Contingent consideration related to business combinations 	130 	— 	— 	130
Total Liabilities 	$3,203 	$÷«— 	$3,073 	$130
December 31, 2021:
Equity securities 	$÷«402 	$402 	$÷÷÷— 	$÷«—
Interest rate swap derivative financial instruments 	87 	— 	87 	—
Foreign currency forward exchange contracts 	292 	— 	292 	—
Total Assets 	$÷«781 	$402 	$÷«379 	$÷«—
Fair value of hedged long-term debt 	$2,926 	$÷«— 	$2,926 	$÷«—
Foreign currency forward exchange contracts 	97 	— 	97 	—
Contingent consideration related to business combinations 	130 	— 	— 	130
Total Liabilities 	$3,153 	$÷«— 	$3,023 	$130
The fair value of foreign currency forward exchange contracts is
determined using a market approach, which utilizes values for
comparable derivative instruments. The fair value of the debt was
determined based on the face value of the debt adjusted for the fair
value of the interest rate swaps, which is based on a discounted
cash flow analysis using significant other observable inputs.
Contingent consideration relates to businesses acquired by Abbott.
The fair value of the contingent consideration was determined
based on independent appraisals at the time of acquisition,
adjusted for the time value of money and other changes in fair
value. The maximum amount for certain contingent consideration
is not determinable as it is based on a percent of certain sales.
Excluding such contingent consideration, the maximum amount
that may be due under the other contingent consideration
arrangements was estimated at December 31, 2022 to be approxi-
mately $235 million, which is dependent upon attaining certain
sales thresholds or upon the occurrence of certain events, such
as regulatory approvals.
NOTE 12 — LITIGATION AND ENVIRONMENTAL MATTERS
Abbott has been identified as a potentially responsible party for
investigation and cleanup costs at a number of locations in the
United States and Puerto Rico under federal and state remediation
laws and is investigating potential contamination at a number of
company-owned locations. Abbott has recorded an estimated
cleanup cost for each site for which management believes Abbott
has a probable loss exposure. No individual site cleanup exposure
is expected to exceed $4 million, and the aggregate cleanup
exposure is not expected to exceed $10 million.
Abbott is involved in various claims and legal proceedings,
and Abbott estimates the range of possible loss for its legal
proceedings and environmental exposures to be from approxi-
mately $40 million to $50 million. The recorded accrual balance
at December 31, 2022 for these proceedings and exposures was
approximately $45 million. This accrual represents management’s
best estimate of probable loss, as defined by FASB ASC No. 450,
“Contingencies.” Within the next year, legal proceedings may occur
that may result in a change in the estimated loss accrued by Abbott.
While it is not feasible to predict the outcome of all such proceed-
ings and exposures with certainty, management believes that their
ultimate disposition should not have a material adverse effect on
Abbott’s financial position, cash flows, or results of operations.

-- 56 of 86 --

55
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 13 — POST-EMPLOYMENT BENEFITS
Retirement plans consist of defined benefit, defined contribution and medical and dental plans. Information for Abbott’s major defined
benefit plans and post-employment medical and dental benefit plans is as follows:
(in millions)
Defined Benefit Plans 	Medical and Dental Plans
2022 	2021 	2022 	2021
Projected benefit obligations, January 1 	$12,773 	$13,129 	$1,566 	$«1,567
Service cost — benefits earned during the year 	374 	391 	50 	56
Interest cost on projected benefit obligations 	300 	248 	36 	33
(Gains) losses, primarily changes in discount rates, plan design changes, law changes
and differences between actual and estimated health care costs 	(3,645) 	(463) 	(437) 	(16)
Benefits paid 	(368) 	(340) 	(70) 	(74)
Other, including foreign currency translation 	(267) 	(192) 	(19) 	—
Projected benefit obligations, December 31 	$÷9,167 	$12,773 	$1,126 	$«1,566
Plan assets at fair value, January 1 	$13,468 	$12,018 	$÷«370 	$÷÷353
Actual return (loss) on plan assets 	(1,856) 	1,521 	(33) 	56
Company contributions 	413 	418 	35 	35
Benefits paid 	(368) 	(340) 	(70) 	(74)
Other, including foreign currency translation 	(284) 	(149) 	— 	—
Plan assets at fair value, December 31 	$11,373 	$13,468 	$÷«302 	$÷÷370
Projected benefit obligations less (greater) than plan assets, December 31 	$÷2,206 	$÷÷«695 	$÷(824) 	$(1,196)
Long-term assets 	$÷3,200 	$÷2,270 	$÷÷÷— 	$÷÷÷«—
Short-term liabilities 	(32) 	(31) 	(2) 	(2)
Long-term liabilities 	(962) 	(1,544) 	(822) 	(1,194)
Net asset (liability) 	$÷2,206 	$÷÷«695 	$÷(824) 	$(1,196)
Amounts Recognized in Accumulated Other Comprehensive Income (loss):
Actuarial losses, net 	$÷1,960 	$÷3,062 	$÷÷«27 	$÷÷412
Prior service cost (credits) 	(6) 	(5) 	(33) 	(39)
Total 	$÷1,954 	$÷3,057 	$÷÷÷(6) 	$÷÷373
The $3.6 billion and $463 million of defined benefit plan gains in
2022 and 2021, respectively, that decreased the projected benefit
obligations primarily reflect the year-over-year increases in the
discount rates used to measure the obligations. The $437 million
of medical and dental plan gains in 2022 that decreased the
projected benefit obligations primarily reflect the year-over-year
increase in the discount rates used to measure the obligations.
The projected benefit obligations for non-U.S. defined benefit
plans were $2.2 billion and $3.7 billion at December 31, 2022 and
2021, respectively. The accumulated benefit obligations for all
defined benefit plans were $8.4 billion and $11.5 billion at
December 31, 2022 and 2021, respectively.
For plans where the projected benefit obligations exceeded
plan assets at December 31, 2022 and 2021, the projected benefit
obligations and the aggregate plan assets were as follows:
(in millions) 	2022 	2021
Projected benefit obligation 	$1,270 	$2,632
Fair value of plan assets 	276 	1,057
For plans where the accumulated benefit obligations exceeded
plan assets at December 31, 2022 and 2021, the aggregate accumu-
lated benefit obligations, the projected benefit obligations and the
aggregate plan assets were as follows:
(in millions) 	2022 	2021
Accumulated benefit obligation 	$1,044 	$1,406
Projected benefit obligation 	1,134 	1,554
Fair value of plan assets 	141 	136

-- 57 of 86 --

56
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The components of the net periodic benefit cost were as follows:
(in millions)
Defined Benefit Plans 	Medical and Dental Plans
2022 	2021 	2020 	2022 	2021 	2020
Service cost — benefits earned during the year 	$«374 	$«391 	$«336 	$«50 	$«56 	$«46
Interest cost on projected benefit obligations 	300 	248 	300 	36 	33 	42
Expected return on plans’ assets 	(931) 	(843) 	(770) 	(30) 	(27) 	(28)
Amortization of actuarial losses 	231 	317 	255 	11 	29 	21
Amortization of prior service cost (credits) 	1 	1 	1 	(24) 	(28) 	(28)
Total net cost 	$÷(25) 	$«114 	$«122 	$«43 	$«63 	$«53
Other comprehensive income (loss) for each respective year
includes the amortization of actuarial losses and prior service
costs (credits) as noted in the previous table. Other comprehensive
income (loss) for each respective year also includes: net actuarial
gains of $858 million for defined benefit plans and a gain of
$374 million for medical and dental plans in 2022; net actuarial
gains of $1.141 billion for defined benefit plans and a gain of
$45 million for medical and dental plans in 2021, and net actuarial
losses of $611 million for defined benefit plans and a gain of
$23 million for medical and dental plans in 2020. The net actuarial
gains in 2022 are primarily due to the year-over-year increase in
discount rates partially offset by the impact of 2022 actual asset
returns being less than expected returns. The net actuarial gains
in 2021 are primarily due to the favorable impact of actual 2021
asset returns in excess of expected returns and the year-over-year
increase in discount rates. The net actuarial losses in 2020 are
primarily due to the year-over-year decline in discount rates
partially offset by the impact of actual asset returns in excess
of expected returns.
The weighted average assumptions used to determine benefit
obligations for defined benefit plans and medical and dental plans
are as follows:
2022 	2021 	2020
Discount rate 	5.0% 	2.7% 	2.3%
Expected aggregate average
long-term change in compensation 	4.5% 	4.3% 	4.3%
The weighted average assumptions used to determine the
net cost for defined benefit plans and medical and dental plans
are as follows:
2022 	2021 	2020
Discount rate 	2.7% 	2.3% 	3.0%
Expected return on plan assets 	7.5% 	7.5% 	7.5%
Expected aggregate average long-
term change in compensation 	4.4% 	4.3% 	4.3%
The assumed health care cost trend rates for medical and dental
plans at December 31 were as follows:
2022 	2021 	2020
Health care cost trend rate
assumed for the next year 	7% 	7% 	8%
Rate that the cost trend rate
gradually declines to 	5% 	5% 	5%
Year that rate reaches the
assumed ultimate rate 	2027 	2026 	2025
The discount rates used to measure liabilities were determined
based on high-quality fixed income securities that match the
duration of the expected retiree benefits. The health care cost
trend rates represent Abbott’s expected annual rates of change in
the cost of health care benefits and are forward projections of
health care costs as of the measurement date.

-- 58 of 86 --

57
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at fair value:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted
Prices in
Active Markets
Significant
Other Observable
Inputs
Significant
Unobservable
Inputs
Measured
at NAV ( j)
December 31, 2022
Equities:
U.S. large cap (a) 	$÷2,866 	$1,840 	$÷÷÷— 	$— 	$1,026
U.S. mid and small cap (b) 	693 	684 	— 	1 	8
International (c) 	2,401 	454 	— 	— 	1,947
Fixed income securities:
U.S. government securities (d) 	362 	5 	341 	— 	16
Corporate debt instruments (e) 	1,318 	123 	890 	— 	305
Non-U.S. government securities (f ) 	419 	16 	— 	— 	403
Other (g) 	775 	297 	75 	— 	403
Absolute return funds (h) 	1,678 	304 	— 	— 	1,374
Cash and Cash Equivalents 	154 	20 	— 	— 	134
Other (i) 	1,009 	7 	— 	— 	1,002
$11,675 	$3,750 	$1,306 	$«1 	$6,618
December 31, 2021
Equities:
U.S. large cap (a) 	$÷3,664 	$2,403 	$÷÷÷— 	$— 	$1,261
U.S. mid and small cap (b) 	936 	876 	— 	4 	56
International (c) 	2,902 	591 	— 	— 	2,311
Fixed income securities:
U.S. government securities (d) 	366 	21 	325 	— 	20
Corporate debt instruments (e) 	1,709 	434 	1,260 	— 	15
Non-U.S. government securities (f ) 	626 	33 	1 	— 	592
Other (g) 	510 	87 	111 	— 	312
Absolute return funds (h) 	1,934 	476 	— 	— 	1,458
Cash and Cash Equivalents 	266 	35 	— 	— 	231
Other (i) 	925 	2 	— 	— 	923
$13,838 	$4,958 	$1,697 	$«4 	$7,179
(a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.
(b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices.
(c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.
(d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices.
(e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices.
(f ) Primarily United Kingdom, Canada, Japan and Eurozone government bonds.
(g) Primarily asset backed securities, bank loans, interest rate swap positions and diversified fixed income vehicles benchmarked to LIBOR, SOFR or EURIBOR.
(h) Primarily hedge funds and funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including,
but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets.
(i) Primarily investments in private funds, such as private equity, private credit, private real estate and private energy funds.
( j) Investments measured at fair value using the net asset value (NAV) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are
intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

-- 59 of 86 --

58
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Equities that are valued using quoted prices are valued at the
published market prices. Equities in a common collective trust or
a registered investment company are valued at the NAV provided
by the fund administrator. The NAV is based on the value of the
underlying assets owned by the fund minus its liabilities. For
approximately half of these funds, investments may be redeemed
once per week or month, with a required 2 to 30 day notice period.
For the remaining funds, daily redemption of an investment is
allowed. Fixed income securities that are valued using significant
other observable inputs are valued at prices obtained from inde-
pendent financial service industry recognized vendors. Abbott
did not have any unfunded commitments related to fixed income
funds at December 31, 2022 and 2021. Fixed income securities in
a common collective trust or a registered investment company
are valued at the NAV provided by the fund administrator. For the
majority of these funds, investments may be redeemed either
weekly or monthly, with a required 2 to 60 day notice period.
For the remaining funds, investments may be generally
redeemed daily.
Absolute return funds are valued at the NAV provided by the
fund administrator. All private funds are valued at the NAV pro-
vided by the fund on a one-quarter lag adjusted for known cash
flows and significant events through the reporting date. Abbott
did not have any unfunded commitments related to absolute
return funds at December 31, 2022 and 2021. Investments in these
funds may be generally redeemed monthly or quarterly with
required notice periods ranging from 45 to 90 days. For approxi-
mately $270 million and $290 million of the absolute return funds,
redemptions are subject to a 33 percent gate and a 25 percent
gate, respectively, and $70 million is subject to a lock until 2025.
Investments in the private funds cannot be redeemed but the
funds will make distributions through liquidation. The estimate
of the liquidation period for each fund ranges from 2023 to 2032.
Abbott’s unfunded commitment in these funds was $569 million
and $585 million as of December 31, 2022 and 2021, respectively.
The investment mix of equity securities, fixed income and other
asset allocation strategies is based upon achieving a desired
return, as well as balancing higher return, more volatile equity
securities with lower return, less volatile fixed income securities.
Investment allocations are made across a range of markets, indus-
try sectors, capitalization sizes, and in the case of fixed income
securities, maturities and credit quality. The plans do not directly
hold any securities of Abbott. There are no known significant
concentrations of risk in the plans’ assets. Abbott’s medical and
dental plans’ assets are invested in a similar mix as the pension
plan assets. The actual asset allocation percentages at year end
are consistent with the company’s targeted asset allocation
percentages.
The plans’ expected return on assets, as shown above, is based on
management’s expectations of long-term average rates of return to
be achieved by the underlying investment portfolios. In establishing
this assumption, management considers historical and expected
returns for the asset classes in which the plans are invested, as well
as current economic and capital market conditions.
Abbott funds its domestic pension plans according to IRS funding
limitations. International pension plans are funded according to
similar regulations. Abbott funded $413 million in 2022 and
$418 million in 2021 to defined pension plans. Abbott expects to
contribute approximately $407 million to its pension plans in 2023.
Total benefit payments expected to be paid to participants, which
includes payments funded from company assets, as well as paid
from the plans, are as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2023 	$÷«368 	$÷67
2024 	387 	68
2025 	406 	69
2026 	427 	71
2027 	449 	74
2028 to 2032 	2,593 	409
The Abbott Stock Retirement Plan is the principal defined contri-
bution plan. Abbott’s contributions to this plan were $190 million
in 2022, $181 million in 2021 and $164 million in 2020.
NOTE 14 — TAXES ON EARNINGS FROM
CONTINUING OPERATIONS
Taxes on earnings from continuing operations reflect the
annual effective rates, including charges for interest and penalties.
Deferred income taxes reflect the tax consequences on future
years of differences between the tax bases of assets and liabilities
and their financial reporting amounts.
In 2022, taxes on earnings from continuing operations include
approximately $43 million in excess tax benefits associated with
share-based compensation and approximately $20 million of net
tax expense as a result of the resolution of various tax positions
related to prior years.
In 2021, taxes on earnings from continuing operations include
approximately $145 million in excess tax benefits associated with
share-based compensation and approximately $55 million of net
tax benefits as a result of the resolution of various tax positions
related to prior years.
In 2020, taxes on earnings from continuing operations include
the recognition of approximately $170 million of tax benefits
associated with the impairment of certain assets, approximately
$140 million of net tax benefits as a result of the resolution of
various tax positions related to prior years, and approximately
$100 million in excess tax benefits associated with share-based
compensation. In 2020, taxes on earnings from continuing opera-
tions also include a $26 million increase to the transition tax
liability associated with the 2017 TCJA. The $26 million increase
to the transition tax liability was the result of the resolution of
various tax positions related to prior years. This adjustment
increased the cumulative net tax expense related to the TCJA to
$1.53 billion. The one-time transition tax is based on Abbott’s
total post-1986 earnings and profits (E&P) that were previously
deferred from U.S. income taxes. The tax computation also requires
the determination of the amount of post-1986 E&P considered
held in cash and other specified assets. As of December 31, 2022,
the remaining balance of Abbott’s transition tax obligation is
approximately $739 million, which will be paid over the next
4 years as allowed by the TCJA. Earnings from discontinued
operations, net of tax, in 2020 reflect the recognition of
$24 million of net tax benefits primarily as a result of the
resolution of various tax positions related to prior years.

-- 60 of 86 --

59
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Undistributed foreign earnings remain indefinitely reinvested
in foreign operations. Determining the amount of unrecognized
deferred tax liability related to any remaining undistributed
foreign earnings not subject to the transition tax and additional
outside basis difference in its foreign entities is not practicable.
In the U.S., Abbott’s federal income tax returns through 2016
are settled. There are numerous other income tax jurisdictions
for which tax returns are not yet settled, none of which are
individually significant. Reserves for interest and penalties are
not significant.
Earnings from continuing operations before taxes, and the
related provisions for taxes on earnings from continuing
operations, were as follows:
(in millions) 	2022 	2021 	2020
Earnings From Continuing
Operations Before Taxes:
Domestic 	$3,732 	$3,264 	$1,588
Foreign 	4,574 	4,947 	3,380
Total 	$8,306 	$8,211 	$4,968
(in millions) 	2022 	2021 	2020
Taxes on Earnings From
Continuing Operations:
Current:
Domestic 	$1,309 	$÷«859 	$÷÷«39
Foreign 	723 	790 	566
Total current 	2,032 	1,649 	605
Deferred:
Domestic 	(610) 	(355) 	(18)
Foreign 	(49) 	(154) 	(90)
Total deferred 	(659) 	(509) 	(108)
Total 	$1,373 	$1,140 	$÷«497
Differences between the effective income tax rate and the U.S.
statutory tax rate were as follows:
2022 	2021 	2020
Statutory tax rate on earnings from
continuing operations 	21.0% 	21.0% 	21.0%
Impact of foreign operations 	(2.5)÷« 	(3.9)÷« 	(3.3)÷«
Impact of TCJA and other related
items 	—÷« 	—÷« 	0.5÷«
Foreign-derived intangible income
benefit 	(2.0)÷« 	(1.1)÷« 	(1.0)÷«
Domestic impairment loss 	—÷« 	(0.1)÷« 	(2.7)÷«
Excess tax benefits related to stock
compensation 	(0.5)÷« 	(1.7)÷« 	(1.9)÷«
Research tax credit 	(0.9)÷« 	(0.6)÷« 	(1.0)÷«
Resolution of certain tax positions
pertaining to prior years 	0.2÷« 	(0.7)÷« 	(2.8)÷«
Intercompany restructurings and
integration 	—÷« 	0.1÷« 	0.5÷«
State taxes, net of federal benefit 	0.7÷« 	0.4÷« 	0.5÷«
All other, net 	0.5÷« 	0.5÷« 	0.2÷«
Effective tax rate on earnings from
continuing operations 	16.5% 	13.9% 	10.0%
Impact of foreign operations is primarily derived from operations
in Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica,
Singapore, and Malta.
The tax effect of the differences that give rise to deferred tax
assets and liabilities were as follows:
(in millions) 	2022 	2021
Deferred tax assets:
Compensation and employee benefits 	$÷÷230 	$÷÷618
Other, primarily reserves not currently
deductible, and NOL’s and credit carryforwards 	2,402 	2,444
Trade receivable reserves 	227 	206
Research and development costs 	319 	—
Inventory reserves 	187 	169
Lease liabilities 	263 	273
Deferred intercompany profit 	260 	261
Total deferred tax assets before valuation
allowance 	3,888 	3,971
Valuation allowance 	(1,169) 	(1,199)
Total deferred tax assets 	2,719 	2,772
Deferred tax liabilities:
Depreciation 	(376) 	(330)
Right of Use lease assets 	(252) 	(264)
Other, primarily the excess of book basis over
tax basis of intangible assets 	(2,038) 	(2,364)
Total deferred tax liabilities 	(2,666) 	(2,958)
Total net deferred tax assets (liabilities) 	$÷÷÷53 	$÷«(186)
Abbott has incurred losses in a foreign jurisdiction where realiza-
tion of the future economic benefit is so remote that the benefit is
not reflected as a deferred tax asset.
The following table summarizes the gross amounts of unrecog-
nized tax benefits without regard to reduction in tax liabilities or
additions to deferred tax assets and liabilities if such unrecognized
tax benefits were settled:
(in millions) 	2022 	2021
January 1 	$1,908 	$1,210
Increase due to current year tax positions 	154 	143
Increase due to prior year tax positions 	108 	748
Decrease due to prior year tax positions 	(115) 	(119)
Settlements 	3 	(35)
Lapse of statute 	(22) 	(39)
December 31 	$2,036 	$1,908
The 2021 increase due to prior year tax positions includes approx-
imately $714 million of international tax positions for which a
deferred tax asset has not been recorded because recognition of
the future benefit is not expected.
The total amount of unrecognized tax benefits that, if recognized,
would impact the effective tax rate is approximately $1.28 billion.
Abbott believes that it is reasonably possible that the recorded
amount of gross unrecognized tax benefits may decrease by
approximately $315 million, including cash adjustments, within
the next twelve months as a result of concluding various domestic
and international tax matters.

-- 61 of 86 --

60
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 15 — SEGMENT AND GEOGRAPHIC AREA INFORMATION
Abbott’s principal business is the discovery, development, manu-
facture and sale of a broad line of health care products. Abbott’s
products are generally sold directly to retailers, wholesalers,
hospitals, health care facilities, laboratories, physicians’ offices
and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a
broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult
and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and
tests for blood banks, hospitals, commercial laboratories and
alternate-care testing sites. For segment reporting purposes, the
Core Laboratories Diagnostics, Rapid Diagnostics, Molecular
Diagnostics and Point of Care Diagnostics divisions are aggregated
and reported as the Diagnostic Products segment.
Medical Devices—Worldwide sales of rhythm management,
electrophysiology, heart failure, vascular, structural heart, neuro-
modulation and diabetes care products. For segment reporting
purposes, the Cardiac Rhythm Management, Electrophysiology,
Heart Failure, Vascular, Structural Heart, Neuromodulation and
Diabetes Care divisions are aggregated and reported as the
Medical Devices segment.
Abbott’s underlying accounting records are maintained on a
legal entity basis for government and public reporting require-
ments. Segment disclosures are on a performance basis consistent
with internal management reporting. The cost of some corporate
functions and the cost of certain employee benefits are charged
to segments at predetermined rates that approximate cost.
Remaining costs, if any, are not allocated to segments. In addition,
intangible asset amortization is not allocated to operating segments,
and intangible assets and goodwill are not included in the measure
of each segment’s assets.
The following segment information has been prepared in
accordance with the internal accounting policies of Abbott,
as described above, and are not presented in accordance with
generally accepted accounting principles applied to the
consolidated financial statements.
(in millions)
Net Sales to External
Customers (a) 	Operating Earnings (a)
2022 	2021 	2020 	2022 	2021 	2020
Established
Pharmaceutical
Products 	$÷4,912 $÷4,718 $÷4,303 	$÷1,049 $÷÷«889 $÷«794
Nutritional
Products 	7,459 	8,294 	7,647 	706 	1,763 	1,751
Diagnostic
Products 	16,584 	15,644 	10,805 	6,667 	6,256 	3,725
Medical Devices 	14,687 	14,367 	11,787 	4,409 	4,514 	3,038
Total Reportable
Segments 	43,642 	43,023 	34,542 	$12,831 $13,422 $9,308
Other 	11 	52 	66
Total 	$43,653 $43,075 $34,608
(a) In 2022 and 2020, the impact of foreign exchange unfavorably impacted net sales and
operating earnings. In 2021, the impact of foreign exchange favorably impacted net sales
and unfavorably impacted operating earnings.
(in millions) 	2022 	2021 	2020
Total Reportable Segment
Operating Earnings 	$12,831 	$13,422 	$«9,308
Corporate functions and
benefit plan costs 	(509) 	(801) 	(518)
Net interest expense 	(375) 	(490) 	(500)
Share-based compensation 	(685) 	(640) 	(546)
Amortization of intangible assets 	(2,013) 	(2,047) 	(2,132)
Other, net (b) 	(943) 	(1,233) 	(644)
Earnings from Continuing
Operations Before Taxes 	$÷8,306 	$÷8,211 	$«4,968
(b) Other, net in 2022 includes $176 million of charges related to a voluntary recall within the
Nutritional Products segment and $111 million of charges related to the impairment of
IPR&D intangible assets. Other, net also includes integration costs associated with the
acquisitions of Alere Inc. and St. Jude Medical and restructuring charges in 2022, 2021 and
2020. Charges for restructuring actions and other cost reduction initiatives were approxi-
mately $265 million in 2022, $375 million in 2021 and $125 million in 2020. Other, net in
2021 also includes costs related to certain litigation. Other, net in 2020 also includes costs
related to asset impairments partially offset by income from the settlement of litigation.

-- 62 of 86 --

61
A B B O T T 2 0 2 2 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
(in millions)
Depreciation
Additions to
Property and Equipment 	Total Assets
2022 	2021 	2020 	2022 	2021 	2020 	2022 	2021 	2020
Established Pharmaceuticals 	$÷÷«97 	$÷÷«94 	$÷÷«88 	$÷«175 	$÷«169 	$÷«109 	$÷2,883 	$÷2,789 	$÷2,888
Nutritionals 	155 	151 	143 	251 	174 	201 	3,625 	3,425 	3,478
Diagnostics 	494 	760 	488 	832 	980 	1,263 	7,985 	7,699 	7,696
Medical Devices 	311 	285 	281 	335 	348 	402 	7,844 	7,261 	6,893
Total Reportable Segments 	1,057 	1,290 	1,000 	1,593 	1,671 	1,975 	$22,337 	$21,174 	$20,955
Other 	197 	201 	195 	182 	201 	218
Total 	$1,254 	$1,491 	$1,195 	$1,775 	$1,872 	$2,193
(in millions) 	2022 	2021
Total Reportable Segment Assets 	$22,337 	$21,174
Cash and investments 	10,936 	11,065
Goodwill and intangible assets 	33,253 	35,970
All other (c) 	7,912 	6,987
Total Assets 	$74,438 	$75,196
(c) All other includes the long-term assets associated with the defined benefit plans of
$3.20 billion in 2022 and $2.27 billion in 2021.
(in millions)
Net Sales to External Customers (d)
2022 	2021 	2020
United States 	$18,142 	$16,642 	$13,022
Germany 	2,340 	2,572 	2,108
China 	2,133 	2,392 	1,965
Japan 	1,932 	1,695 	1,386
India 	1,649 	1,561 	1,323
Switzerland 	1,336 	1,313 	1,140
Canada 	1,280 	1,385 	841
All Other Countries 	14,841 	15,515 	12,823
Consolidated 	$43,653 	$43,075 	$34,608
(d) Sales by country are based on the country that sold the product.
Long-lived assets on a geographic basis primarily include
property and equipment. It excludes goodwill, intangible assets,
deferred tax assets, and financial instruments. At December 31,
2022 and 2021, long-lived assets totaled $14.2 billion and
$13.1 billion, respectively, and in the United States such assets
totaled $7.7 billion and $6.8 billion, respectively. Long-lived asset
balances associated with other countries were not material on
an individual country basis in either of the two years.
NOTE 16 — SUBSEQUENT EVENT
On February 8, 2023, Abbott entered into a definitive agreement
to acquire Cardiovascular Systems, Inc. (CSI). CSI sells an
atherectomy system used in treating peripheral and coronary
artery disease. The acquisition, which is expected to add comple-
mentary technologies to Abbott’s portfolio of vascular device
offerings, is subject to the approval of CSI shareholders and the
satisfaction of customary closing conditions, including applicable
regulatory approvals. Under the terms of the agreement, Abbott
will pay $20 per common share at a total expected equity value
of approximately $890 million. The acquisition is expected to
be funded with cash on hand.

-- 63 of 86 --

62
A B B O T T 2 0 2 2 A N N U A L R E P O R T
M A N A G E M E N T R E P O R T O N I N T E R N A L
C O N T R O L O V E R F I N A N C I A L R E P O R T I N G
R E P O R T O F I N D E P E N D E N T R E G I S T E R E D
P U B L I C A C C O U N T I N G F I R M
The management of Abbott Laboratories is responsible for estab-
lishing and maintaining adequate internal control over financial
reporting. Abbott’s internal control system was designed to pro-
vide reasonable assurance to the company’s management and
board of directors regarding the preparation and fair presentation
of published financial statements.
All internal control systems, no matter how well designed, have
inherent limitations. Therefore, even those systems determined to
be effective can provide only reasonable assurance with respect to
financial statement preparation and presentation.
Abbott’s management assessed the effectiveness of the company’s
internal control over financial reporting as of December 31, 2022.
In making this assessment, it used the criteria set forth in Internal
Control — Integrated Framework (2013) issued by the Committee of
Sponsoring Organizations of the Treadway Commission. Based on
our assessment, we believe that, as of December 31, 2022, the
company’s internal control over financial reporting was effective
based on those criteria.
Abbott’s independent registered public accounting firm has issued
an audit report on their assessment of the effectiveness of the
company’s internal control over financial reporting. This report
appears on page 64.
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Robert E. Funck, Jr.
Executive Vice President, Finance and Chief Financial Officer
Philip P. Boudreau
Vice President, Finance and Controller
February 17, 2023
To the Shareholders and Board of Directors of Abbott Laboratories
OPINION ON THE FINANCIAL STATEMENTS
We have audited the accompanying consolidated balance sheets
of Abbott Laboratories and subsidiaries (the Company) as of
December 31, 2022 and 2021, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2022, and the related notes (collectively referred to
as the “consolidated financial statements”). In our opinion, the
consolidated financial statements present fairly, in all material
respects, the financial position of the Company at December 31,
2022 and 2021, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 2022,
in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting
as of December 31, 2022, based on criteria established in Internal
Control — Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (2013
framework), and our report dated February 17, 2023 expressed
an unqualified opinion thereon.
BASIS FOR OPINION
These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a
public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accor-
dance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and
the PCAOB.
We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to
error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial state-
ments, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining,
on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reason-
able basis for our opinion.

-- 64 of 86 --

63
A B B O T T 2 0 2 2 A N N U A L R E P O R T
CRITICAL AUDIT MATTER
The critical audit matter communicated below is a matter arising
from the current period audit of the financial statements that
was communicated or required to be communicated to the audit
committee and that: (1) relates to accounts or disclosures that are
material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communica-
tion of the critical audit matter does not alter in any way our
opinion on the consolidated financial statements, taken as a whole,
and we are not, by communicating the critical audit matter below,
providing a separate opinion on the critical audit matter or on the
accounts or disclosures to which it relates.
Income taxes – Unrecognized tax benefits
Description of the Matter
As described in Note 14 to the consolidated financial statements,
unrecognized tax benefits were approximately $2.0 billion at
December 31, 2022. Unrecognized tax benefits are assessed by
management quarterly for identification and measurement, or
more frequently if there are any indicators suggesting a change
in unrecognized tax benefits. Assessing tax positions involves
judgment including interpreting tax laws of multiple jurisdictions
and assumptions relevant to the measurement of an unrecognized
tax benefit, including the estimated amount of tax liability that
may be incurred should the tax position not be sustained upon
inspection by a tax authority. These judgments and assumptions
can significantly affect unrecognized tax benefits.
How We Addressed the Matter in our Audit
We obtained an understanding, evaluated the design and tested
the operating effectiveness of controls over the Company’s identi-
fication and measurement of unrecognized tax benefits, as well
as its process for the assessment of events that may indicate a
change in unrecognized tax benefits is warranted. For example,
we tested controls over management’s review of the completeness
of identified unrecognized tax benefits, as well as controls over
management’s review of significant assumptions used within
the measurement of unrecognized tax benefits.
With the support of our tax professionals, among other audit
procedures performed, we evaluated the reasonableness of
management’s judgment with respect to the interpretation of tax
laws of multiple jurisdictions by reading and evaluating manage-
ment’s documentation, including relevant accounting policies,
and by considering how tax law, including statutes, regulations,
and case law, affected management’s judgments. We tested the
completeness of management’s assessment of the identification
of unrecognized tax benefits and possible outcomes related to it
including evaluation of technical merits of the unrecognized
tax benefits. We also tested the appropriateness and consistency
of management’s methods and significant assumptions associated
with the measurement of unrecognized tax benefits, including
assessing the estimated amount of tax liability that may be
incurred should the tax position not be sustained upon inspec-
tion by a tax authority.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Chicago, Illinois
February 17, 2023

-- 65 of 86 --

64
A B B O T T 2 0 2 2 A N N U A L R E P O R T
R E P O R T O F I N D E P E N D E N T R E G I S T E R E D
P U B L I C A C C O U N T I N G F I R M
To the Shareholders and Board of Directors of Abbott Laboratories
OPINION ON INTERNAL CONTROL
OVER FINANCIAL REPORTING
We have audited Abbott Laboratories and subsidiaries’ internal
control over financial reporting as of December 31, 2022, based
on criteria established in Internal Control—Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria).
In our opinion, Abbott Laboratories and subsidiaries (the
Company) maintained, in all material respects, effective internal
control over financial reporting as of December 31, 2022, based
on the COSO criteria.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of
December 31, 2022 and 2021, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2022, and the related notes and our report dated
February 17, 2023 expressed an unqualified opinion thereon.
BASIS FOR OPINION
The Company’s management is responsible for maintaining
effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial
reporting included in the accompanying Management Report on
Internal Control Over Financial Reporting. Our responsibility is
to express an opinion on the Company’s internal control over
financial reporting based on our audit. We are a public accounting
firm registered with the PCAOB and are required to be indepen-
dent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of
the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal
control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary
in the circumstances. We believe that our audit provides a
reasonable basis for our opinion.
DEFINITION AND LIMITATIONS OF INTERNAL CONTROL
OVER FINANCIAL REPORTING
A company’s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted
accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain to
the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets of
the company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of manage-
ment and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unautho-
rized acquisition, use, or disposition of the company’s assets that
could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projec-
tions of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 17, 2023

-- 66 of 86 --

65
A B B O T T 2 0 2 2 A N N U A L R E P O R T
F I N A N C I A L I N S T R U M E N T S A N D R I S K M A N A G E M E N T
MARKET PRICE SENSITIVE INVESTMENTS
The fair value of equity securities held by Abbott with a readily
determinable fair value was approximately $9 million and
$11 million as of December 31, 2022 and 2021, respectively. These
equity securities are subject to potential changes in fair value.
A hypothetical 20 percent decrease in the share prices of these
investments would decrease their fair value at December 31, 2022
by approximately $2 million. Changes in the fair value of these
securities are recorded in earnings. The fair value of investments
in mutual funds that are held in a rabbi trust for the purpose of
paying benefits under a deferred compensation plan was approxi-
mately $298 million and $391 million as of December 31, 2022 and
2021, respectively. Changes in the fair value of these investments,
as well as an offsetting change in the benefit obligation, are
recorded in earnings.
NON-PUBLICLY TRADED EQUIT Y SECURITIES
Abbott holds equity securities that are not traded on public stock
exchanges. The carrying value of these investments was
$83 million and $90 million as of December 31, 2022 and 2021,
respectively. No individual investment is recorded at a value in
excess of $15 million. Abbott measures these investments at cost
minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical
or a similar investment of the same issuer.
INTEREST RATE SENSITIVE FINANCIAL INSTRUMENTS
At December 31, 2022 and 2021, Abbott had interest rate hedge
contracts totaling $2.9 billion to manage its exposure to changes in
the fair value of debt. The effect of these hedges is to change the
fixed interest rate to a variable rate for the portion of the debt that
is hedged. Abbott does not use derivative financial instruments,
such as interest rate swaps, to manage its exposure to changes in
interest rates for its investment securities. The fair value of long-
term debt at December 31, 2022 and 2021 amounted to $16.3 billion
and $21.2 billion, respectively (average interest rates of 3.5% and
3.4% as of December 31, 2022 and 2021, respectively) with matur-
ities through 2046. At December 31, 2022 and 2021, the fair value
of current and long-term investment securities amounted to
approximately $1.1 billion and $1.3 billion, respectively. A hypo-
thetical 100-basis point change in the interest rates would not have
a material effect on cash flows, income or fair values.
FOREIGN CURRENCY SENSITIVE FINANCIAL INSTRUMENTS
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates for anticipated intercompany purchases by
those subsidiaries whose functional currencies are not the U.S.
dollar. These contracts are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign currency
exchange rates and are marked-to-market with the resulting gains or
losses reflected in Accumulated other comprehensive income (loss).
Gains or losses will be included in Cost of products sold at the time
the products are sold, generally within the next twelve to eighteen
months. At December 31, 2022 and 2021, Abbott held $7.7 billion
and $8.6 billion, respectively, of such contracts. Contracts held at
December 31, 2022 will mature in 2023 or 2024 depending on the
contract. Contracts held at December 31, 2021 matured in 2022 or
will mature in 2023 depending upon the contract.
Abbott enters into foreign currency forward exchange contracts
to manage its exposure to foreign currency denominated inter-
company loans and trade payables and third-party trade payables
and receivables. The contracts are marked-to-market, and result-
ing gains or losses are reflected in income and are generally offset
by losses or gains on the foreign currency exposure being man-
aged. At December 31, 2022 and 2021, Abbott held $12.0 billion
and $12.2 billion, respectively, of such contracts, which mature in
the next 13 months.
Abbott has designated a yen-denominated, 5-year term loan of
approximately $446 million and $521 million as of December 31,
2022 and December 31, 2021, respectively, as a hedge of the net
investment in certain foreign subsidiaries. The change in the
value of the debt, which is due to changes in foreign exchange
rates, is recorded in Accumulated other comprehensive income
(loss), net of tax.
The following table reflects the total foreign currency forward exchange contracts outstanding at December 31, 2022 and 2021:
(dollars in millions)
2022 	2021
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying
Value
Receivable/
(Payable)
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying
Value
Receivable/
(Payable)
Primarily U.S. dollars to be exchanged for
the following currencies:
Euro 	$÷7,656 	1.0664 	$÷92 	$÷8,698 	1.1360 	$÷90
Chinese Yuan 	2,264 	6.8825 	12 	2,148 	6.5744 	(35)
Japanese Yen 	1,797 	133.0344 	(7) 	1,497 	111.7260 	31
All other currencies 	8,029 	n/a 	89 	8,426 	n/a 	109
Total 	$19,746 	$186 	$20,769 	$195

-- 67 of 86 --

F I N A N C I A L R E V I E W
66
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Abbott’s revenues are derived primarily from the sale of a broad
line of health care products under short-term receivable arrange-
ments. Abbott’s primary products are medical devices, diagnostic
testing products, nutritional products and branded generic phar-
maceuticals. Patent protection and licenses, technological and
performance features, and inclusion of Abbott’s products under
a contract most impact which products are sold; price controls,
competition and rebates most impact the net selling prices of
products; and the measurement of net sales and costs is impacted
by foreign currency translation. Sales in international markets
comprise 58 percent of consolidated net sales.
The coronavirus (COVID-19) pandemic affected Abbott’s diversi-
fied health care businesses in various ways over the 2020 through
2022 period. Abbott’s Diagnostics segment experienced the most
significant change in sales from 2020 to 2022 as a result of the
COVID-19 pandemic. (The Diagnostics segment includes the
Rapid Diagnostics, Core Laboratory Diagnostics, Molecular
Diagnostics and Point of Care Diagnostics divisions.) In 2020 and
2021, Abbott mobilized its teams across multiple fronts to develop
and launch various new diagnostic tests to detect COVID-19.
Rapid diagnostic tests developed by Abbott to detect COVID-19
included, among others, the following:
• a molecular test on Abbott’s ID NOW® rapid point-of-care
platform launched in March 2020,
• the professional BinaxNOW® COVID-19 Ag Card test, a porta-
ble, lateral flow rapid test launched in August 2020, and
• an over-the-counter, non-prescription BinaxNOW COVID-19
Ag Self Test for individuals with or without symptoms
launched in March 2021.
Each of these tests was launched in the U.S. pursuant to an
Emergency Use Authorization (EUA).
Outside the U.S., in September 2020, Rapid Diagnostics launched
its Panbio® rapid antigen test to detect COVID-19 pursuant to a
CE Mark. In June 2021, Abbott announced that it had received
CE Mark for its over-the-counter Panbio COVID-19 Antigen
Self-Test for individuals with or without symptoms.
In 2020, Molecular Diagnostics developed and launched molecu-
lar tests to detect COVID-19 using polymerase chain reaction
(PCR) methods on its m2000® RealTime lab-based platform and
its Alinity® m system pursuant to EUAs in the U.S. and CE Marks.
Molecular Diagnostics also developed and launched its multiplex
molecular test on its Alinity m system to detect COVID-19, influ-
enza A, influenza B, and respiratory syncytial virus (RSV) in one
test. This multiplex molecular test was launched pursuant to a
CE Mark in December 2020 and an EUA in the U.S. in March 2021.
In 2020 and 2021, Core Laboratory Diagnostics developed and
launched various lab-based serology blood tests on its
ARCHITECT® i1000SR® and ARCHITECT i2000SR® laboratory
instruments and on its Alinity i system for the detection of an
antibody to determine if someone was previously infected with the
COVID-19 virus. The tests were launched under EUAs in the U.S.
and CE Marks.
Abbott’s COVID-19 testing-related sales totaled approximately
$8.4 billion in 2022, $7.7 billion in 2021, and $3.9 billion in 2020,
led by sales related to Abbott’s BinaxNOW, Panbio and ID NOW
rapid testing platforms. The demand for COVID-19 tests has been
volatile over the last two years as the number of COVID-19 cases,
especially in the U.S., has fluctuated during this period. On
January 30, 2023, the U.S. government announced that it plans to
end the COVID-19 public health emergency on May 11, 2023.
Abbott is evaluating the potential impacts of the end of the public
health emergency, and it will continue to monitor further regula-
tory actions from relevant U.S. government agencies and assess
potential impacts on pandemic-related government policies and
product authorizations. Abbott expects the COVID-19 pandemic
to shift to an endemic state in 2023, which would likely result in
significantly lower demand for COVID-19 tests. Due to the unpre-
dictability of the pandemic, including how and when it will shift to
an endemic state, the extent to which COVID-19 will have a mate-
rial effect on Abbott’s business, financial condition or results of
operations is uncertain.
With respect to other products sold by the Diagnostics segment,
demand for routine diagnostic testing generally fluctuated with
changes in the number of COVID-19 cases in various geographic
regions throughout the 2020 - 2022 period. Across Abbott’s car-
diovascular and neuromodulation businesses, procedure volumes
were negatively impacted in 2021 and 2022 by surges of COVID-19
in various geographies as well as intermittent COVID-19 lockdown
restrictions and healthcare staffing challenges. Despite such chal-
lenges, overall volume trends improved in several cardiovascular
businesses in 2021 and 2022. While Abbott’s branded generic
pharmaceuticals business was also negatively affected by the
pandemic in 2020 as COVID-19 spread across emerging market
countries, volumes recovered and grew in 2021 and 2022. Abbott’s
nutritional and diabetes care businesses were the least affected by
the pandemic.
Abbott is continually monitoring the effects of the pandemic on
its operations. Throughout the pandemic, Abbott has continued to
ensure that its operations throughout the world are aligned with
the specific governmental orders and guidelines affecting each
location. Abbott has taken aggressive steps to limit exposure to
COVID-19 and enhance the safety of facilities for its employees.
While Abbott’s 2022 and 2021 sales were most significantly
affected by the COVID-19 pandemic, the increase in total sales
since 2020 also reflects the introduction of new products across
various businesses as well as higher sales of various existing prod-
ucts. Sales in emerging markets, which represent approximately
35 percent of total company sales, increased 5.6 percent in 2022
and 19.6 percent in 2021, excluding the impact of foreign exchange.
(Emerging markets include all countries except the United States,
Western Europe, Japan, Canada, Australia and New Zealand.)
In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall
in February 2022 of certain infant powder formula products
manufactured at its facility in Sturgis, Michigan and stopped
production at the facility. On May 16, 2022, Abbott entered into a
consent decree with the U.S. Food and Drug Administration (FDA)
on the steps necessary to resume production and maintain the

-- 68 of 86 --

F I N A N C I A L R E V I E W
67
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Sturgis facility and operations. On July 1, Abbott restarted partial
production at the facility beginning with its specialty formula
EleCare® and metabolic formulas. Subsequently, Abbott restarted
Similac® production. The consent decree does not affect any other
Abbott plants or operations.
In 2022, Abbott took various actions to mitigate the impact of
the recall on the supply of formula in the U.S. These actions
included the shipment of infant formula powder into the U.S. from
Abbott’s FDA-registered facility in Ireland; prioritization of infant
formula production at its Columbus, Ohio facility; conversion of
other liquid manufacturing lines into manufacturing Similac
liquid ready-to-feed product; increased production of powder
infant formula at its Casa Grande, Arizona manufacturing site;
and importation of product from its facility in Spain as permitted
by the FDA.
Over the last three years, Abbott’s operating margin as a percent-
age of sales increased from 15.5 percent in 2020 to 19.6 percent in
2021 and then decreased to 19.2 percent in 2022. The decrease in
2022 from 2021 reflects the impact of the voluntary infant product
recall and manufacturing stoppage in U.S. Pediatric Nutritionals
and the impact of inflation and supply chain challenges on various
manufacturing inputs and transportation costs across Abbott’s
businesses, partially offset by the favorable impact of margin
improvement initiatives. The increase in 2021 from 2020 reflects
the impact of sales volume increases for COVID-19 tests in Rapid
Diagnostics and growth across virtually all of Abbott’s businesses
due, in part, to partial recovery from the COVID-19 pandemic,
partially offset by the impact of inflation and supply chain chal-
lenges on various manufacturing inputs and transportation costs
and an increase in restructuring costs.
In 2022 and 2021, Abbott experienced availability issues with
some services and materials used in its products. To date, Abbott
has been able to manage the various supply chain challenges
without significant supply disruption or shortage for services,
raw materials and supplies. The future extent to which inflation,
supply chain disruptions, and unfavorable foreign exchange rates
may have a material effect on Abbott’s operating results is uncer-
tain. While Abbott expects inflationary pressures on various raw
materials, packaging materials and transportation costs to con-
tinue in 2023, the impact of such cost increases is expected to be
at least partially mitigated by price increases in certain businesses
and the impact of continued gross margin improvement initiatives.
To the extent that supply chain challenges in the industries in
which Abbott operates normalize over time, this may lessen
inflationary pressures.
With respect to the performance of each reportable segment over
the last three years, sales in the Medical Devices segment, exclud-
ing the impact of foreign exchange, increased 8.1 percent in 2022
and 19.4 percent in 2021. The sales increase in 2022 was driven by
growth in Diabetes Care, Structural Heart, Electrophysiology, and
Heart Failure. The sales increase in 2021 was driven by double-
digit growth across all of Abbott’s Medical Devices divisions, led
by Diabetes Care, Structural Heart and Electrophysiology, due, in
part, to a partial recovery from the COVID-19 pandemic.
In 2022, operating earnings for the Medical Devices segment
decreased 2.3 percent. Excluding the impact of foreign exchange,
Medical Devices operating earnings increased 9.3 percent. The
operating margin profile for the Medical Devices segment
increased from 25.8 percent of sales in 2020 to 31.4 percent in 2021
and then decreased to 30.0 percent in 2022. The overall increase
over the two years reflects the impact of higher sales volumes
across the Medical Device businesses, partially offset by continued
pricing pressures on drug eluting stents (DES) and other products.
The decrease in 2022 from 2021 reflects various factors, including
the impacts of inflationary pressures and supply chain challenges
related to various manufacturing inputs and processes.
In 2022, key product approvals in the Medical Devices
segment included:
• FDA clearance for the EnSite® X EP System with EnSite OT,
which leverages the Advisor® HD Grid Catheter to provide a
360-degree view of the heart without regard to the orientation
of the catheter in the heart,
• FDA clearance of the Freestyle Libre® 3 system which automati-
cally delivers up-to-the minute glucose readings and 14-day
accuracy in a wearable sensor,
• FDA approval for an expanded indication for the CardioMEMS®
HF system, a small implantable pulmonary artery sensor and
remote monitoring system that can detect early warning signs of
worsening heart failure,
• FDA approval for the Aveir® single-chamber leadless pacemaker
for the treatment of patients with slow heart rhythms, and
• FDA approval of the EternaTM rechargeable spinal cord stimu-
lation system for the treatment of chronic pain.
In Abbott’s Diagnostics segment, sales increased 10.4 percent in
2022 and 42.7 percent in 2021, excluding the impact of foreign
exchange. As was discussed above, sales growth in 2022 and 2021
was driven by demand for Abbott’s portfolio of rapid diagnostics
tests for COVID-19 and higher routine diagnostics testing in the
core laboratory business, partially offset by lower demand for
Abbott’s laboratory-based tests for COVID-19 in the molecular
diagnostics business.
In 2022, operating earnings for the Diagnostics segment increased
6.6 percent. The operating margin profile increased from
34.3 percent of sales in 2020 to 40.2 percent in 2022 primarily due
to higher sales in Rapid Diagnostics and the impact of increased
routine diagnostics testing on Core Laboratory Diagnostics versus
2020 levels.
Abbott has regulatory approvals in the U.S., Europe, China, and
other markets for the “Alinity c” and “Alinity i” instruments and
has continued to build out its test menu for clinical chemistry
and immunoassay diagnostics. Abbott has obtained regulatory
approval for the “Alinity h” system for hematology in Europe,
Japan and other regions. Abbott has also obtained regulatory
approvals in the U.S., Europe and other markets for the “Alinity s”
(blood screening) and “Alinity m” (molecular) instruments and
several testing assays.

-- 69 of 86 --

F I N A N C I A L R E V I E W
68
A B B O T T 2 0 2 2 A N N U A L R E P O R T
In Abbott’s Nutritional Products segment, total pediatric nutri-
tion sales, excluding the impact of foreign exchange, decreased
16.6 percent in 2022 as a result of the voluntary recall and manu-
facturing stoppage discussed above as well as challenging market
dynamics in Greater China. In December 2022, Abbott initiated
steps to exit its pediatric nutrition business in China. Excluding
the impact of foreign exchange, total pediatric nutrition sales
increased 3.3 percent in 2021 driven by the Pedialyte®, PediaSure®
and Similac® brands in the U.S. as well as infant and toddler prod-
uct growth across several international markets, partially offset
by challenging market dynamics in the Greater China infant
category. Excluding the impact of foreign exchange, total adult
nutrition sales increased 4.8 percent in 2022 and 12.8 percent in
2021, led by the continued growth of Ensure®, Abbott’s market-
leading complete and balanced nutrition brand, and Glucerna®,
Abbott’s market-leading diabetes-specific nutrition brand,
across several countries.
In 2022, operating earnings for the Nutritional Products segment
decreased 60.0 percent. Operating margins for the worldwide
nutritional products business decreased from 22.9 percent in 2020
to 9.5 percent in 2022. The decrease was driven by the impact of
the voluntary infant product recall and manufacturing stoppage as
well as higher manufacturing and distribution costs, including
commodity prices, partially offset by the impact of gross margin
improvement initiatives and select product price increases.
The Established Pharmaceutical Products segment focuses on
the sale of its products in emerging markets. Excluding the impact
of foreign exchange, Established Pharmaceutical sales increased
10.6 percent in 2022 and 10.4 percent in 2021. The sales increases
in 2022 and 2021 reflect higher sales in several geographies
including India, China, and Brazil. In 2022, operating earnings
for the Established Pharmaceutical Products segment increased
18.0 percent. Operating margins increased from 18.5 percent of
sales in 2020 to 21.4 percent in 2022 primarily due to the impact
of gross margin improvement initiatives and higher selling prices
partially offset by inflation on various product inputs.
With respect to Abbott’s financial position, at December 31, 2022
and 2021, Abbott’s cash and cash equivalents and short-term
investments total approximately $10.2 billion. Abbott’s long-term
debt totals $16.8 billion and $18.1 billion at December 31, 2022 and
2021, respectively.
Abbott declared dividends of $1.92 per share in 2022 and $1.82 per
share in 2021, an increase of approximately 5.5 percent. Dividends
paid totaled $3.309 billion in 2022 compared to $3.202 billion in
2021. The year-over-year change in the amount of dividends paid
reflects the increase in the dividend rate. In December 2022,
Abbott increased the company’s quarterly dividend by 8.5 percent
to $0.51 per share from $0.47 per share, effective with the dividend
paid in February 2023. In December 2021, Abbott increased the
company’s quarterly dividend by 4.4 percent to $0.47 per share
from $0.45 per share, effective with the dividend paid in
February 2022.
On February 8, 2023, Abbott entered into a definitive agreement to
acquire Cardiovascular Systems, Inc. (CSI). CSI sells an atherec-
tomy system used in treating peripheral and coronary artery
disease. The acquisition, which is expected to add complementary
technologies to Abbott’s portfolio of vascular device offerings, is
subject to the approval of CSI shareholders and the satisfaction
of customary closing conditions, including applicable regulatory
approvals. Under the terms of the agreement, Abbott will pay
$20 per common share at a total expected equity value of approxi-
mately $890 million. The acquisition is expected to be funded
with cash on hand.
In 2023, Abbott will also focus on continuing to invest in product
development areas that provide the opportunity for strong
sustainable growth over the next several years. In its diagnostics
business, Abbott’s focus will include driving sales growth from its
Alinity suite of diagnostics instruments and its portfolio of rapid
diagnostic testing systems as well as continuing to meet COVID-19
test demand. In the Medical Devices segment, Abbott will focus on
launching various new products and expanding its market position
across the various businesses. In its nutritional business, Abbott
will continue to focus on executing the actions needed to achieve
a recovery in its infant formula business and growth globally.
In the established pharmaceuticals business, Abbott will continue
to focus on growing its business with the depth and breadth of its
portfolio in emerging markets.
CRITICAL ACCOUNTING POLICIES
Sales Rebates — In 2022, approximately 45 percent of Abbott’s
consolidated gross revenues were subject to various forms of
rebates and allowances that Abbott recorded as reductions of
revenues at the time of sale. Most of these rebates and allowances
in 2022 are in the Nutritional Products and Diabetes Care busi-
nesses. Abbott provides rebates to state agencies that administer
the Special Supplemental Nutrition Program for Women, Infants,
and Children (WIC), wholesalers, group purchasing organizations,
and other government agencies and private entities. Rebate
amounts are usually based upon the volume of purchases using
contractual or statutory prices for a product. Factors used in the
rebate calculations include the identification of which products
have been sold subject to a rebate, which customer or government
agency price terms apply, and the estimated lag time between
sale and payment of a rebate. Using historical trends, adjusted for
current changes, Abbott estimates the amount of the rebate that
will be paid, and records the liability as a reduction of gross sales
when Abbott records its sale of the product. Settlement of the
rebate generally occurs from one to six months after sale. Abbott
regularly analyzes the historical rebate trends and makes adjust-
ments to reserves for changes in trends and terms of rebate
programs. Rebates and chargebacks charged against gross sales
in 2022, 2021, and 2020 amounted to approximately $3.9 billion,
$3.9 billion, and $3.3 billion, respectively, or 17.6 percent,
17.5 percent, and 20.1 percent of gross sales, respectively, based
on gross sales of approximately $22.4 billion, $22.3 billion, and
$16.6 billion, respectively, subject to rebate. A one-percentage
point increase in the percentage of rebates to related gross sales
would decrease net sales by approximately $224 million in 2022.
Abbott considers a one-percentage point increase to be a reason-
ably likely increase in the percentage of rebates to related gross
sales. Other allowances charged against gross sales were

-- 70 of 86 --

F I N A N C I A L R E V I E W
69
A B B O T T 2 0 2 2 A N N U A L R E P O R T
approximately $280 million, $268 million, and $207 million
for cash discounts in 2022, 2021, and 2020, respectively, and
$379 million, $211 million, and $232 million for returns in 2022,
2021, and 2020, respectively. Cash discounts are known within
15 to 30 days of sale, and therefore can be reliably estimated.
Returns can be reliably estimated because Abbott’s historical
returns are low, and because sales returns terms and other sales
terms have remained relatively unchanged for several periods.
Management analyzes the adequacy of ending rebate accrual
balances each quarter. In the domestic nutritional business,
management uses both internal and external data available to
estimate the accruals. In the WIC business, estimates are required
for the amount of WIC sales within each state where Abbott holds
the WIC contract. The state where the sale is made, which is the
determining factor for the applicable rebated price, is reliably
determinable. Rebated prices are based on contractually obligated
agreements generally lasting a period of two to four years. Except
for a change in contract price or a transition period before or after
a change in the supplier for the WIC business in a state, accruals
are based on historical redemption rates and data from the U.S.
Department of Agriculture (USDA) and the states submitting
rebate claims. The USDA, which administers the WIC program,
has been making its data available for many years. Management
also estimates the states’ processing lag time based on sales and
claims data. Management has access to several large customers’
inventory management data, which allows management to make
reliable estimates of inventory in the retail distribution channel.
At December 31, 2022, Abbott had WIC business in 37 states.
Historically, adjustments to prior years’ rebate accruals have not
been material to net income. Abbott employs various techniques to
verify the accuracy of claims submitted to it, and where possible,
works with the organizations submitting claims to gain insight
into changes that might affect the rebate amounts. For government
agency programs, the calculation of a rebate involves interpreta-
tions of relevant regulations, which are subject to challenge or
change in interpretation.
Income Taxes — Abbott operates in numerous countries where its
income tax returns are subject to audits and adjustments. Because
Abbott operates globally, the nature of the audit items is often very
complex, and the objectives of the government auditors can result
in a tax on the same income in more than one country. Abbott
employs internal and external tax professionals to minimize audit
adjustment amounts where possible. In accordance with the
accounting rules relating to the measurement of tax contingencies,
in order to recognize an uncertain tax benefit, the taxpayer must
be more likely than not of sustaining the position, and the mea-
surement of the benefit is calculated as the largest amount that is
more than 50 percent likely to be realized upon resolution of the
benefit. Application of these rules requires a significant amount of
judgment. In the U.S., Abbott’s federal income tax returns through
2016 were settled as of December 31, 2022. Undistributed foreign
earnings remain indefinitely reinvested in foreign operations.
Determining the amount of unrecognized deferred tax liability
related to any remaining undistributed foreign earnings not sub-
ject to the transition tax and additional outside basis difference in
its foreign entities is not practicable.
Pension and Post-Employment Benefits — Abbott offers pension
benefits and post-employment health care to many of its employ-
ees. Abbott engages outside actuaries to assist in the determination
of the obligations and costs under these programs. Abbott must
develop long-term assumptions, the most significant of which
are the health care cost trend rates, discount rates and the
expected return on plan assets. The discount rates used to
measure liabilities were determined based on high-quality fixed
income securities that match the duration of the expected retiree
benefits. The health care cost trend rates represent Abbott’s
expected annual rates of change in the cost of health care benefits
and are a forward projection of health care costs as of the mea-
surement date. A difference between the assumed rates and the
actual rates, which will not be known for years, can be significant
in relation to the obligations and the annual cost recorded for
these programs. The significant net actuarial gains for these plans
in 2022 reflects the impact of higher discount rates on the mea-
surement of plan liabilities, partially offset by lower asset returns
during the year. At December 31, 2022, pretax net actuarial losses
and prior service costs and (credits) recognized in Accumulated
other comprehensive income (loss) were net losses of $2.0 billion
for Abbott’s defined benefit plans and net gains of $6 million for
Abbott’s medical and dental plans. Actuarial losses and gains are
amortized over the remaining service attribution periods of the
employees under the corridor method, in accordance with the
rules for accounting for post-employment benefits. Differences
between the expected long-term return on plan assets and the
actual annual return are amortized over a five-year period.
Valuation of Intangible Assets — Abbott has acquired and contin-
ues to acquire significant intangible assets that Abbott records at
fair value at the acquisition date. Transactions involving the pur-
chase or sale of intangible assets occur with some frequency
between companies in the health care field and valuations are
usually based on a discounted cash flow analysis. The discounted
cash flow model requires assumptions about the timing and
amount of future net cash flows, risk, cost of capital, terminal
values and market participants. Each of these factors can signifi-
cantly affect the value of the intangible asset. Abbott engages
independent valuation experts who review Abbott’s critical
assumptions and calculations for acquisitions of significant
intangibles. Abbott reviews definite-lived intangible assets for
impairment each quarter using an undiscounted net cash
flows approach. If the undiscounted cash flows of an intangible
asset are less than the carrying value of an intangible asset, the
intangible asset is written down to its fair value, which is usually
the discounted cash flow amount. Where cash flows cannot be
identified for an individual asset, the review is applied at the
lowest group level for which cash flows are identifiable. Goodwill
and indefinite-lived intangible assets, which relate to in-process
research and development acquired in a business combination, are
reviewed for impairment annually or when an event that could
result in an impairment occurs. At December 31, 2022, goodwill
amounted to $22.8 billion and net intangibles amounted to
$10.5 billion. Amortization expense in continuing operations for
intangible assets amounted to $2.0 billion in 2022 and 2021 and
$2.1 billion in 2020. There was no reduction of goodwill relating
to impairments in 2022, 2021, and 2020.

-- 71 of 86 --

F I N A N C I A L R E V I E W
70
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. These estimates are often initially developed substan-
tially earlier than the ultimate loss is known, and the estimates are
refined each accounting period as additional information becomes
known. Accordingly, Abbott is often initially unable to develop a
best estimate of loss, and therefore the minimum amount, which
could be zero, is recorded. As information becomes known, either
the minimum loss amount is increased, resulting in additional loss
provisions, or a best estimate can be made, also resulting in addi-
tional loss provisions. Occasionally, a best estimate amount is
changed to a lower amount when events result in an expectation
of a more favorable outcome than previously expected. Abbott
estimates the range of possible loss to be from approximately
$40 million to $50 million for its legal proceedings and environ-
mental exposures. Accruals of approximately $45 million have
been recorded at December 31, 2022 for these proceedings and
exposures. These accruals represent management’s best estimate
of probable loss, as defined by FASB ASC No. 450, “Contingencies.”
RESULTS OF OPERATIONS
SALES
The following table details the components of sales growth by
reportable segment for the last two years:
Total %
Change
Components of % Change
Price 	Volume 	Exchange
Total Net Sales
2022 vs. 2021 	1.3 	(0.3) 	6.7 	(5.1)
2021 vs. 2020 	24.5 	(1.5) 	24.4 	1.6
Total U.S.
2022 vs. 2021 	9.0 	(0.6) 	9.6 	—
2021 vs. 2020 	27.8 	(1.9) 	29.7 	—
Total International
2022 vs. 2021 	(3.5) 	— 	4.7 	(8.2)
2021 vs. 2020 	22.5 	(1.3) 	21.2 	2.6
Established Pharmaceutical Products Segment
2022 vs. 2021 	4.1 	3.7 	6.9 	(6.5)
2021 vs. 2020 	9.6 	4.2 	6.2 	(0.8)
Nutritional Products Segment
2022 vs. 2021 	(10.1) 	7.4 	(13.6) 	(3.9)
2021 vs. 2020 	8.5 	1.0 	6.7 	0.8
Diagnostic Products Segment
2022 vs. 2021 	6.0 	(5.5) 	15.9 	(4.4)
2021 vs. 2020 	44.8 	(6.2) 	48.9 	2.1
Medical Devices Segment
2022 vs. 2021 	2.2 	(0.2) 	8.3 	(5.9)
2021 vs. 2020 	21.9 	(0.9) 	20.3 	2.5
The increase in Total Net Sales in 2022 reflects growth in demand
for Abbott’s rapid diagnostic tests to detect COVID-19 as well as
growth in the Established Pharmaceutical Products and Medical
Devices segments, partially offset by lower Nutritional Products
sales. Abbott’s COVID-19 testing-related sales totaled approxi-
mately $8.4 billion in 2022, $7.7 billion in 2021 and $3.9 billion in
2020. Excluding the impact of COVID-19 testing-related sales,
Abbott’s total net sales decreased 0.3 percent in 2022. Excluding
the impacts of COVID-19 testing-related sales and foreign
exchange, Abbott’s total net sales increased 5.1 percent. Abbott’s
net sales in 2022 were unfavorably impacted by changes in foreign
exchange rates as the relatively stronger U.S. dollar decreased total
international sales by 8.2 percent and total sales by 5.1 percent.
The increase in Total Net Sales in 2021 reflects volume growth
across all of Abbott’s segments. In 2021, excluding the impact of
COVID-19 testing-related sales, Abbott’s total net sales increased
15.2 percent. Excluding the impacts of COVID-19 testing-related
sales and foreign exchange, Abbott’s total net sales increased
13.7 percent.
The price declines related to the Diagnostic Products segment in
2022 and 2021 primarily reflect lower pricing for COVID-19 tests.
The table below provides detail by sales category for the years
ended December 31. percent changes are versus the prior year
and are based on unrounded numbers.
(dollars in millions) 	2022 	2021
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals —
Key Emerging
Markets 	$÷3,728 	$3,539 	5% 	(7)«% 	12%
Other 	1,184 	1,179 	—÷« 	(7)÷÷ 	7÷«
Nutritionals —
International
Pediatric
Nutritionals 	1,919 	2,106 	(9)÷« 	(5)÷÷ 	(4)÷«
U.S. Pediatric
Nutritionals 	1,562 	2,192 	(29)÷« 	—÷÷ 	(29)÷«
International Adult
Nutritionals 	2,621 	2,632 	—÷« 	(8)÷÷ 	8÷«
U.S. Adult
Nutritionals 	1,357 	1,364 	(1)÷« 	—÷÷ 	(1)÷«
Diagnostics —
Core Laboratory 	4,888 	5,128 	(5)÷« 	(7)÷÷ 	2÷«
Molecular 	995 	1,427 	(30)÷« 	(3)÷÷ 	(27)÷«
Point of Care 	525 	536 	(2)÷« 	(1)÷÷ 	(1)÷«
Rapid Diagnostics 	10,176 	8,553 	19÷« 	(4)÷÷ 	23÷«
Medical Devices —
Rhythm
Management 	2,119 	2,198 	(4)÷« 	(6)÷÷ 	2÷«
Electrophysiology 	1,927 	1,907 	1÷« 	(6)÷÷ 	7÷«
Heart Failure 	920 	889 	4÷« 	(2)÷÷ 	6÷«
Vascular 	2,483 	2,654 	(6)÷« 	(5)÷÷ 	(1)÷«
Structural Heart 	1,712 	1,610 	6÷« 	(7)÷÷ 	13÷«
Neuromodulation 	770 	781 	(1)÷« 	(2)÷÷ 	1÷«
Diabetes Care 	4,756 	4,328 	10÷« 	(7)÷÷ 	17÷«

-- 72 of 86 --

F I N A N C I A L R E V I E W
71
A B B O T T 2 0 2 2 A N N U A L R E P O R T
(dollars in millions) 	2021 	2020
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals —
Key Emerging
Markets 	$3,539 	$3,209 	10% 	(2)«% 	12%
Other 	1,179 	1,094 	8÷« 	2÷÷ 	6÷«
Nutritionals —
International
Pediatric
Nutritionals 	2,106 	2,140 	(2)÷« 	1÷÷ 	(3)÷«
U.S. Pediatric
Nutritionals 	2,192 	1,987 	10÷« 	—÷÷ 	10÷«
International Adult
Nutritionals 	2,632 	2,228 	18÷« 	1÷÷ 	17÷«
U.S. Adult
Nutritionals 	1,364 	1,292 	6÷« 	—÷÷ 	6÷«
Diagnostics —
Core Laboratory 	5,128 	4,475 	15÷« 	3÷÷ 	12÷«
Molecular 	1,427 	1,438 	(1)÷« 	2÷÷ 	(3)÷«
Point of Care 	536 	516 	4÷« 	1÷÷ 	3÷«
Rapid Diagnostics 	8,553 	4,376 	95÷« 	2÷÷ 	93÷«
Medical Devices —
Rhythm
Management 	2,198 	1,914 	15÷« 	2÷÷ 	13÷«
Electrophysiology 	1,907 	1,578 	21÷« 	2÷÷ 	19÷«
Heart Failure 	889 	740 	20÷« 	1÷÷ 	19÷«
Vascular 	2,654 	2,339 	14÷« 	3÷÷ 	11÷«
Structural Heart 	1,610 	1,247 	29÷« 	2÷÷ 	27÷«
Neuromodulation 	781 	702 	11÷« 	1÷÷ 	10÷«
Diabetes Care 	4,328 	3,267 	33÷« 	4÷÷ 	29÷«
In order to compute results excluding the impact of exchange rates, current year U.S. dollar
sales are multiplied or divided, as appropriate, by the current year average foreign exchange
rates and then those amounts are multiplied or divided, as appropriate, by the prior year
average foreign exchange rates.
Total Established Pharmaceutical Products sales increased
10.6 percent in 2022 and 10.4 percent in 2021, excluding the
unfavorable impact of foreign exchange. Excluding the impact of
foreign exchange, total sales in Key Emerging markets increased
11.8 percent in 2022 and 11.9 percent in 2021 due to higher sales
in various geographies including India, China, and Brazil, and
several therapeutic areas, including gastroenterology, central
nervous system/pain management, and cardiometabolic products.
Excluding the impact of foreign exchange, sales in Established
Pharmaceuticals’ other emerging markets increased 7.3 percent
in 2022 and 6.0 percent in 2021.
Excluding the impact of foreign exchange, total Nutritional
Products sales decreased 6.2 percent in 2022 compared to a
7.7 percent increase in 2021. The 28.7 percent decrease in U.S.
Pediatric Nutritional sales in 2022 reflects the impact of the
voluntary recall and production stoppage of certain infant powder
formula products manufactured at Abbott’s facility in Sturgis,
Michigan, partially offset by increased demand for Abbott’s
Pedialyte products. U.S. sales of infant powder formula brands
associated with the recall were $479 million and $1.2 billion in
2022 and 2021, respectively. In 2021, U.S. Pediatric Nutritional
sales increased 10.3 percent compared to 2020, reflecting growth
in Pedialyte, Similac, and PediaSure.
International Pediatric Nutritional sales, excluding the effect of
foreign exchange, decreased 3.9 percent in 2022 and 3.2 percent in
2021. The 2022 decrease reflects the impact of challenging market
dynamics in the infant category in Greater China, partially offset
by higher sales volumes in several countries in Southeast Asia and
Latin America. The 2021 decrease reflects lower sales in China,
the Middle East and various countries in Southeast Asia, partially
offset by higher volumes sold in various countries in Latin
America and Europe.
International Adult Nutritional sales, excluding the effect of
foreign exchange, increased 7.6 percent in 2022 and 17.0 percent in
2021, reflecting continued growth of the Ensure® and Glucerna®
brands in various countries. In 2022, U.S. Adult Nutritional sales
decreased 0.5 percent as continued growth of the Ensure brand
was offset by lower sales of other products and the impact of
temporarily utilizing liquid manufacturing capacity to manufac-
ture infant formula. In 2021, U.S. Adult Nutritional sales increased
5.6 percent, primarily due to growth of Ensure and Glucerna.
Excluding the effect of foreign exchange, Diagnostics segment
sales increased 10.4 percent in 2022 and 42.7 percent in 2021,
driven by demand for Abbott’s portfolio of COVID-19 tests in
Rapid Diagnostics. Rapid Diagnostics sales increased 22.5 percent
and 93.3 percent in 2022 and 2021, respectively, excluding the
effect of foreign exchange. The increases reflect COVID-19 test
demand across Abbott’s rapid testing platforms, including the
Panbio® system, the ID NOW® platform, and the BinaxNOW®
COVID-19 Ag Card test. Rapid Diagnostics COVID-19 testing-
related sales were $7.9 billion in 2022, $6.6 billion in 2021 and
$2.6 billion in 2020.
In 2022, Rapid Diagnostics sales increased 15.8 percent, excluding
COVID-19 testing-related sales, and 19.1 percent, excluding the
impact of foreign exchange and COVID-19 testing-related sales.
These increases reflect higher sales of ID NOW tests for flu,
strep, and respiratory syncytial virus (RSV) as well as growth
in various other Rapid Diagnostics products. In 2021, Rapid
Diagnostics sales increased 10.4 percent, excluding COVID-19
testing-related sales, and 9.2 percent, excluding the impact of
foreign exchange and COVID-19 testing-related sales. These
increases reflected the recovery of routine diagnostic testing
from the 2020 impact of the pandemic.

-- 73 of 86 --

F I N A N C I A L R E V I E W
72
A B B O T T 2 0 2 2 A N N U A L R E P O R T
In Core Laboratory Diagnostics, sales increased 1.9 percent in
2022, excluding the effect of foreign exchange, due to the higher
volume of routine diagnostic testing from the continued roll-out
of the Alinity® platform and an expanded menu of tests. These
higher volumes were partially offset by lower sales of Abbott’s
laboratory-based tests for the detection of COVID-19 IgG and
IgM antibodies as well as intermittent market disruptions in China
due to COVID-19 quarantine restrictions in various cities. Core
Laboratory Diagnostics COVID-19 testing-related sales on Abbott’s
ARCHITECT and Alinity i platforms were $62 million in 2022,
$204 million in 2021, and $262 million in 2020. In 2022, Core
Laboratory Diagnostics sales decreased 2.0 percent, excluding
COVID-19 testing-related sales, and increased 4.8 percent,
excluding the impact of foreign exchange and COVID-19 testing-
related sales.
In 2021, Core Laboratory Diagnostics sales increased 12.4 percent,
excluding the effect of foreign exchange, as a higher volume of
routine diagnostic testing performed in hospitals and other labora-
tories was partially offset by lower sales of tests for the detection
of COVID-19 IgG and IgM antibodies.
In Molecular Diagnostics, sales decreased 27.4 percent in 2022
and 2.9 percent in 2021, excluding the effect of foreign exchange.
In both years, the decreases were driven by lower demand for
Abbott’s laboratory-based PCR molecular tests for COVID-19,
partially offset by growth in other areas from the continued roll-
out of the Alinity m platform. Molecular Diagnostics COVID-19
testing-related sales were $411 million in 2022, $891 million in
2021, and $1.0 billion in 2020. In 2022, Molecular Diagnostics sales
increased 9.0 percent, excluding COVID-19 testing-related sales,
and 13.8 percent, excluding the impact of foreign exchange and
COVID-19 testing-related sales. In 2021, Molecular Diagnostics
sales increased 29.2 percent, excluding COVID-19 testing-related
sales, and increased 27.0 percent, excluding the impact of foreign
exchange and COVID-19 testing-related sales.
Excluding the effect of foreign exchange, total Medical Devices
sales grew 8.1 percent in 2022 and 19.4 percent in 2021. In 2022
and 2021, the increase was driven by growth in Diabetes Care,
Structural Heart, Electrophysiology and Heart Failure. The 2022
and 2021 growth in Diabetes Care sales was driven by continued
growth of FreeStyle Libre, Abbott’s continuous glucose monitoring
system, in the U.S. and internationally. FreeStyle Libre sales
totaled $4.3 billion in 2022, which reflected a 22.4 percent
increase, excluding the effect of foreign exchange, over 2021.
FreeStyle Libre sales totaled $3.7 billion in 2021, which reflected
a 36.8 percent increase, excluding the effect of foreign exchange,
over 2020 when sales totaled $2.6 billion.
In 2022, while procedure volumes across Abbott’s cardiovascular
and neuromodulation businesses were negatively impacted by new
surges of COVID-19 in various geographies as well as intermittent
COVID-19 lockdown restrictions in China and healthcare staffing
challenges throughout the year, overall volumes improved in
several businesses versus 2021. In Electrophysiology, the
7.3 percent growth, excluding the effect of foreign exchange,
reflects the increase in procedure volumes and the continued
roll-out of Abbott’s EnSite® X EP System with Ensite Omnipolar
Technology (OT), a new cardiac mapping platform available in
the U.S., Japan and across Europe.
Growth in Structural Heart, excluding the effect of foreign
exchange, was 13.0 percent in 2022, driven by growth across
several areas of the business, including Amplatzer® Amulet® Left
Atrial Appendage Occluder, which offers immediate closure of the
left atrial appendage, an area in the heart where blood clots can
form and MitraClip®, Abbott’s market-leading device for the mini-
mally invasive treatment of mitral regurgitation, a leaky heart
valve. In Vascular, 2022 sales decreased 1.0 percent, excluding the
impact of exchange, as higher endovascular sales were offset by
the negative effect of lower average selling prices globally on
traditional DES and other coronary products and a lower recovery
of percutaneous coronary intervention (PCI) procedures which
impacted the coronary business.
In 2021, while procedure volumes across Abbott’s cardiovascular
and neuromodulation businesses were negatively impacted early
in the year by elevated COVID-19 case rates in certain countries,
including the U.S., overall volumes improved over the course of
2021 across various businesses. The year-over-year increases in
the various businesses reflect a recovery from the 2020 levels
when the pandemic reduced procedure volumes as well as sales
growth from pre-pandemic levels in Structural Heart,
Electrophysiology, and Heart Failure, excluding the effect of
foreign exchange. The growth in Structural Heart during 2021
was broad-based across several areas of the business, including
MitraClip and TriClip®, the world’s first minimally invasive,
clip-based device for repair of a leaky tricuspid heart valve.
Abbott’s operations in Russia and Ukraine represent approxi-
mately 2 percent of Abbott’s total revenues and net assets, and to
date the financial impact of Russia’s invasion of Ukraine has not
been material to Abbott’s operations or financial condition. Future
implications are difficult to predict, but at present Abbott does not
anticipate that the Russia-Ukraine conflict will have a material
impact on its operations or financial condition. A more detailed
discussion of the risks associated with the Russia-Ukraine conflict
is contained in Item 1A. Risk Factors.
Abbott has periodically sold product rights to non-strategic prod-
ucts and has recorded the related gains in net sales in accordance
with Abbott’s revenue recognition policies as discussed in Note 1
to the consolidated financial statements. Related net sales were
not significant in 2022, 2021, or 2020.
The expiration of licenses and patent protection can affect the
future revenues and operating income of Abbott. There are no
significant patent or license expirations in the next three years
that are expected to materially affect Abbott.

-- 74 of 86 --

F I N A N C I A L R E V I E W
73
A B B O T T 2 0 2 2 A N N U A L R E P O R T
OPERATING EARNINGS
Gross profit margins were 51.5 percent of net sales in 2022,
52.2 percent of net sales in 2021, and 50.5 percent in 2020.
The decrease in 2022 reflects the impact of the voluntary infant
product recall and Sturgis manufacturing stoppage as well as the
prioritization of infant formula sales related to the WIC Program
in the Nutritional business. The decrease also reflects higher
manufacturing and supply chain costs across Abbott’s businesses,
including inflation, commodities and distribution expenses. In
2021, the increase primarily reflects the effects of higher sales
volume, higher manufacturing utilization, and the nonrecurrence
of a 2020 impairment of intangible assets, partially offset by
increases in various manufacturing costs and the impact of
higher restructuring charges.
Research and development (R&D) expenses were $2.9 billion in
2022, $2.7 billion in 2021, and $2.4 billion in 2020. The increase
primarily reflects higher spending on various projects to advance
products in development as well as the impairment of certain
in-process R&D intangible assets partially offset by the favorable
impact of foreign exchange. The increase in 2021 R&D spending
was primarily driven by higher spending on various projects to
advance products in development.
Selling, general and administrative (SG&A) expenses were virtu-
ally unchanged in 2022 compared to 2021 as higher selling and
marketing spending to drive growth was offset by the favorable
impact of foreign exchange. SG&A expenses increased 16.8 percent
in 2021 due primarily to higher selling and marketing spending
and the nonrecurrence of $100 million of income in 2020 from a
litigation settlement. The increase in 2021 also includes charges
related to certain litigation.
RESTRUCTURINGS
In 2022, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in its
medical devices, nutritional, diagnostic, and established pharma-
ceutical businesses. Abbott recorded employee related severance
and other charges of approximately $234 million of which approx-
imately $59 million was recorded in Cost of products sold,
approximately $36 million was recorded in Research and develop-
ment and approximately $139 million was recorded in Selling,
general and administrative expenses. In addition, Abbott recog-
nized inventory related charges of approximately $23 million and
fixed assets impairment charges of approximately $4 million
related to these restructuring plans.
In 2021, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in
Abbott’s diagnostic, established pharmaceutical, nutritional, and
medical device businesses. Abbott recorded employee related
severance and other charges of approximately $68 million of
which approximately $16 million was recorded in Cost of products
sold, approximately $4 million was recorded in Research and
development and approximately $48 million was recorded in
Selling, general and administrative expenses.
On May 27, 2021, Abbott management approved a restructuring
plan related to its Diagnostic Products segment to align its manu-
facturing network for COVID-19 diagnostic tests with changes in
the second quarter of 2021 in projected testing demand driven
by several factors, including significant reductions in cases in the
U.S. and other major developed countries, the accelerated rollout
of COVID-19 vaccines globally and the U.S. health authority’s
updated guidance on testing for fully vaccinated individuals.
In the second quarter of 2021, Abbott recorded charges of
$499 million under this plan in Cost of products sold. The charge
recognized in the second quarter included fixed asset write-downs
of $80 million, inventory-related charges of $248 million, and
other exit costs, which included contract cancellations and
employee-related costs of $171 million.
In the second half of 2021, as the Delta and Omicron variants
of COVID-19 spread and the number of new COVID-19 cases
increased significantly, particularly in the U.S., demand for rapid
COVID-19 tests increased significantly. As a result, in the second
half of 2021, Abbott sold approximately $181 million of inventory
that was previously estimated to have no net realizable value
under the second quarter restructuring action. In addition, the
estimate of other exit costs was reduced by a net $58 million as
Abbott fulfilled its purchase obligations under certain contracts
for which a liability was recorded in the second quarter or Abbott
settled with the counterparty in the second half of 2021.
INTEREST EXPENSE AND INTEREST (INCOME)
Interest expense, net decreased $115 million in 2022 due to the
impact of higher interest rates and cash and short-term invest-
ment balances on interest income and the repayment of debt in
the first quarter of 2022 partially offset by the impact of interest
rate hedge contracts related to certain fixed-rate debt. Interest
expense, net decreased $10 million in 2021 due to the reduction
of interest expense driven by lower interest rates in 2021. The
effects of higher cash and short-term investment balances were
more than offset by the impact of lower interest rates on interest
income in 2021.
OTHER (INCOME) EXPENSE, NET
Other (income) expense, net includes income of approximately
$406 million, $270 million, and $205 million in 2022, 2021, and
2020, respectively, related to the non-service cost components of
the net periodic benefit costs associated with the pension and
post-retirement medical plans. Other (income) expense, net also
includes equity investment impairments that totaled approxi-
mately $45 million in 2022 and $115 million in 2020 and a gain
on the sale of an equity method investment in 2021.

-- 75 of 86 --

F I N A N C I A L R E V I E W
74
A B B O T T 2 0 2 2 A N N U A L R E P O R T
TAXES ON EARNINGS
The income tax rates on earnings from continuing operations were
16.5 percent in 2022, 13.9 percent in 2021, and 10.0 percent in 2020.
In 2022, taxes on earnings from continuing operations include
approximately $43 million in excess tax benefits associated with
share-based compensation and approximately $20 million of net
tax expense as a result of the resolution of various tax positions
related to prior years.
In 2021, taxes on earnings from continuing operations include
approximately $145 million in excess tax benefits associated with
share-based compensation and approximately $55 million of net
tax benefits as a result of the resolution of various tax positions
related to prior years.
In 2020, taxes on earnings from continuing operations include
the recognition of approximately $170 million of tax benefits
associated with the impairment of certain assets, approximately
$140 million of net tax benefits as a result of the resolution of
various tax positions related to prior years, and approximately
$100 million in excess tax benefits associated with share-based
compensation. In 2020, taxes on earnings from continuing opera-
tions also include a $26 million increase to the transition tax
liability associated with the 2017 Tax Cuts and Jobs Act (TCJA).
The $26 million increase to the transition tax liability was the
result of the resolution of various tax positions related to prior
years. This adjustment increased the cumulative net tax expense
related to the TCJA to $1.53 billion. As of December 31, 2022, the
remaining balance of Abbott’s transition tax obligation is approxi-
mately $739 million, which will be paid over the next four years
as allowed by the TCJA. Earnings from discontinued operations,
net of tax, in 2020 reflect the recognition of $24 million of net
tax benefits primarily as a result of the resolution of various tax
positions related to prior years.
Exclusive of these discrete items, tax expense was favorably
impacted by lower tax rates and tax exemptions on foreign income
primarily derived from operations in Puerto Rico, Switzerland,
Ireland, the Netherlands, Costa Rica, Singapore, and Malta. Abbott
benefits from a combination of favorable statutory tax rules, tax
rulings, grants, and exemptions in these tax jurisdictions.
Abbott’s future effective tax rate could be impacted by changes in
federal, state or international tax laws or tax rulings. In December
2022, the European Union approved a tax directive that instructs
its member states to adopt local legislation that ensures that every
multinational company pays a minimum 15 percent tax rate in
every jurisdiction in which it operates, beginning in 2024. Other
non-EU countries have also announced their intentions to adopt
a similar policy. Widespread adoption of a minimum tax rate
regime could have an unfavorable impact on Abbott’s future
effective tax rate.
See Note 14 to the consolidated financial statements for a
full reconciliation of the effective tax rate to the U.S. federal
statutory rate.
RESEARCH AND DEVELOPMENT PROGRAMS
Abbott currently has numerous pharmaceutical, medical devices,
diagnostic and nutritional products in development.
RESEARCH AND DEVELOPMENT PROCESS
In the Established Pharmaceuticals segment, the development
process focuses on the geographic expansion and continuous
improvement of the segment’s existing products to provide bene-
fits to patients and customers. As Established Pharmaceuticals
does not actively pursue primary research, development usually
begins with work on existing products or after the acquisition of
an advanced stage licensing opportunity.
Depending upon the product, the phases of development
may include:
• Drug product development.
• Phase I bioequivalence studies to compare a future Established
Pharmaceutical’s brand with an already marketed compound
with the same active pharmaceutical ingredient (API).
• Phase II studies to test the efficacy of benefits in a small group
of patients.
• Phase III studies to broaden the testing to a wider population
that reflects the actual medical use.
• Phase IV and other post-marketing studies to obtain new clini-
cal use data on existing products within approved indications.
The specific requirements (e.g., scope of clinical trials) for
obtaining regulatory approval vary across different countries and
geographic regions. The process may range from one year for a
bioequivalence study project to six or more years for complex
formulations, new indications, or geographic expansion in specific
countries, such as China.
In the Diagnostics segment, the phases of the research and
development process include:
• Discovery which focuses on identification of a product that
will address a specific therapeutic area, platform, or unmet
clinical need.
• Concept/Feasibility during which the materials and manufac-
turing processes are evaluated, testing may include product
characterization and analysis is performed to confirm clinical
utility.
• Development during which extensive testing is performed to
demonstrate that the product meets specified design require-
ments and that the design specifications conform to user needs
and intended uses.
The regulatory requirements for diagnostic products vary across
different countries and geographic regions. In the U.S., the FDA
classifies diagnostic products into classes (I, II, or III) and the
classification determines the regulatory process for approval.

-- 76 of 86 --

F I N A N C I A L R E V I E W
75
A B B O T T 2 0 2 2 A N N U A L R E P O R T
While the Diagnostics segment has products in all three classes,
the vast majority of its products are categorized as Class I or
Class II. Submission of a separate regulatory filing is not required
for Class I products. Class II devices typically require pre-market
notification to the FDA through a regulatory filing known as a
510(k) submission. Most Class III products are subject to the
FDA’s Premarket Approval (PMA) requirements. Other Class III
products, such as those used to screen blood, require the submis-
sion and approval of a Biological License Application (BLA).
In the European Union (EU), diagnostic products are also catego-
rized into different categories and the regulatory process, which
has been governed by the European In Vitro Diagnostic Medical
Device Directive, depends upon the category, with certain product
categories requiring review and approval by an independent com-
pany, known as a Notified Body, before the manufacturer can affix
a CE mark to the product to declare conformity to the Directive.
Other products only require a self-certification process. In 2017,
the EU adopted the new In Vitro Diagnostic Regulation (IVDR)
which replaced the existing directive in the EU for in vitro diag-
nostic products and imposed additional premarket and
post-market regulatory requirements on manufacturers of such
products. In December 2021, the IVDR was amended to extend
the regulation’s previous two-year transition period by a range of
one to three years, with the transition period extending to May
2027 for certain classes of diagnostic devices. However, the
amendment did not delay the date of application of the IVDR
itself which took effect on May 26, 2022.
In the Medical Devices segment, the research and development
process begins with research on a specific technology that is
evaluated for feasibility and commercial viability. If the research
program passes that hurdle, it moves forward into development.
The development process includes evaluation, selection and
qualification of a product design, completion of applicable clinical
trials to test the product’s safety and efficacy, and validation of
the manufacturing process to demonstrate its repeatability and
ability to consistently meet pre-determined specifications.
Similar to the diagnostic products discussed above, in the U.S.,
medical devices are classified as Class I, II, or III. Most of Abbott’s
medical device products are classified as Class II devices that
follow the 510(k) regulatory process or Class III devices that are
subject to the PMA process.
In the EU, medical devices are also categorized into different
classes and the regulatory process, which had been governed
by the European Medical Device Directive and the Active
Implantable Medical Device Directive, varies by class. In the
second quarter of 2017, the EU adopted the new Medical Devices
Regulation (MDR) which replaced the existing directives in the
EU for medical devices and imposes additional premarket and
post-market regulatory requirements on manufacturers of such
products. The MDR applies to manufacturers as of May 26, 2021
with a transition period until May 26, 2024. Each product must
bear a CE mark to show compliance with the MDR.
Some products require submission of a design dossier to the
appropriate regulatory authority for review and approval prior to
CE marking of the device. For other products, the company is
required to prepare a technical file which includes testing results
and clinical evaluations but can self-certify its ability to apply the
CE mark to the product. Outside the U.S. and the EU, the regula-
tory requirements vary across different countries and regions.
After approval and commercial launch of some medical devices,
post-market trials may be conducted either due to a conditional
requirement of the regulatory market approval or with the objec-
tive of proving product superiority.
In the Nutritional segment, the research and development pro-
cess generally focuses on identifying and developing ingredients
and products that address the nutritional needs of particular
populations (e.g., infants and adults) or patients (e.g., people with
diabetes). Depending upon the country and/or region, if claims
regarding a product’s efficacy will be made, clinical studies
typically must be conducted.
In the U.S., the FDA requires that it be notified of proposed new
formulations and formulation or packaging changes related to
infant formula products. Prior to the launch of an infant formula
or product packaging change, the company is required to obtain
the FDA’s confirmation that it has no objections to the proposed
product or packaging. For other nutritional products, notification
or pre-approval from the FDA is not required unless the product
includes a new food additive. In some countries, regulatory
approval may be required for certain nutritional products,
including infant formula and medical nutritional products.
AREAS OF FOCUS
In 2023 and beyond, Abbott’s significant areas of therapeutic
focus will include the following:
Established Pharmaceuticals — Abbott focuses on building
country-specific portfolios made up of high-quality medicines
that meet the needs of people in emerging markets. Over the next
several years, Abbott plans to expand its product portfolio in key
therapeutic areas with the aim of addressing the health needs of
more people in emerging markets and being among the first to
launch new off-patent and differentiated medicines. In addition,
Abbott continues to expand existing brands into new markets,
implement product enhancements that provide value to patients
and acquire strategic products and technology through licensing
activities. Abbott is also actively working on the further develop-
ment of several key brands such as Creon™, Duphaston™,
Femoston™ and Influvac™. Depending on the product, the activi-
ties focus on development of new data, markets, formulations,
delivery systems, or indications.

-- 77 of 86 --

F I N A N C I A L R E V I E W
76
A B B O T T 2 0 2 2 A N N U A L R E P O R T
Medical Devices — Abbott’s research and development programs
focus on:
• Cardiac Rhythm Management – Development of next-generation
rhythm management technologies, including advanced commu-
nication capabilities and leadless pacing therapies.
• Heart Failure – Continued enhancements to Abbott’s mechani-
cal circulatory support and pulmonary artery pressure systems,
including enhanced clinical performance and usability.
• Electrophysiology – Development of next-generation technolo-
gies in the areas of ablation, diagnostic, mapping, and
visualization and recording.
• Vascular – Development of next-generation technologies for
use in coronary and peripheral vascular procedures.
• Structural Heart – Development of transcatheter and surgical
devices for the repair and replacement of heart valves, and
occlusion therapies for congenital heart defects and stroke-
risk reduction.
• Neuromodulation – Development of clinical evidence and
next-generation technologies leveraging digital health to
support improved patient clinical outcomes, physician engage-
ment, and expanded indications in the treatment of chronic
pain, movement disorders and other indications.
• Diabetes Care – Develop enhancements and additional indica-
tions for the FreeStyle Libre platform of continuous glucose
monitoring products to help patients improve their ability to
manage diabetes and for use beyond diabetes.
Nutritionals — Abbott is focusing its research and development
spend on platforms that span the pediatric and adult nutrition
areas: gastrointestinal/immunity health, brain health, mobility
and metabolism, and user experience platforms. Numerous new
products that build on advances in these platforms are currently
under development, including clinical outcome testing, and are
expected to be launched over the coming years.
Core Laboratory Diagnostics — Abbott continues to commercialize
its next-generation blood and plasma screening, immunoassay,
clinical chemistry and hematology systems, along with assays,
including a focus on unmet medical need, in various areas includ-
ing but not limited to infectious disease, cardiac care, metabolics,
oncology, and neurologic assays as well as informatics solutions to
help optimize diagnostics laboratory performance and automation
solutions to increase efficiency in laboratories.
Molecular Diagnostics — Several new molecular in vitro diagnostic
(IVD) tests are in various stages of development and launch.
Rapid Diagnostics — Abbott’s research and development programs
focus on the development of diagnostic products for infectious
disease, cardiometabolic disease and toxicology.
In addition, the Diagnostics segment is pursuing the FDA’s cus-
tomary regulatory process for various COVID-19 tests for which
EUAs were obtained.
Given the diversity of Abbott’s business, its intention to remain a
broad-based health care company and the numerous sources for
potential future growth, no individual project is expected to be
material to cash flows or results of operations over the next five
years. Factors considered included research and development
expenses projected to be incurred for the project over the next year
relative to Abbott’s total research and development expenses, as
well as qualitative factors, such as marketplace perceptions and
impact of a new product on Abbott’s overall market position. There
were no delays in Abbott’s 2022 research and development activi-
ties that are expected to have a material impact on operations.
While the aggregate cost to complete the numerous projects
currently in development is expected to be material, the total
cost to complete will depend upon Abbott’s ability to successfully
finish each project, the rate at which each project advances, and
the ultimate timing for completion. Given the potential for signifi-
cant delays and the risk of failure inherent in the development
of medical device, diagnostic and pharmaceutical products and
technologies, it is not possible to accurately estimate the total
cost to complete all projects currently in development. Abbott
plans to manage its portfolio of projects to achieve research and
development spending that will be competitive in each of the
businesses in which it participates, and such spending is targeted
at approximately 7 percent of total Abbott sales in 2023. Abbott
does not regularly accumulate or make management decisions
based on the total expenses incurred for a particular development
phase in a given period.
GOODWILL
At December 31, 2022, goodwill recorded as a result of business
combinations totaled $22.8 billion. Goodwill is reviewed for
impairment annually in the third quarter or when an event that
could result in an impairment occurs, using a quantitative assess-
ment to determine whether it is more likely than not that the fair
value of any reporting unit is less than its carrying amount. The
income and market approaches are used to calculate the fair value
of each reporting unit. The results of the last impairment test
indicated that the fair value of each reporting unit was substan-
tially in excess of its carrying value.

-- 78 of 86 --

F I N A N C I A L R E V I E W
77
A B B O T T 2 0 2 2 A N N U A L R E P O R T
FINANCIAL CONDITION
CASH FLOW
Net cash from operating activities amounted to $9.6 billion,
$10.5 billion, and $7.9 billion in 2022, 2021, and 2020, respectively.
The decrease in Net cash from operating activities in 2022 was
primarily due to the unfavorable cash flow impact of an increased
investment in working capital partially offset by reduced expendi-
tures related to restructuring actions and lower cash payments for
income taxes. The increase in Net cash from operating activities in
2021 was primarily due to the favorable cash flow impact of higher
segment operating earnings and improved working capital man-
agement partially offset by higher cash taxes paid and the net
impact of litigation settlements.
A substantial portion of Abbott’s cash and cash equivalents at
December 31, 2022, is held by Abbott affiliates outside of the U.S.
If these funds were needed for operations in the U.S., Abbott does
not expect to incur significant additional income taxes in the
future to repatriate these funds.
Abbott funded $413 million in 2022, $418 million in 2021, and
$400 million in 2020 to defined benefit pension plans. Abbott
expects pension funding of approximately $407 million in 2023 for
its pension plans. Abbott expects annual cash flow from operating
activities to continue to exceed Abbott’s capital expenditures and
cash dividends.
DEBT AND CAPITAL
At December 31, 2022, Abbott’s long-term debt rating was AA- by
Standard & Poor’s Corporation and A1 by Moody’s. Abbott expects
to maintain an investment grade rating.
Abbott has readily available financial resources, including unused
lines of credit that support commercial paper borrowing arrange-
ments and provide Abbott with the ability to borrow up to
$5 billion on an unsecured basis. The lines of credit are part of a
Five Year Credit Agreement (Revolving Credit Agreement) that
Abbott entered into on November 12, 2020. Any borrowings under
the Revolving Credit Agreement will mature and be payable on
November 12, 2025, and will bear interest, at Abbott’s option,
based on either a base rate or Eurodollar rate, plus an applicable
margin based on Abbott’s credit ratings.
As of December 31, 2022, Abbott’s total debt outstanding was
$16.8 billion, of which $2.25 billion will mature in 2023. The
repayment of the debt maturing in 2023 is expected to be funded
from cash on hand.
On March 15, 2022, Abbott repaid the $750 million outstanding
principal amount of its 2.55% Notes upon maturity.
In 2021, Abbott repaid approximately $195 million on a short-term
facility upon maturity. After the repayment, Abbott has no short-
term debt.
In 2020, financing activities related to the issuance and repayment
of long-term debt included the following:
• On June 24, 2020, Abbott completed the issuance of $1.3 billion
aggregate principal amount of senior notes, consisting of
$650 million of its 1.15% Notes due 2028 and $650 million of its
1.40% Notes due 2030.
• On September 28, 2020, Abbott repaid the €1.140 billion out-
standing principal amount of its 0.00% Notes due 2020 upon
maturity. The repayment equated to approximately $1.3 billion.
In September 2019, the board of directors authorized the early
redemption of up to $5 billion of outstanding long-term notes. As
of December 31, 2022, $2.15 billion of the $5 billion authorization
remains available.
In October 2019, the board of directors authorized the repurchase
of up to $3 billion of Abbott’s common shares from time to time.
This authorization was in addition to the unused portion of a
previous share repurchase program that was authorized in 2014.
Under the program authorized in 2014, Abbott repurchased
1.6 million shares at a cost of $173 million in 2020.
In 2021, Abbott repurchased 16.6 million of its common shares for
$2.016 billion which fully utilized the authorization remaining
under the 2014 share repurchase program and a portion of the
2019 authorization. In December 2021, the board of directors
authorized the repurchase of up to $5 billion of Abbott’s common
shares from time to time. This authorization was in addition to the
$1.081 billion portion of the share repurchase program authorized
in 2019 that was unused as of December 31, 2021. In 2022, Abbott
repurchased 32.3 million of its common shares for $3.65 billion
which fully utilized the authorization remaining under the 2019
share repurchase program and a portion of the 2021 authorization.
As of December 31, 2022, $2.43 billion remains available for repur-
chase under the 2021 repurchase program.
Abbott declared dividends of $1.92 per share in 2022 compared to
$1.82 per share in 2021, an increase of approximately 5.5 percent.
Dividends paid were $3.309 billion in 2022 compared to
$3.202 billion in 2021. The year-over-year change in dividends
paid reflects the impact of the increase in the dividend rate.

-- 79 of 86 --

F I N A N C I A L R E V I E W
78
A B B O T T 2 0 2 2 A N N U A L R E P O R T
WORKING CAPITAL
Working capital was $9.7 billion at December 31, 2022 and
$11.1 billion at December 31, 2021. The decrease was due largely
to the classification of $2.3 billion of Senior Notes due in 2023 as
current liabilities, partially offset by an increase in inventory.
Abbott monitors the credit worthiness of customers and estab-
lishes an allowance that reflects the current estimate of credit
losses expected to be incurred over the life of the financial asset.
Abbott considers various factors in establishing, monitoring, and
adjusting its allowance for doubtful accounts, including the aging
of the accounts and aging trends, the historical level of charge-
offs, and specific exposures related to particular customers.
Abbott also monitors other risk factors and forward-looking
information, such as country risk, when determining credit limits
for customers and establishing adequate allowances.
CAPITAL EXPENDITURES
Capital expenditures of $1.8 billion in 2022, $1.9 billion in 2021,
and $2.2 billion in 2020 were principally for upgrading and
expanding manufacturing and research and development facilities
and equipment in various segments, investments in information
technology, and laboratory instruments placed with customers.
2020 capital expenditures also included the building of capacity
for the manufacture of COVID-19 diagnostics tests.
CONTRACTUAL OBLIGATIONS
Abbott believes that its available cash and cash equivalents along
with its ability to generate operating cash flow and continued
access to debt markets are sufficient to fund existing and planned
cash requirements. Abbott’s material cash requirements include
the following contractual obligations:
Debt — Principal payments required on long-term debt outstand-
ing at December 31, 2022 are $2.3 billion in 2023, $1.1 billion in
2024, $1.5 billion in 2025, $2.9 billion in 2026, $0.6 billion in
2027 and $8.7 billion in 2028 and thereafter. Interest payments
required on long-term debt outstanding at December 31, 2022
are $567 million in 2023, $525 million in 2024, $493 million in
2025, $462 million in 2026, $391 million in 2027 and $5.4 billion
in 2028 and thereafter.
Operating leases — As of December 31, 2022, estimated contractual
obligations for operating lease payments were $1.341 billion, with
$258 million due within 12 months.
In addition, Abbott enters into purchase commitments in the
normal course of business to meet operational and capital
expenditure requirements. The majority of outstanding purchase
commitments generally do not extend past one year.
CONTINGENT OBLIGATIONS
Abbott periodically acquires a business or product rights in which
Abbott agrees to pay contingent consideration based on attaining
certain thresholds or based on the occurrence of certain events.
LEGISLATIVE ISSUES
Abbott’s primary markets are highly competitive and subject to
substantial government regulations throughout the world. Abbott
expects debate to continue over the availability, method of deliv-
ery, and payment for health care products and services. It is not
possible to predict the extent to which Abbott or the health care
industry in general might be adversely affected by these factors in
the future. A more complete discussion of these factors is con-
tained in Item 1, Business, and Item 1A, Risk Factors.
RECENTLY ISSUED ACCOUNTING STANDARDS
In December 2019, the Financial Accounting Standards Board
(FASB) issued Accounting Standards Update (ASU) 2019-12,
Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes, which among other things, eliminates certain exceptions in
the current rules regarding the approach for intraperiod tax allo-
cations and the methodology for calculating income taxes in an
interim period, and clarifies the accounting for transactions that
result in a step-up in the tax basis of goodwill. Abbott adopted the
standard on January 1, 2021. The new standard did not have an
impact on its consolidated financial statements.
RECENT ACCOUNTING STANDARDS NOT YET ADOPTED
In September 2022, the FASB issued ASU 2022-04, Disclosure
of Supplier Finance Program Obligations, which requires an entity
to report information about its supplier finance program. The
standard becomes effective for Abbott in the first quarter of 2023.
Abbott does not expect adoption of this new standard to have a
material impact on its consolidated financial statements.
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 —
A CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
Under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, Abbott cautions investors that
any forward-looking statements or projections made by Abbott,
including those made in this document, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Economic, competitive, governmental,
technological and other factors that may affect Abbott’s opera-
tions are discussed in Item 1A, Risk Factors.

-- 80 of 86 --

F I N A N C I A L R E V I E W
79
A B B O T T 2 0 2 2 A N N U A L R E P O R T
P E R F O R M A N C E G R A P H
Assuming $100 invested on December 31, 2017 with dividends reinvested.
Abbott Laboratories
S&P 500 Index
S&P 500 Health Care
2018	2017 	2019 	2020 	2021 	2022
$0
$50
$150
$100
$200
$250
$300 	This graph compares the change
in Abbott’s cumulative total shareholder
return on its common shares with the
Standard & Poor’s 500 Index and the
Standard & Poor’s 500 Health Care Index.

-- 81 of 86 --

80
A B B O T T 2 0 2 2 A N N U A L R E P O R T
S U M M A R Y O F S E L E C T E D F I N A N C I A L D ATA
(Dollars in millions except per share data)
Year Ended December 31 	2022 	2021 	2020 	2019 	2018
Summary of Operations:
Net Sales 	$ 	43,653 	43,075 	34,608 	31,904 	30,578
Cost of products sold 	$ 	21,155 	20,584 	17,135 	15,167 	14,884
Research & development 	$ 	2,888 	2,742 	2,420 	2,440 	2,300
Selling, general, and administrative 	$ 	11,248 	11,324 	9,696 	9,765 	9,744
Operating earnings 	$ 	8,362 	8,425 	5,357 	4,532 	3,650
Interest expense 	$ 	558 	533 	546 	670 	826
Interest income 	$ 	(183) 	(43) 	(46) 	(94) 	(105)
Other (income) expense, net (a) 	$ 	(319) 	(276) 	(111) 	(121) 	56
Earnings before taxes 	$ 	8,306 	8,211 	4,968 	4,077 	2,873
Taxes on earnings from continuing operations 	$ 	1,373 	1,140 	497 	390 	539
Earnings from continuing operations 	$ 	6,933 	7,071 	4,471 	3,687 	2,334
Net earnings 	$ 	6,933 	7,071 	4,495 	3,687 	2,368
Basic earnings per common share from continuing operations 	$ 	3.94 	3.97 	2.51 	2.07 	1.32
Basic earnings per common share 	$ 	3.94 	3.97 	2.52 	2.07 	1.34
Diluted earnings per common share from continuing operations 	$ 	3.91 	3.94 	2.49 	2.06 	1.31
Diluted earnings per common share 	$ 	3.91 	3.94 	2.50 	2.06 	1.33
Financial Positions:
Working capital 	$ 	9,735 	11,134 	8,534 	4,804 	5,620
Long-term investment securities 	$ 	766 	816 	821 	883 	897
Net property & equipment 	$ 	9,162 	8,959 	9,029 	8,038 	7,563
Total assets 	$ 	74,438 	75,196 	72,548 	67,887 	67,173
Long-term debt, including current portion 	$ 	16,773 	18,050 	18,534 	17,938 	19,366
Shareholders’ investment 	$ 	36,905 	36,024 	33,003 	31,301 	30,722
Book value per share 	$ 	21.24 	20.42 	18.63 	17.76 	17.50
Other Statistics:
Gross profit margin 	% 	51.5 	52.2 	50.5 	52.5 	51.3
Research and development to net sales 	% 	6.6 	6.4 	7.0 	7.6 	7.5
Net cash from operating activities 	$ 	9,581 	10,533 	7,901 	6,136 	6,300
Capital expenditures 	$ 	1,777 	1,885 	2,177 	1,638 	1,394
Cash dividends declared per common share 	$ 	1.92 	1.82 	1.53 	1.32 	1.16
Common shares outstanding (in thousands) 	1,737,795 	1,764,082 	1,771,230 	1,762,503 	1,755,619
Number of common shareholders 	34,019 	35,926 	37,450 	38,990 	42,827
Market price per share – high 	$ 	139.83 	142.60 	115.14 	89.24 	74.92
Market price per share – low 	$ 	93.25 	105.36 	61.61 	65.50 	55.58
Market price per share – close 	$ 	109.79 	140.74 	109.49 	86.80 	72.33
a) These amounts include net foreign exchange (gain) loss in each year and debt extinguishment costs in 2019 and 2018.

-- 82 of 86 --

81	*Denotes executive officer
D I R EC TO R S
Robert J. Alpern, M.D.
Ensign Professor of Medicine
and Physiology and Professor
of Internal Medicine and
Cellular and Molecular
Physiology, and Former Dean
of Yale School of Medicine
Claire Babineaux-Fontenot
Chief Executive Officer,
Feeding America
Sally E. Blount, Ph.D.
President and Chief
Executive Officer, Catholic
Charities of the Archdiocese
of Chicago and
Michael L. Nemmers
Professor of Strategy and
Former Dean of the
J.L. Kellogg Graduate School
of Management at
Northwestern University
Robert B. Ford
Chairman of the Board and
Chief Executive Officer,
Abbott Laboratories
Paola Gonzalez
Vice President and Treasurer
of The Clorox Company
Michelle A. Kumbier
President, Turf &
Consumer Products,
Briggs & Stratton, LLC
Darren W. McDew
Retired General, United
States Air Force, and
Former Commander of U.S.
Transportation Command
Nancy McKinstry
Chief Executive Officer
and Chairman of the
Executive Board of
Wolters Kluwer N.V.
William A. Osborn
Retired Chairman and
Chief Executive Officer of
Northern Trust Corporation
Michael F. Roman
Chairman of the Board,
President and
Chief Executive Officer,
3M Company
Daniel J. Starks
Retired Chairman, President
and Chief Executive Officer
of St. Jude Medical, Inc.
John G. Stratton
Executive Chairman of
Frontier Communications
Parent, Inc.
Glenn F. Tilton
Retired Chairman,
President and Chief
Executive Officer
of UAL Corporation
S E N I O R M A N AG E M E N T
Robert B. Ford*
Chairman of the Board and
Chief Executive Officer
Hubert L. Allen*
Executive Vice President,
General Counsel and
Secretary
John M. Capek*
Executive Vice President,
Ventures
Lisa D. Earnhardt*
Executive Vice President,
Medical Devices
Robert E. Funck, Jr.*
Executive Vice President,
Finance and
Chief Financial Officer
John F. Ginascol*
Executive Vice President,
Core Diagnostics
Joseph Manning*
Executive Vice President,
Nutritional Products
Mary K. Moreland*
Executive Vice President,
Human Resources
Daniel Salvadori*
Executive Vice President and
Group President, Established
Pharmaceuticals
and Nutritional Products
Andrea Wainer*
Executive Vice President,
Rapid and Molecular
Diagnostics
Gregory A. Ahlberg*
Senior Vice President,
Core Laboratory Diagnostics,
Commercial Operations
Christopher J. Calamari*
Senior Vice President,
U.S. Nutrition
Michael D. Dale*
Senior Vice President,
Structural Heart
J. Scott House
Senior Vice President,
Quality Assurance,
Regulatory and Engineering
Services
Sammy Karam*
Senior Vice President,
Established Pharmaceuticals,
Emerging Markets
Fernando Mateus*
Senior Vice President,
International Nutrition
Louis H. Morrone*
Senior Vice President,
Rapid Diagnostics
Michael J. Pederson*
Senior Vice President,
Electrophysiology
Julie L. Tyler*
Senior Vice President,
Abbott Vascular
Jared L. Watkin*
Senior Vice President,
Diabetes Care
Alejandro D. Wellisch*
Senior Vice President,
Established Pharmaceuticals,
Latin America
Randel W. Woodgrift*
Senior Vice President,
Cardiac Rhythm
Management
CO R P O R AT E V I C E PR E S I D E N T S
Venu Ambati
Vice President, Established
Pharmaceuticals, India
Elizabeth M. Balthrop
Vice President,
Transfusion Medicine
Erica L. Battaglia
Vice President, Chief Ethics
and Compliance Officer
Keith Boettiger
Vice President,
Heart Failure
Philip P. Boudreau*
Vice President,
Finance and Controller
Melissa D. Brotz
Vice President,
Public Affairs and
Corporate Marketing
P. Claude Burcky
Vice President,
Government Affairs
Fanny Chen
Vice President,
Core Diagnostics, China
Keith Cienkus
Vice President.
Molecular Diagnostics
Kathryn S. Collins
Vice President,
Commercial Legal
Operations
Elizabeth C. Cushman
Vice President,
Specialty Legal
Thomas C. Evers
Vice President,
U.S. Government Affairs
Sabina A. Ewing
Vice President, Business
and Technology Services
John S. Frels
Vice President,
Research and Development,
Immunoassay/Clinical
Chemistry
Jeffrey N. Haas II
Vice President,
Infectious Disease,
Developed Markets,
Rapid Diagnostics
Damian P. Halloran
Vice President,
Infectious Disease,
Emerging Markets,
Rapid Diagnostics
Gene Huang, Ph.D.
Vice President,
Chief Economist
Gary C. Johnson
Vice President, Clinical,
Regulatory and Health
Economics Outcomes
Research, Cardiovascular
and Neuromodulation
Robert R. Kunkler
Vice President,
Toxicology, Cardiometabolic
and Consumer Products
and Services
Brian Lehman
Vice President,
Commercial Operations,
Electrophysiology
Scott M. Leinenweber
Vice President, Investor
Relations, Licensing
and Acquisitions
Pedro Malha
Vice President,
Neuromodulation
John A. McCoy Jr.
Vice President,
Treasurer
Jana Mihaylova
Vice President,
Nutrition, Asia Pacific
Shawn D. Millerick
Vice President,
Pediatric Nutrition
John M. Murphy
Vice President,
Nutrition Supply Chain
Joseph L. Novak
Vice President, Taxes
Ric A. Schneider
Vice President,
Chief Procurement Officer
Christopher J. Scoggins
Vice President,
Commercial Operations
and Marketing,
Abbott Diabetes Care
Eric Shroff
Vice President,
Abbott Point of Care
Frank Weitekamper
Vice President,
Abbott Transition
Organization
James R. Wenner
Vice President,
Internal Audit
Monica J. Wilkins
Vice President,
Regulatory and Quality
D I R E C T O R S A N D C O R P O R AT E O F F I C E R S
A B B O T T 2 0 2 2 A N N U A L R E P O R T

-- 83 of 86 --

82
Abbott trademarks and
products in-licensed by
Abbott are shown in italics in
the text of this report.
© 2023 Abbott Laboratories
Some statements in this
annual report may be
forward-looking statements
for purposes of the Private
Securities Litigation Reform
Act of 1995. Abbott cautions
that these forward-looking
statements are subject to
risks and uncertainties, that
may cause actual results to
differ materially from those
indicated in the forward-
looking statements.
Economic, competitive,
governmental, technological
and other factors that may
affect Abbott’s operations are
discussed in Item 1A, “Risk
Factors,” in our Securities
and Exchange Commission
2022 Form 10-K and are
incorporated by reference.
We undertake no obligation to
release publicly any revisions
to forward-looking statements
as the result of subsequent
events or developments,
except as required by law.
The Abbott 2022 Annual
Report cover and text is
printed on recycled paper
that contains a minimum of
10% post-consumer fiber
and the financial pages on
30% post-consumer fiber.
S H A R E S L I S T I N G
The ticker symbol for Abbott’s common
shares is ABT. The principal market for
Abbott’s common shares is the New York
Stock Exchange. Shares are also listed on
the Chicago Stock Exchange and traded on
various regional and electronic exchanges.
Outside the United States, Abbott’s shares
are listed on the Swiss Stock Exchange.
Q UA R T E R LY D I V I D E N D DAT E S
Dividends are expected to be declared,
recorded, and paid on the following
schedule in 2023, pending approval by the
Board of Directors:
Quarter 	Declared Recorded Paid
First 	2/17 	4/14 	5/15
Second 	6/9 	7/14 	8/15
Third 	9/21 	10/13 	11/15
Fourth 	12/15 	1/12/24 	2/15/24
TA X INFORM ATION FOR SHAREHOLDERS
Abbott is an Illinois High Impact
Business (HIB) through June 2023 and is
located in a U.S. federal Foreign Trade
Sub-Zone (Sub-Zone 22F). Abbott intends to
apply for a renewal of its HIB designation.
Dividends may be eligible for a subtraction
from base income for Illinois income-tax
purposes. If you have any questions, please
contact your tax advisor.
D I V I D E N D R E I N V E S TM E N T PL A N
The Abbott Dividend Reinvestment
Plan offers registered shareholders
an opportunity to purchase additional
shares, commission-free, through
automatic dividend reinvestment and/or
optional cash investments. Interested
persons may contact the transfer agent, or
call Abbott’s Investor Newsline, as listed in
the right-hand column.
D I V I D E N D D I R EC T D E P O S IT
Shareholders may have quarterly dividends
deposited directly into a checking or savings
account at any financial institution that
participates in the Automated Clearing
House system. For more information, please
contact the transfer agent, listed at right.
D I R EC T R EG I S T R AT I O N S Y S T E M
In August 2008, Abbott implemented a
Direct Registration System (DRS) for all
registered shareholder transactions.
Shareholders will be sent a statement in
lieu of a physical stock certificate for
Abbott Laboratories common shares.
Please contact the transfer agent with
any questions.
A N N UA L M E E T I N G
The Annual Meeting of Shareholders will
be held virtually at 9 a.m. Central Time on
Friday, April 28, 2023. There will not be a
physical location for the Annual Meeting,
and shareholders will not be able to attend
the Annual Meeting in person. Questions
regarding the Annual Meeting may be
directed to the Corporate Secretary. A copy
of Abbott’s 2022 Form 10-K Annual Report,
as filed with the Securities and Exchange
Commission, is available on Abbott’s Web
site at www.abbott.com or by calling the
Investor Newsline (above, right).
C EO A N D C FO C E R T I FI C AT I O N S
In 2022, Abbott’s chief executive officer
(CEO) provided to the New York Stock
Exchange the annual CEO certification
regarding Abbott’s compliance with the
New York Stock Exchange’s corporate-
governance listing standards. In addition,
Abbott’s CEO and chief financial officer
(CFO) filed with the U.S. Securities and
Exchange Commission all required
certifications regarding the quality of
Abbott’s public disclosures in its fiscal
2022 reports.
I N V E S TO R N E WS L I N E
224-667-7300
I N V E S TO R R E L AT I O N S
Dept. 362, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 USA
224-667-6100
S H A R E H O L D E R S E RV I C E S ,
T R A N S FE R AG E N T A N D R EG I S T R A R
Computershare
P.O. Box 43078
Providence, RI 02940-3078
888-332-2268 (U.S. or Canada)
781-575-3910 (outside U.S. or Canada)
www.computershare.com
CO R P O R AT E S EC R E TA RY
Dept. 364, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 USA
224-667-6100
WE B S IT E
www.abbott.com
A B B OT T O N L I N E A N N UA L R E P O R T
www.abbott.com/annualreport
G LO B A L S U S TA I N A B I L IT Y R E P O R T
www.abbott.com/sustainability
S H A R E H O L D E R I N FO RM AT I O N
Shareholders with questions about their
accounts may contact the transfer agent,
listed above.
Individuals who would like to receive
additional information, or have questions
regarding Abbott’s business activities, may
call the Investor Newsline at the number
listed above, write Abbott Investor Relations
at the address above, or visit Abbott’s website,
www.abbott.com.
A B B O T T 2 0 2 2 A N N U A L R E P O R T
S H A R E H O L D E R A N D C O R P O R AT E I N F O R M AT I O N

-- 84 of 86 --



-- 85 of 86 --



-- 86 of 86 --